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Cutaneous squamous cell carcinoma (cSCC) is the second most common non-melanoma skin 
tumor in humans with increasing incidence. cSCC is a result of malignant transformation of 
epidermal cells with ultraviolet (UV) radiation being the major cause of the disease. 
Currently, gold standard therapy involves surgical excision, which in most of the cases is 
sufficient to remove a primary tumor. However, a subset of patients develops recurrent or 
metastatic disease, for which there are no treatment options. Therefore, understanding of 
molecular mechanisms governing cSCC development and progression are pending to propose 
new targeted therapy.   
cSCC is often characterized by overexpression of epidermal growth factor receptor (EGFR), 
which nowadays is a main target in clinical trials. Besides, cSCCs often display activation of 
RAS/MEK/ERK, PI3K/AKT and mTOR signaling pathways. Clinical data show that mTOR 
inhibition markedly reduces the risk of cSCC development in organ transplant recipients 
(OTRs). Recently, also the Hedgehog (HH) signaling pathway, which is often deregulated in 
various cancers, has been shown to be involved in cSCC. Thus, mutations in Patched1 
(PTCH), the receptor for HH ligands, were described in 15% of the cases and several studies 
show expression of HH pathway components in cSCC including glioma-associated oncogene 
homolog 1 (GLI1), the major readout for HH pathway activity. However, the importance of 
these pathways and their putative crosstalk in cSCC remain elusive. 
In this thesis, the role and putative interaction of HH and EGF signaling as well as its 
downstream effector pathways i.e. MEK/ERK, PI3K/AKT and mTOR were investigated in 
human cSCC. By in situ hybridization and immunohistochemical analysis we showed that 
both GLI1 and EGF are strongly expressed in human cSCC tissue sections. However, while 
nearly the entire tumor was positive for EGF, GLI1 was highly expressed only in the center of 
the tumor while outer parts and invading cells were GLI1 negative or only moderately 
positive. As opposed, phosphorylated ribosomal protein S6 (pS6), the main readout for 
mTOR activity was strongly expressed in outer parts of the tumor and cells invading the 
dermis while its expression in the tumor center was weak. Moreover, GLI1 positive areas 
were surrounded by pERK positive stromal cells. Indeed, in cell culture model we showed 
that co-culture of cSCC cells with fibroblasts resulted in GLI1 inhibition in the tumor cells 




Together with the lack of Sonic Hedgehog (SHH), the major ligand that activates HH 
signaling throughout the tumor tissue, the data indicate that GLI1 is regulated rather in a 
SHH-independent and thus noncanonical way in cSCC. 
Indeed, our in vitro data show that canonical HH signaling does not play a role in cSCC. 
However, the data provide evidence that GLI1 can be regulated via MEK/ERK, PI3K/AKT 
and mTOR pathways in cSCC cell lines. Thus, pharmacological inhibition of PI3K, AKT or 
mTOR with specific inhibitors resulted in a significant decrease in GLI1 expression level in 
SCL-I, MET-1 and MET-4 cells suggesting a positive regulation of GLI1 by these pathways. 
However, transfection with constitutively active or dominant negative Akt1 variants did not 
affect GLI1 expression in SCL-I and MET-4 cells thereby questioning the role of AKT in 
cSCC. On the other hand, MEK1/2 inhibition with UO126 resulted in upregulation of GLI1 
expression in SCL-I cells and did not alter GLI1 transcript levels in MET-1 and MET-4 cells. 
This indicates that MEK/ERK can negatively regulate GLI1 expression in some cSCCs. 
Interestingly, when we applied EGF ligand to the cells, we noted a strong inhibition of GLI1 
transcription in all three cell lines. Moreover, combination of EGF with UO126, led to an 
upregulation of GLI1 expression level when compared to EGF treatment alone. Together the 
data suggest that EGF inhibits GLI1 expression via activation of MEK/ERK signaling in 
cSCC cell lines.  
In addition, we analyzed an impact of MEK/ERK, PI3K/AKT, mTOR and HH pathway 
inhibition on cell viability, proliferation and apoptosis. In general, the data showed that 
PI3K/AKT inhibitors and the HH pathway inhibitor HhA remarkably reduced cell viability 
and proliferation, while mTOR and MEK inhibitors as well as the HH pathway inhibitor 
vismodegib showed only moderate decrease in the percentage of viable or proliferating cells. 
However, the magnitude of change for each inhibitor was cell line-dependent. Moreover, 
cytotoxic effects of the inhibitors could not be excluded. Concerning apoptosis, UO126 
increased the number of early apoptotic SCL-1 cells. Together with increased GLI1 
expression upon treatment with UO126 in this very cell line, it can be speculated that GLI1 
can promote apoptosis.  
In the last part of this thesis we investigated the role of GLI1 in proliferation of cSCC cells. 
We showed that neither knockdown nor overexpression of GLI1 affected BrdU incorporation 




In summary, our data indicate that EGF negatively regulates GLI1 expression via activation of 























2.1.  Cutaneous squamous cell carcinoma (cSCC) 
Cutaneous squamous cell carcinoma (cSCC) is, following basal cell carcinoma (BCC), the 
second most common non-melanoma skin tumor in humans with increasing incidence. The 
highest incidence rate of cSCC is recorded in Australia with 387 new cases per 100000 
person-years (py) (Staples et al., 2006) and in North America with the numbers ranging from 
60 to 290 cases per 100000 py (Harris et al., 2001; Jung et al., 2010). In Europe the highest 
number of new cases is noted in the U.K. (15-33/100000 py) (Lomas et al., 2012), 
Netherlands (22-35/100000 py) (Hollestein et al., 2014) and Norway (15-20/100000 py) 
(Robsahm et al., 2015). Surgical excision is usually sufficient to remove a primary tumor. 
However, a 10-years retrospective study of a large cohort of cSCC revealed local recurrence 
in 4.6%, nodal metastasis in 3.7% and disease-associated death in 2.1% of patients (Schmults 
et al., 2013). Moreover, epidemiological data show that men are more frequently affected than 
women and the risk of cSCC development markedly rises with increasing age. Additionally, 
cSCC most commonly develops in fair-skinned people with pale hair and blue eyes who are 
prone to sunburn (reviewed in (Green and Olsen, 2017)). This is linked to the fact that the 
main cause of cSCC is cumulative ultraviolet (UV) exposure, mainly UVB, which usually 
results in multistage carcinogenesis.  
The process of cSCC formation starts with actinic keratosis (AK), which is a precursor lesion 
for cSCC and which occurs as scaly, reddish plaques. It may give rise to locally advanced 
cSCC manifested as ulcerating papules and may further develop into invasive or metastatic 
tumors (reviewed in (Alam and Ratner, 2001)). Microarray data show a similar genetic profile 
between AK and cSCC with however additional genetic abnormalities in the latter one. This is 
an indication that AK is a pre-cancerous lesion of cSCC (Padilla et al., 2010; Ra et al., 2011). 
cSCC may also develop de novo in immunosuppressed organ transplant recipients (OTRs) or 
in chronically inflamed skin areas. In fact, the risk of cSCC development in OTRs is 65-250 
higher than in the general population (Euvrard et al., 2003). Besides, patients suffering from 
acquired immune deficiency syndrome (AIDS) or chronic lymphocytic leukemia as well as 
patients with rheumatoid arthritis who receive immunomodulatory medicines display higher 
rates of cSCC occurrence (Amari et al., 2011; Levi et al., 1996; Zhao et al., 2016). 




increase the risk of cSCC (Jensen et al., 2009; Karagas et al., 2001). Altogether, these and 
many more reports establish a strong link between immunosuppression and cSCC 
development. Additional minor risk factors that are implicated in development of cSCC 
include ionization radiation, tobacco smoking, infection with papilloma virus and exposure to 
chemical agents. Moreover, some hereditary disorders such as xeroderma pigmentosum or 
oculocutaneous albinism may also predispose to cSCC development (Nikolaou et al., 2012). 
As mentioned above, standard treatment involves surgical excision, which is usually effective 
in most of cSCC cases. Alternative treatment options involve topical application of 5-
fluoruracil (5-FU), imiquimod or diclofenac (McGillis and Fein, 2004), electrodessication, 
curettage, cryotherapy and fractionated radiation (reviewed in (Alam and Ratner, 2001)). 
Nevertheless, in some cases these treatment options are not applicable due to tumor location 
or recurrence/metastasis. Therefore, there is a need for better understanding of molecular 
mechanisms responsible for cSCC tumor formation to develop new treatment strategies. 
Despite the knowledge about several cSCC-predisposing factors, not much is known about 
molecular mechanisms driving malignant transformation of normal keratinocytes to cSCC. 
PATCHED1 (PTCH) mutations have been described in a subset of cSCC but the relevance of 
canonical HH/GLI signaling pathway in the pathogenesis of cSCC still remains unknown (see 
below for detailed description). Several studies unraveled certain pathways that are 
specifically upregulated in cSCC when compared to normal skin. Mutations in the well-
known tumor suppressor p53 are common in cSCC and are found in approximately 58 % of 
cases (Brash et al., 1991). These mutations carry hallmarks of UV-induced mutagenesis i.e. 
C-T or CC-TT transitions. The relevance of p53 mutations as a driving force for the 
neoplastic transformation is further supported by in vivo studies in mice, in which somatic 
inactivation of Trp53 leads to the spontaneous development of cSCC in the murine epidermis, 
which can be accelerated by simultaneous inactivation of retinoblastoma (Rb) (Martinez-Cruz 
et al., 2008). Thus, UV-induced p53 mutations are considered to be a driving force in a 
majority of cSCC. Additionally, microarray data show upregulation of Wnt/ß-catenin-, 
calcium- and integrin- signaling pathways in cSCC when compared to normal skin (Ra et al., 
2011). The Wnt/ß-catenin signaling pathway regulates cellular proliferation via induction of 
c-myc and cyclin D1 expression and is also active in many other cancers (Doglioni et al., 
2003; El-Bahrawy et al., 2003). Also, calcium may play a role in cSCC pathogenesis. 




i.e. cell-cycle regulation, proliferation and apoptosis. Indeed, rearrangement of calcium pumps 
has been linked to carcinogenesis (Capiod et al., 2007) and calcium is especially important for 
keratinocytes differentiation (Bikle et al., 2004). Furthermore, integrins, which are usually 
associated with invasive and metastatic potential of different malignancies, were shown to 
play an important role in inhibition of apoptosis and differentiation processes in the 
epidermis. Integrin overexpression has also been shown to be associated with SCC formation 
(reviewed in (Janes and Watt, 2006)). 
Finally, many studies point to the relevance of EGFR and its downstream effectors i.e. pAKT, 
pERK and mTOR in pathology of cSCC (see below for detailed description). Currently, 
EGFR is the most promising target for therapy of cSCC. Nowadays many EGFR inhibitors 
are being tested in clinical trials for different tumor entities but their efficacy in the treatment 
of cSCC is still under evaluation (see below 2.3.4.). Another important target in cSCC therapy 
is the mTOR signaling cascade. Indeed, several reports demonstrated that immunosuppressive 
drugs, which belong to the group of mTOR inhibitors i.e. rapamycin (sirolimus) display 
strong anti-cSCC activity in OTRs, who are prone to cSCC development. Thus, patients 
receiving sirolimus develop significantly fewer new cSCC and even show regression of 
already existing lesions (Salgo et al., 2010; Tessmer et al., 2006). 
2.2. The Hedgehog signaling pathway 
Many components of the Hh signaling cascade were initially described by the two Nobel 
laureates Nüsslein-Volhard and Wieschaus in 1980. In their systematic search for Drosophila 
melanogaster mutants they identified several genes that when mutated, altered the segmental 
pattern of the larva. One of the mutant larvae failed to develop the naked posterior part of 
each segment and showed duplication of the anterior denticle band. Since these mutants were 
almost entirely covered with denticles leading to a 'hedgehog-like' appearance, the responsible 
gene was named Hedgehog (Hh). Besides the Hh gene, other genes were identified, which 
later turned out to be key components of the Hh signaling pathway. These genes include the 
Hh receptor Patched (Ptch), the downstream kinase fused (fu) and transcription factor cubitus 
interuptus (ci) (Nusslein-Volhard and Wieschaus, 1980). Later it was discovered that the Hh 
pathway is conserved between species and also plays a very important role in mammals, being 
crucial for embryonic development, tissue patterning, cellular proliferation and cell fate 




substantially silenced in an adult organism. However, it remains functional in a subset of cells 
and is very important for stem cells maintenance, cell differentiation, tissue repair and 
homeostasis (reviewed in (Petrova and Joyner, 2014)).  
2.2.1. Canonical Hedgehog signaling  
The most important components of the canonical HH signaling axis are the ligand HH, the 12-
pass transmembrane receptor PATCHED1 (PTCH), its interacting partner SMOOTHENED 
(SMO), which is a 7-pass transmembrane protein and the family of glioma-associated 
oncogene (GLI) transcription factors. In mammals, three different forms of HH ligands exist, 
which play distinct roles in the organism. Sonic hedgehog (SHH) is the most potent and 
widely expressed HH ligand and regulates the development of the central nervous system and 
the limbs (reviewed in (Ingham et al., 2011)). Indian hedgehog (IHH) is expressed in the gut 
and cartilage and mainly regulates cartilage and bone development (U. I. Chung et al., 2001). 
The expression of Desert hedgehog (DHH) is restricted to Sertoli cells in the testis, where it is 
important for the development of germ cells (Clark et al., 2000) and to Schwann cells, where 
it is responsible for proper peripheral nerve development (Parmantier et al., 1999). The 
ligands are synthesized within the cell in an inactive form and undergo cleavage as well as 
post-translational modification to become active soluble ligands (reviewed in (Briscoe and 
Therond, 2013)). All three HH ligands can bind to their receptor PTCH. In the absence of the 
ligands, PTCH inhibits the activity of SMO. The inhibitory mechanism is still poorly 
understood but there is evidence that PTCH mediates the transmembrane transport of sterol-
like small molecules that are able to inhibit SMO, which is known to have a sterol binding 
domain (Nedelcu et al., 2013). When SMO is inactive, the GLI transcription factors GLI2 and 
GLI3 that are present in the cytoplasm become phosphorylated by proteinase kinase A (PKA), 
glycogen synthase kinase 3-ß (GSK3ß) and casein kinase 1 (CK1) (reviewed in (Aberger and 
Ruiz, 2014)). This phosphorylation occurs at six conserved serine (Ser) residues at the 
carboxyterminal (C-terminal) ends of the proteins and leads to the recruitment of E3 ubiquitin 
ligase. This results in the proteolytic cleavage of GLIs into their respective repressor forms 
(Niewiadomski et al., 2014). More specifically, GLI3 processing by E3 ubiquitin ligase leads 
to the formation of a truncated repressor form of GLI3. On the other hand, GLI1 is fully 
degraded while GLI2 is regulated in both ways i.e. generation of the repressor form and 
degradation of the whole protein (Di Marcotullio et al., 2007). This results in the repression of 




transcription factors in the cytoplasm, thereby preventing their translocation into the nucleus 
(reviewed in (Briscoe and Therond, 2013)). Thus, in addition to PTCH, SuFu is another 
negative regulator of the pathway. Moreover, SuFu was also shown to stabilize full-length, 
unprocessed GLIs and to protect them from ubiquitin-mediated degradation, thereby 
increasing the overall level of potential GLI activator and repressor forms (S. J. Chen et al., 
2009).  
When the HH ligands bind to PTCH, the pathway becomes active, because binding of HH 
inhibits the function of PTCH and thus restores SMO activity. Activation of SMO is based on  
trafficking into primary cilium as well as on conformational changes (Wilson et al., 2009). 
This results in stabilization of GLI activator forms. Formation of GLI activator forms is a 
multistep process, which first requires dephosphorylation of C-terminal Ser residues. This is 
then followed by phosphorylation of GLI amino acids residues located at amino terminus (N-
terminus) by different kinases i.e. PKA, AKT, ERK or S6K1. This indicates that the N-
terminus of GLI proteins is an integration site for different signaling pathways (reviewed in 
(Aberger and Ruiz, 2014)). Upon GLI phosphorylation, activated GLI forms dissociate from 
the SuFu complex, translocate into the nucleus and drive the transcription of target genes. 
Target genes include components of the pathway itself such like GLI1, the most reliable 
readout for HH pathway activity and that amplifies the HH signal on transcriptional level. 
Indeed, the mRNA level of GLI1 as the most important marker for HH signaling activity has 
been studied in many cancer entities. Other targets are PTCH and hedgehog interacting 
protein (HHIP), which can be expressed upon activation of HH signaling in specific tissues 
and which then establish a negative feedback for the pathway’s activity. HHIP is a vertebrate-
specific membrane glycoprotein that is known to bind all three HH ligands with similar 
affinity as PTCH and to attenuate HH signaling (Chuang and McMahon, 1999). The 














Figure 1: Schematic and simplified representation of the canonical HH signaling pathway. Four major 
components of the pathway are indicated; the ligand Hedgehog (HH), the 12-transmembrane receptor Patched 
(PTCH), the 7-transmembrane signal transduction protein Smoothened (SMO) and the GLI transcription factors 
in an activator and repressor form (GLI act and GLI rep, respectively). A. In the absence of the HH ligand, 
PTCH inhibits SMO. This results in the cleavage of GLIs into their repressor forms. GLI rep translocates into the 
nucleus and inhibits the transcription of target genes. B. Upon HH ligand binding to its receptor PTCH, the 
inhibition on SMO is suspended. This results in stabilization of the GLI activator forms, their translocation to the 
nucleus and the transcription of target genes. 
2.2.2. Canonical Hedgehog signaling in cancer 
Due to the role of HH signaling pathway in proliferation, apoptosis and stem cell maintenance 
(described above), deregulation of this pathway has a great potential to drive tumorigenesis. 
The primary link between HH pathway activation and tumor development was established by 
two independent groups showing that loss of heterozygosity (LOH) of the PTCH locus is a 
hallmark of basal cell nevus syndrome, which is a hereditary disorder that predisposes 
patients to development of BCC and medulloblastoma (MB) (Hahn et al., 1996; Johnson et 
al., 1996). To this day, numerous studies have shown that pathological activation of canonical 
HH signaling is the driving force for many tumor entities including gliomas (Takezaki et al., 
2011), BCC, MB (Hahn et al., 1996; Johnson et al., 1996) or prostate cancer (reviewed in 
(Xie, 2005)). Two different mechanisms for overactivation of the canonical 
HH/PTCH/SMO/GLI axis can be distinguished. Whereas the ligand-dependent mode of 
action is based on the excess of HH ligand that continuously binds to PTCH (see Fig. 2 A) the 
ligand-independent mode is driven by inactivating mutations in HH pathway suppressors 
(PTCH or SuFu), by activating mutation in SMO or GLI amplification (see Fig. 2 B; reviewed 




Ligand-dependent HH signaling overactivation has been described in several different tumor 
entities. For example, ligand-dependent activation is necessary to maintain glioma progenitor 
cells within a subset of gliomas (Ehtesham et al., 2007). Another study shows that transgenic 
mice overexpressing SHH in skin develop BCC, which implies that ligand overexpression is 
sufficient to drive tumorigenesis in an autocrine manner (Oro et al., 1997). However, ligand-
dependent HH pathway activation might also require tumor-stroma cells interaction due to 
paracrine signaling (Yauch et al., 2008). Indeed, activation of HH signaling in stromal cells 
promotes growth of human prostate cancer in the mouse xenograft model (Shaw et al., 2009).  
Ligand-independent activation of canonical HH signaling occurs frequently due to mutations 
in PTCH. PTCH inactivating mutations have been well described in BCC and MB. Indeed, 
the vast majority of BCC arises due to mutations in this gene (reviewed in (Epstein, 2008)) 
and only a small subset of BCC shows activating SMO or inactivating SuFu mutations, which 
also can be modelled in mice (Lam et al., 1999; Xie et al., 1998). Furthermore, PTCH 
mutations have been identified in 9% of MB (Taylor et al., 2002), in 7% of esophageal SCC 
(Maesawa et al., 1998) and in 4% of colorectal tumors (J. H. Chung and Bunz, 2013). MB 
also can harbor inactivating mutations in the SuFu tumor suppressor (Taylor et al., 2002). 
Loss-of-function mutations in SuFu have also been detected in prostate cancer, although HH 
pathway activation in this tumor entity is mainly ligand-dependent (Sheng et al., 2004). 
Activating mutations in SMO causing abnormal HH pathway signaling have been described in 
primitive neuroectodermal tumors (Reifenberger et al., 1998), in 10% of gastric cancers (Z. C. 
Wang et al., 2013) and, as already said in BCC. In contrast, mutations in GLI have not been 
described so far. However, GLI1 amplification accompanied by increased GLI1 mRNA level 
was described in malignant glioma tumors and a cell line derived from one of these lesions 
(Kinzler et al., 1987; Wong et al., 1987). Furthermore, molecular and cytogenetic analysis 
reveals amplification of GLI1 in a subset of alveolar rhabdomyosarcoma (RMS) (Gordon et 
al., 2000). Additionally, a so-called Shh-subgroup of MB, which is thought to be driven by 
pathological HH pathway activation (Taylor et al., 2012) carries amplified copy numbers of 













Figure 2: Most frequent alterations in the canonical HH signaling pathway in cancer. Two mechanisms of 
HH pathway overactivation are presented. A. Upregulation of the pathway’s activity in a ligand-dependent 
manner. HH ligands are highly produced by either the tumor itself or by the tumor stroma and bind to the PTCH 
receptor leading to activation of SMO and translocation of GLI to the nucleus. B. Activation of the pathway in a 
ligand-independent manner. Inactivating mutations in PTCH (indicated in red) or activating mutations in SMO 
(indicated in green) or GLI amplification can lead to enhanced activity of GLI transcription factors and thus 
constitutive pathway activation. 
Due to overactivation of HH signaling in a broad spectrum of different tumors, HH pathway 
inhibitors have gained great interest in the past. The first HH pathway inhibitor identified was 
cyclopamine. Cyclopamine is a naturally occurring alkaloid that was isolated from the corn 
lily Veratrum californicum and was shown to cause developmental defects in lambs via 
binding to and inhibiting the function of SMO (Binns et al., 1968; J. K. Chen et al., 2002a). 
However, due to its poor oral solubility, low potency and relevant toxicity, it is not suitable 
for therapy in humans (Lipinski et al., 2008). Therefore, other more potent small-molecule 
inhibitors targeting SMO have been developed and synthesized and are currently being 
investigated in many clinical trials of a variety of cancers including pancreatic cancer, breast 
cancer, esophageal cancer, inoperable metastatic gastric cancer as well as hematologic 
malignancies (reviewed in (Amakye et al., 2013)). Up to date two of them reached US Food 
and Drug Administration (FDA) approval for treatment of locally advanced and metastatic 
BCC. These drugs are vismodegib from Curis/Roche (also named GDC-0449, approved in 
2012) and sonidegib from Novartis (also named LDE225, approved in 2015). However, SMO 
inhibitors are only efficient in tumors overexpressing HH ligands or in those bearing PTCH 
mutations, whereas malignancies driven by SMO activating mutations or GLI amplification 




might occur due to GLI regulation by other signaling pathways that are independent of SMO. 
This mechanism is known as noncanonical HH signaling and is described in detail in chapter 
2.2.4. (see below). In this scenario, SMO inhibitors fail to inhibit tumor growth and thus 
development of alternative therapies is urgently needed. 
2.2.3. Canonical Hedgehog signaling in cSCC 
Mutations in members of the HH signaling pathway have also been described in cSCC. Thus, 
15% of cSCC cases show mutations in PTCH (Ping et al., 2001). Moreover, screening of a 
large cohort of cSCC revealed LOH at the PTCH locus on chromosome 9q22 in 
approximately 50% of cases (Danaee et al., 2006). In addition, besides SHH and PTCH1, 
cSCC expresses GLI1, the major target of active HH signaling. As shown by 
immunohistochemistry SHH was expressed in 67%, PTCH1 in 90% and GLI1 in 42% of 
analyzed human cSCC samples (Schneider et al., 2011). This indicates that HH signaling may 
be active in cSCC. However, these results are different from ours and are discussed in more 
detail in section 7.1.1. 
Nevertheless, the role of HH signaling pathway in cSCC is still poorly understood. While 
SMO inhibitors e.g. vismodegib (Dubey et al., 2013) or sonidegib (Burness, 2015) have been 
approved for the treatment of BCC that harbor PTCH mutations, several of these cases 
developed actinic keratosis (Aasi et al., 2013). Later, several similar studies were published, 
reporting even patients who developed cSCC under the treatment of BCC with vismodegib 
(Orouji et al., 2014; Poulalhon et al., 2015; Saintes et al., 2015). So far, SMO inhibitors have 
not been tested in cSCC. It is possible that some of cSCC e.g. those bearing PTCH mutations 
would benefit from the therapy with SMO inhibitors. However, it seems that a subset of cSCC 
can also develop after this type of treatment. Altogether, these data clearly show that there is a 
need for profound understanding of the role of HH signaling pathway in cSCC. 
2.2.4. Noncanonical Hedgehog signaling 
Noncanonical HH signaling can be defined by two distinct modes of action. One assumes the 
function of either PTCH or SMO independently of GLI transcription factors while the second 
one involves regulation of GLIs by other signaling pathways. Indeed, it was shown that PTCH 
can have a direct effect on cellular biology without involvement of other components of the 




has a pro-apoptotic function that is independent of Smo or Gli and rather relies on a caspase-
mediated cleavage of the C-terminal cytoplasmic domain of Ptch (Thibert et al., 2003). 
Moreover, Ptch can act as a direct interaction partner of phosphorylated cyclin B1 and block 
cell cycle progression by promoting cytoplasmic localization of cyclin B1 (Barnes et al., 
2001). Other studies showed that the Shh/Ptch/Smo axis is involved in the cytoskeletal 
rearrangements that are mediated via ras homolog family member A (RhoA) and Ras-related 
C3 botulinum toxin substrate 1 (Rac1) but not by Gli (Polizio et al., 2011). However, the 
exact mechanism by which Smo activates these 2 small GTPases still needs to be elucidated.  
Regulation of GLI transcriptional activity in a SMO-independent manner has recently reached 
strong interest mostly due to many unsuccessful clinical trials using inhibitors that specifically 
target SMO (see below; (Berlin et al., 2013; Kaye et al., 2012; Kim et al., 2014)). There are 
many studies showing involvement of other signaling pathways in the regulation of GLIs. 
These pathways involve transforming growth factor β (TGFβ) signaling, protein kinase C 
(PKC) signaling, mitogen-activated protein kinase kinase/extracellular signal-regulated 
kinases (MEK/ERK), phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B 
(PI3K/AKT) or the mechanistic target of rapamycin (mTOR). 
2.2.5. Noncanonical Hedgehog signaling in cancer and cSCC 
Noncanonical HH signaling has been described in many tumor entities. There is growing 
evidence that TGFβ may regulate expression of GLIs independently of SMO. Thus, Smad-
mediated TGFβ signaling stimulated the rapid expression of GLI2 followed by delayed 
upregulation of GLI1 in human HaCaT keratinocytes, neonatal dermal fibroblasts and in a 
breast carcinoma cell line (Dennler et al., 2007). Moreover, cyclopamine treatment did not 
inhibit TGFβ-mediated upregulation of GLI1 suggesting a SMO-independent mode of action. 
The authors also showed that overexpression of TGF-β1 in the epidermis of transgenic mice 
resulted in elevated levels of Gli1 and Gli2 in comparison to control mice (Dennler et al., 
2007). TGFβ-associated GLI1 and GLI3 overexpression was also noted in SMO-depleted 
pancreatic ductual adenocarcinoma cells supporting the SMO-independent mechanism 
(Nolan-Stevaux et al., 2009). Furthermore, analysis of the human GLI2 promoter region 
revealed binding sites for SMAD transcription factors and lymphoid enhancer factor/T cell 
factor (LEF/TCF). These data suggest a direct regulation of GLI2 by SMAD proteins as well 




cooperation between Wnt/β-catenin/LEF and HH signaling pathway was indeed shown to 
play a role in cancer formation. In in vitro models of stomach, colon and lung cancer, 
exogenous overexpresison of β-catenin increased the transcriptional activity of GLI 
transcription factors, which however seemed to be TCF/LEF-independent (Maeda et al., 
2006). Further experiments in embryonic kindey 293T cells suggested that Wnt/β-catenin 
increases GLI1 expression and its transcriptional activity via induction of coding region 
determinant-binding protein (CRD-BP). CRD-BP is an mRNA binding protein, which 
stabilizes GLI1 mRNA leading to increased GLI1 protein level and increased GLI1 
transcription as a result of positive feedback loop (Noubissi et al., 2009). 
Other studies focused on the crosstalk between HH/GLI signaling and IGF-2. Igf-2 expression 
is enhanced in RMS, MB as well as normal tissue of Ptch deficient mice and indispensable for 
RMS and MB formation driven by Ptch loss of function (Hahn et al., 2000). In cerebellar 
granule cell precursors that are believed to be the origin of desmoplastic MB, Shh and Igf-2 
were shown to synergistically induce expression of HH pathway target genes i.e. Gli1 and 
cyclin D1 (Hartmann et al., 2005). 
GLI protein activity and GLI transcriptional level can also be regulated by kinases that act 
independently of SMO i.e. PKC-Ϭ, DYRK1 or DYRK2. For example in NIH3T3 cells it has 
been shown that activation of PKC-Ϭ by phorbol esters i.e. 12-O-tetradecanoylphorbol 13-
acetate (TPA) leads to ligand-independent activation of Gli transcriptional activity as well as 
elevated Gli1 and Ptch1 transcription level. Nevertheless, a certain level of PKC-Ϭ activity 
seems to be also necessary for Shh-driven Gli activity (Riobo et al., 2006). In addition, further 
studies have demonstrated that PKC-Ϭ positively regulates GLI transcriptional activity 
downstream of SuFu  (Lauth et al., 2007). GLI function can also be regulated by DYRK1 and 
DYRK2. DYRK1A has been shown to promote translocation of GLI1 to the nucleus and thus 
to enhance its transcriptional activity (Mao et al., 2002). On the other hand, DYRK2 has been 
shown to phosphorylate GLI2 and thereby to promote its proteasomal degradation (Varjosalo 
et al., 2008). Also the EWS-FLI1 fusion oncogene observed in Ewing sarcoma can increase 
GLI1 transcription by direct binding to its promotor (Beauchamp et al., 2009; Beauchamp et 
al., 2011). Several independent studies also present a negative crosstalk between GLI1 and 
the tumor suppressor p53 (Abe et al., 2008; Stecca and Ruiz i Altaba, 2009; Yoon et al., 
2015). The exact mechanism by which p53 represses GLI1 function is not known but p53 can 




negatively regulate p53, which suggests the existence of a negative  feedback loop between 
these two proteins (Stecca and Ruiz i Altaba, 2009). Also Notch signaling has been identified 
as another negative regulator of Gli transcription factors in murine skin. Specifically, 
depletion of Notch1 results in elevated expression of Gli2 and development of BCC-like 
tumors in the murine epidermis. Moreover this mechanism seems to be mediated by 
derepression of ß-catenin signaling (Nicolas et al., 2003). On the other hand, in mice, Smo-
driven MB shows the expected increase in Gli1 expression but concomitantly elevated level 
of Notch target genes i.e. Hes5. This suggests that Hh pathway activation is sufficient to 
activate Notch signaling and that activity of both pathways is required for MB development in 
mice. Also in human MB, HH pathway components and Notch signaling target genes were 
concomitantly elevated when compared to normal cerebellum (Hallahan et al., 2004). 
The activity of GLI proteins can also be mediated via growth factor receptor signaling such as 
the epidermal growth factor EGF and its receptor EGFR (please see also section 2.3.). These 
so-called receptor tyrosine kinase (RTK) can activate e.g. RAS/RAF/MEK. The interaction of 
the latter pathway with GLIs was extensively studied in pancreatic cancers and showed a 
positive influence on GLI transcriptional activity (Eberl et al., 2012; Ji et al., 2007). The 
detailed mechanism still remains to be discovered but computational predictions suggest that 
mitogen-activated protein kinase (MAPK or ERK) can directly phosphorylate and thus 
activate GLI transcription factors (Whisenant et al., 2010). Additionally, in keratinocytes it 
has been shown that EGFR-mediated activation of MEK/ERK cooperates with GLI 
transcription factors to induce neoplastic transformation (Kasper et al., 2006a; Schnidar et al., 
2009). However, in MB, fibroblast growth factor (FGF)-mediated ERK activation inhibits HH 
pathway target genes expression including GLI1 (M. P. Fogarty et al., 2007b). This suggests 
that growth factors can impact on GLI in either a cell type- or growth factor-specific manner.  
Another important pathway that acts downstream of RTKs and is involved in GLI regulation 
is the PI3K/AKT axis. For example in melanoma this pathway promotes nuclear localization 
and thus transcriptional activity of GLI transcription factors (Stecca et al., 2007). Moreover, 
PI3K/AKT synergizes with SHH signaling to support tumor growth of MB cells, most likely 
via activation of the mTOR pathway (Filbin et al., 2013). Indeed, the latter pathway can 
phosphorylate GLI1 in esophageal adenocarcinoma via activation of ribosomal protein S6 




GLI1 from SuFu and its translocation into the nucleus. Moreover, this study showed that 
GLI1 activation is important for viability, proliferation and invasion of the tumor cells. 
The relevance of noncanonical HH signaling in cSCC is not known. Although activation of 
many oncogenic pathways i.e. EGF/EGFR, PI3K/AKT, MEK/ERK and mTOR was shown in 
cSCC (see section 2.1. and 2.3.4.) their role in the regulation of GLI has not been studied so 
far. 
As described above, the involvement of noncanonical HH signaling in cancer has been 
established in various tumors and in many cases explains the inefficiency of SMO inhibitors 
as a treatment strategy. Therefore, to overcome the influence of downstream signaling 
pathways on GLI activity, inhibitors against GLIs as terminal effectors of HH pathway are 
currently in development. Two forms of GLI1 antagonists (GANT) have been discovered in 
GLI luciferase reporter assay in HEK293 cells, which are GANT-58 and GANT-61. GANT-
61 is more specific than GANT-58 and is able to inhibit GLI1 and GLI2 DNA-binding 
capability. It was shown to be effective in the cell lines derived from various cancers i.e. 
RMS, osteosarcoma, neuroblastoma and ovarian cancer. However, up to date there are no 
clinical trials using GANT inhibitors. Another GLI inhibitor is arsenic trioxide (ATO). It has 
been described to effectively block GLI1 and GLI2 transcriptional activity in vitro and in 
vivo. But it was also shown to induce apoptosis via interaction with glutathione-related 
enzymes or via degradation of peroxides. The exact mechanism of action is not yet known, 
however it was proposed that ATO promotes apoptosis via activation of Jun N-terminal 
kinase (Sun et al., 2016). Despite the multitude of action, ATO has met approval of the FDA 
for the treatment of acute promyelocytic leukemia and is currently being evaluated in clinical 
trials for the treatment of various cancers i.e. non-small cell lung cancer (NSCLC), malignant 
gliomas, hepatocellular carcinoma and many hematological malignancies (reviewed in 
(Rimkus et al., 2016)). 
2.3. Epidermal growth factor/Epidermal growth factor receptor signaling 
The epidermal growth factor receptor (EGFR, ErbB1, HER1) is a transmembrane receptor 
displaying tyrosine kinase activity. As a RTK it regulates activity of downstream signal 
transduction pathways that are crucial for proliferation and survival of normal and cancerous 
cells. It belongs to the family of HER (ErbB) receptors comprised of HER1 (EGFR), HER2, 




constitute a family of small molecules that includes epidermal growth factor (EGF), 
transforming growth factor-α (TGF-α) and amphiregulin, which specifically bind to EGFR. 
Other molecules such as epiregulin, betacellulin and heparin-binding EGF associate with 
EGFR and HER4, whereas some neuregulins bind selectively to HER3 and/or HER4 
(reviewed in (Brand et al., 2011)). 
EGF was initially isolated from the murine submaxillary gland and was reported to accelerate 
eyelid separation and incisors eruption in mice (Cohen, 1962). This study was followed by 
identification and isolation of human EGF from urine, which was shown to stimulate growth 
of human foreskin fibroblasts in vitro and corneal epithelial cells in organ culture. In vivo it 
had similar effects as murine EGF and induced premature eyelids opening (Cohen and 
Carpenter, 1975). Up to date there have been a lot of studies focusing on EGF/EGFR 
interaction and signaling as well as its biological relevance. Nowadays, the EGF ligand is a 
prototype for all ligands that can bind EGFR (HER1). These ligands all share structural 
similarity in the extracellular domain called EGF-like motif, which is composed of six 
conserved cysteine residues within 35-40 amino acids sequence (reviewed in (Zeng and 
Harris, 2014)). The cysteine residues pair and form disulfide bonds that are necessary for their 
biological activity and binding to EGFR (Savage et al., 1973). The disulfide bonds provide a 
three-looped structure to EGF with linear N- and C-terminus. The amino acid composition of 
the N-terminal part is crucial for the ligand specificity. For example, a substitution of four N-
terminal amino acids of heregulin (ligand belonging to a group of neuregulins) with a N-
terminal sequence specific for EGF was sufficient to allow affinity binding of the chimeric 
heregulin to the HER1 receptor (Barbacci et al., 1995). Another example is the decreased 
EGF binding affinity and specificity upon replacement of as few as 2 amino acids within its 
N-terminal linear region (Stortelers et al., 2002). Altogether, despite structural similarities 
between EGF-like ligands within the looped structure, the N-terminal amino acid composition 
plays a crucial role in tight regulation of ligand specificity. Additionally, binding of EGF to 
EGFR is regulated by post-translational modifications of the receptor’s extracellular domain. 
For example, site-specific methylation by protein arginine methyltransferase 1 (PRMT1) of 
the extracellular domain of EGFR enhances EGF binding affinity, thereby inducing receptor 
dimerization and signal transduction (Liao et al., 2015). Depending on the ligand type and the 
composition of the dimer, HER receptors activate different signaling molecules that mediate 




tyrosine kinase activity of the receptor, which leads to autophosphorylation of the C-terminal 
domain of the receptor. The respective phosphorylated tyrosine (Tyr) residues constitute a 
docking site for different signaling molecules that contain Src Homology 2 (SH2) domain. 
This further activates downstream signaling molecules or signaling cascades such as the 
RAS/RAF/MEK/ERK, PI3K/AKT or phospholipase Cϒ/protein kinase C (PLCϒ/PKC) that 
are all involved in cellular proliferation, apoptosis, differentiation, migration or invasion. 
Moreover, several studies have shown that EGFR can localize into the nucleus of many cell 
types and thus function as transcription factor itself. However, it remains to be unraveled 
whether it can directly bind to DNA (Lin et al., 2001). 
2.3.1. Activation of RAS/RAF/MEK/ERK signaling pathway 
The mechanism of signal transduction by EGFR is similar for the whole group of RTKs 
including fibroblast growth factor receptor (FGFR), vascular endothelial growth factor 
receptor (VEGFR) and platelet derived growth factor receptor (PDGFR). One of the main 
pathways activated by EGFR signaling is the RAS/RAF/MEK/ERK cascade. Upon activation 
of autophosphorylation, phosphorylated Tyr residues on the C-terminal of the receptor are 
recognized and bound by growth factor receptor-bound protein 2 (Grb2) containing a Src 
homology 3 domain (SH3), which recruits the son of sevenless (SOS) guanine nucleotide 
exchange factor. This further promotes guanosine triphosphate (GTP)-dependent activation of 
Rat sarcoma (RAS). RAS belongs to the family of small GTPases, which transmit signals 
within the cells. GTP-RAS stimulates RAF/MEK/ERK kinase cascade by recruitment of the 
rapidly accelerated fibrosarcoma (RAF) kinase to the plasma membrane and its subsequent 
activation. RAF then phosphorylates and activates MEK kinases. MEKs constitute an 
evolutionary conserved group of kinases. In mammals, it occurs in 3 isoforms i.e. MEK1 (45 
kDa), inactive MEK1b (43 kDa) and MEK2 (46 kDa). MEK1 and MEK2 are composed of a 
N-terminal regulatory domain, a catalytic kinase domain and a C-terminal domain. Typically, 
their activation is triggered by phosphorylation of two Ser residues (Ser 218 and Ser 222) by 
MAPKKK i.e. A-Raf, B-Raf, Raf-1 or MOS kinases. In fact, the regulation of MEK activity is 
a much more complex process, which involves phosphorylation of other Ser and threonine 
(Thr) residues by a spectrum of other kinases. Inactivation of MEK1/2 is dependent on 
dephosphorylation of Ser 218 and Ser 222 by protein phosphatase 2 (PP2A). Activated MEKs 
function as tyrosine/threonine (Tyr/Thr) kinases with ERK being their only known 




genes (ERK1 and ERK2) and are also evolutionary conserved. They are composed of a 
catalytic kinase domain, regulatory elements containing Tyr and Thr residues and a C-
terminal docking domain responsible for interaction with MEK and other regulatory proteins. 
MEKs bind to the C-terminus of ERKs and phosphorylate their Tyr and Thr residues. This 
double phosphorylation seems to be exclusively exerted by MEKs. Inactivation of ERKs 
relies on Tyr/Thr dephosphorylation, which can be accomplished by different phosphatases. 
Activated ERKs are potent Ser/Thr kinases which phosphorylate Ser and Thr residues within 
specific consensus sequences of many different substrates both in the cytoplasm and the 
nucleus. Most of these substrates are transcription factors such like Elk-1, c-Myc, c-Fos, p53 
or c-Jun, which drive the expression of target genes involved in proliferation, differentiation 
and apoptotic processes (reviewed in (Shaul and Seger, 2007)). On the other hand, ERKs can 
also further activate other kinases including ribosomal kinase S6K1, which then drives the 
transcription of other subset of genes. Specificity of ERK kinases is regulated on many 
different levels and depends on strength and duration of the cascade signaling, their 
subcellular localization as well as crosstalk with different scaffold proteins and other 
signaling pathways (reviewed in (Shaul and Seger, 2007)). A simplified representation of 























Figure 3: Schematic representation of RAS/RAF/MEK/ERK activation by EGFR. Upon binding of the EGF 
ligand, monomeric EGFR receptors dimerize leading to tyrosine kinase (TK) domain activation. Phosphorylated 
residues in the receptor’s cytoplasmic domain are bound by the GRB2 docking protein. GRB2 is recognized by 
the SOS protein, which subsequently activates RAS via induction of GDP to GTP exchange. Activated GTP-




2.3.2. Activation of PI3K/AKT and mTOR signaling pathways 
Another important pathway regulated by RTKs is PI3K/AKT, which is known to inhibit 
caspase-mediated apoptosis or stimulate proliferation and cell metabolism (H. Zhou et al., 
2000b). The most commonly described way of PI3K activation is based on ligand binding to 
insulin-like growth factor 1 receptor (IGF1R) (Myers et al., 1994). Phosphorylated Tyr 
residues of the receptor are recognized and bound by insulin receptor substrate 1 (IRS-1) 
protein, which constitutes a docking site for PI3K. Nevertheless, PI3K can also directly 
recognize phosphorylated Tyr residues at the C-terminus of other RTKs such as EGFR. The 
third way of PI3K activation is exerted by GTP-bound RAS protein. Regardless of the way of 
activation, activated PI3K is recruited to the cell membrane where it binds and phosphorylates 
phosphatidylinositol 4,5-bisphosphate (PIP2), which is a regular component of the cell 
membrane. Phosphorylated PIP2 forms a second messenger called phosphatidylinositol 
(3,4,5)-trisphosphate (PIP3), which is able to activate the Ser/Thr kinase AKT. Upon binding 
to PIP3 via its plextrin homology domain (PH), AKT becomes activated in a two-step 
phosphorylation exerted by two different kinases. These are the phosphoinositide dependent 
kinase 1 (PDK1) and the mammalian target of rapamycin (mTOR) within complex 2 
(mTORC2) (Alessi et al., 1997; Sarbassov et al., 2005). Fully activated AKT regulates 
important processes in the cell i.e. proliferation, cell survival and protein synthesis. One of the 
well-known effectors of AKT is the mammalian target of rapamycin complex 1 (mTORC1). 
The activation of mTORC1 is a multistep process involving inactivation of the tuberous 
sclerosis 2 (TSC2) complex, which results in activation of the Ras homolog enriched in brain 
(RHEB). Activated RHEB binds to a catalytic domain of mTORC1 driving thereby the kinase 
function of mTOR. The two major substrates of mTORC1 are S6K1 kinase and eIF4E-
binding protein 1 (4E-BP1) that are involved in protein synthesis (reviewed in (Laplante and 
Sabatini, 2012)). Thus, the PI3K/AKT/mTOR axis is very important for cell survival. In 
addition, it is frequently overactivated in tumor cells. This cascade is negatively regulated by 
phosphatase and tensin homolog (PTEN), which is a well-known tumor suppressor that 
dephosphorylates PIP3 to PIP2. In fact, inactivating mutations in PTEN are commonly found 
in a variety of cancers (Chalhoub and Baker, 2009). The exemplary activation of PI3K/AKT 





























Figure 4: Schematic representation of PI3K/AKT pathway activation by EGFR. Upon RTK activation, 
PI3K binds to phosphorylated tyrosine residues via its SH2 domain. PIP2, which is a component of the cell 
membrane, becomes phosphorylated via activated PI3K to form PIP3. PIP3 is recognized by AKT via its PH 
domain. This results in phosphorylation and activation of AKT by two different kinases i.e. PDK1 and 
mTORC2. 
2.3.3. Epidermal growth factor/epidermal growth factor receptor signaling in cancer 
EGF has been shown to stimulate growth of various cell types in vitro including rodent and 
human mammary epithelium, murine neocortical cells with stem cell properties and rat 
thyroid cells (Asmis et al., 1995; Osborne et al., 1980; Palma and Ruiz i Altaba, 2004). In 
cancer, EGF has been revealed to stimulate growth, invasion and metastasis of breast cancer 
cells (Lu et al., 2001; Osborne et al., 1980). In cervical cancer cells, EGF-mediated EGFR 
signaling promotes epithelial-to-mesenchymal (EMT) transition and thus tumor progression 
(Lee et al., 2008). Moreover, autocrine EGF signaling has been shown to promote the growth 
of prostate cancer cells (Tillotson and Rose, 1991). It was also shown in vivo that EGF 
production by NSCLC is required for EGFR activation and tumor growth in mice (W. Wu et 
al., 2007). Another study showed that co-expression of EGF and EGFR is correlated with 
progression of colon carcinoma (Iqbal and Lenz, 2004).  
However, the great majority of studies focus on EGFR itself. Thus, constitutive activation of 
the EGFR is detected in many tumors. Most frequently these cancers are of epithelial origin 
and include head and neck squamous cell carcinoma (HNSCC) (Weichselbaum et al., 1989), 
NSCLC (Veale et al., 1987) or breast cancer (Masuda et al., 2012; Sainsbury et al., 1987). 
Nevertheless, pathological activation of EGFR signaling is not restricted to epithelial tumors 




mechanisms resulting in constitutive activation of EGFR signaling i.e. excess of ligand 
production in autocrine or paracrine way (Sizeland and Burgess, 1992), amplification of the 
EGFR receptor or activating mutations within the receptor. In case of EGFR amplification in 
tumors such as breast cancer and malignant glioma (Al-Kuraya et al., 2004; Sainsbury et al., 
1987; Wong et al., 1987), the monomeric receptors on the cell membrane may spontaneously 
dimerize leading to the activation of downstream signaling pathways independently of ligand 
binding. Besides, overexpression of EGFR receptors without any mutations or amplification is 
observed in many different tumor entities including pancreatic cancer (Korc et al., 1992), 
anaplastic thyroid cancer (Schiff et al., 2004) and also cSCC (G. B. Fogarty et al., 2007a; 
Mauerer et al., 2011) (see below for more detailed information). Constitutive activation may 
also be conferred by mutations in the extracellular, transmembrane or cytoplasmic domains of 
EGFR. Thus, EGFR is quite often a target for therapy in cancer. Two distinct groups of drugs 
targeting EGFR have been developed. The first is a group of small molecule tyrosine kinase 
inhibitors (TKI), which inhibit the cytoplasmic tyrosine kinase activity via occupying the 
binding site for ATP (Busse et al., 2001). There are three TKI that have been already 
approved by FDA. These are erlotinib for treatment of NSCLC and pancreatic cancer, 
gefintinb for NSCLC and lapatinib for breast cancer. The second group is composed of 
monoclonal antibodies, which block ligand binding to the extracellular domain of the receptor 
(reviewed in (Martinelli et al., 2009)) with Cetuximab being approved by the FDA for the 
treatment of HNSCC as well as colorectal cancer. However, small molecules as well as anti-
EGFR monoclonal antibodies do not work in patients bearing the mutations in downstream 
proteins such as e.g. KRAS (Soeda et al., 2013).   
2.3.4. Epidermal growth factor/epidermal growth factor receptor signaling in cSCC 
In the literature, there are not many reports showing the importance of EGF ligand in cSCC. 
One study shows that EGF treatment of cSCC cell lines induces EGFR signaling as shown by 
increase in the levels of pEGFR (Galer et al., 2011). However, the authors did not investigate 
the role of the ligand in tumor growth but rather focused on EGFR inhibition. The EGFR is 
indeed an interesting target for cSCC therapy. This is due to the fact that it is overexpressed in 
43% of cSCC, whereby half of them show positivity for the phosphorylated form of the 
receptor (G. B. Fogarty et al., 2007a). This is in contrast to BCC or normal skin. Apparently, 
the number of cSCC showing mutations in the EGFR gene is quite low (3%) (Mauerer et al., 




(Toll et al., 2010). Interestingly, EGFR overexpression might be correlated with disease 
progression as metastatic tumors show stronger staining signal when compared to the primary 
counterparts (Shimizu et al., 2001). Currently, the EGFR monoclonal antibody Cetuximab is 
in phase 2 in clinical trials for cSCC with promising results for patients with tumors that 
overexpress EGFR but lack RAS mutations. Indeed, the RAS mutation rate in cSCC is very 
low (Uribe and Gonzalez, 2011). Out of the three RAS forms in humans i.e. NRAS, KRAS 
and HRAS, the latter one is most frequently mutated in non-melanoma skin cancers (Pierceall 
et al., 1991). Finally, EGFR phosphorylation in cSCC is frequently accompanied by an 
increase in phosphorylated forms of AKT and ERK1/2 (Rittie et al., 2007). However, the 
importance of AKT and/or ERK1/2 for cSCC needs to be validated prior to clinical trials 
applying inhibitors of the respective proteins. 
2.4. Crosstalk between Hedgehog and epidermal growth factor/epidermal growth 
factor receptor signaling in tumors 
Interestingly and as already mentioned in section 2.2.5., several studies identified a cross-talk 
between EGFR and HH signaling. For example, a synergistic effect of both pathways was 
discovered in human keratinocytes and BCC (Schnidar et al., 2009). Thus, simultaneous 
activation of EGFR and HH signaling induced oncogenic transformation of the human 
keratinocyte HaCaT cell line. Furthermore, co-inhibition of EGFR with Gefitinib and GLI 
activity with GANT61 significantly reduced viability and proliferation of murine BCC cell 
lines (Schnidar et al., 2009). On the other hand, simultaneous incubation of the 
medulloblastoma cell line Daoy with HH and EGF inhibited the expression of canonical HH 
signaling target genes i.e. PTCH, GLI1 and HHIP. The mechanism of this inhibition is 
unknown because HH plus EGF resulted in stabilization of GLI1 protein. Concomitantly, the 
authors found an extreme upregulation of typical EGF target genes involved in tumor 
promotion i.e. VEGFA, MMP and IL-8. Together, these data show that the knowledge about 
the interaction of EGF/EGFR and HH signaling in cancer is sparse. In addition, the data 
suggest that the interaction of EGF/EGFR and HH signaling is tumor type-specific and should 
be thoroughly studied for each single tumor entity.  
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3. Aim of the study 
The aim of this thesis was to evaluate the role of canonical and putative noncanonical HH 
signaling in cSCC. For this purpose, GLI1 as well as EGF, PI3K/AKT, MEK/ERK and 
mTOR activity was assessed in human tumor cSCC tissue samples as well as in cSCC cell 
lines.  
To investigate the relevance of canonical and noncanonical HH signaling in vitro, changes in 
GLI1 expression were measured upon treatment of cSCC cells with HH inhibitors (that inhibit 
the HH pathway at the level of SMO), specific inhibitors of PI3K, AKT, mTOR and MEK1/2 
signaling pathways or with EGF and IGF1 ligands. In addition, cells were treated with EGF 
ligand in combination with the specific inhibitors in order to unravel the mechanism of the 
interaction between EGF signaling and its downstream effector pathways in GLI1 regulation. 
Furthermore, the putative influence of the tumor microenvironment on GLI1 expression 
within tumor cells was evaluated.  
Finally, the impact of HH, PI3K/AKT, mTOR and MEK/ERK signaling on metabolic 
activity, proliferation and apoptosis of the cSCC cells was assessed. Moreover, the role of 
GLI1 in proliferation of cSCC cell lines was elucidated by taking advantage of overexpression 














4.1. Technical equipment 
Table 1: Laboratory equipment 
Equipment Supplier 
Accu-jet  Brand GmbH & Co. KG, Wertheim 
Agarose gel electrophoresis chamber Peqlab Biotechnology GmbH, Erlangen 
Arium® 611 VF water purification system Sartorius, Göttingen 
Autoclave (sanoclav) W. Krannich GmbH & Co. KG, Göttingen 
Autoclave (Systec DX-150) Systec GmbH & Co. KG, Linden 
Biophotometer (6131) Eppendorf AG, Hamburg 
Bunsen burner (Gasprofi 2 scs) WLD-TEC GmbH, Göttingen 
Centrifuges (Biofuge pico, fresco, primo, 
Multifuge 3LR) 
Kendro Laboratory Products GmbH, Hanau, 
Germany 
Digital Monochrome Printer P91D Mitsubishi, Ratingen 
Digital Photocamera (PowerShot G2) Canon Deutschland GmbH, Krefeld 
FACS Calibur BD Biosciences GmbH, Heidelberg 
Fluorchem Q Fisher Scientific GmbH, Schwerte 
Freezer (-20°C) Liebherr GmbH, Ochshausen 
Freezer (-80°C) (MDF-U71V) Sanyo Electric Co., Ltd., Japan 
Fridge (4°C) Robert Bosch GmbH, Stuttgart 
Heating block (Thermomixer) Eppendorf AG, Hamburg 
Heating stirrer (MR 3000/3001) Heidolph Instruments, Schwabach 
High-precision scales (Sartorius Basic plus) Sartorius AG, Göttingen 
Hybridization oven (HB-1000 Hybridizer) UVP, Inc., Upland, USA 
Inverted tissue culture fluorescence 
microscope (Axiovert 25) 
Carl Zeiss Jena GmbH, Jena 
Liquid nitrogen tank L’air liquid S.A., Paris, France 
Luminometer (Synergy Mx) BioTek Instruments, Inc., Bad 
Friedrichshall 




Microscope (Olympus BX 60) Olympus Deutschland GmbH, Hamburg 
Microtome (HN 40) New Brunswick Scientific GmbH, 
Nürtingen, Germany 
Microwave (Dimension 4) Panasonic, Hamburg 
Mini centrifuge Carl Roth GmbH & Co. KG, Karlsruhe 
Multipette Eppendorf AG, Hamburg 
Paraffin tissue floating bath Medax GmbH & Co. KG, Rendburg 
pH-meter (inoLab pH Level 1) WTW GmbH, Vienna, Austria 
Pipettes (one-channel) Eppendorf AG, Hamburg 
Power supply for electrophoresis Peqlab Biotechnology GmbH, Erlangen 
Real-Time PCR System (ABI Prism 
7900HT) 
Life Technologies GmbH, Darmstadt 
Sequencer (ABI 3500 XL) Life Technologies GmbH, Darmstadt 
Scale (Sartorius Basic plus) Sartorius AG, Göttingen 
Spectrophotometer (NanoDrop 8000) Thermo Scientific, Wilmington, USA 
Shaker (Unimax 1010) Heidolph Instruments GmbH & Co. KG, 
Schwabach 
Stereo microscope (Stemi 2000) Carl Zeiss Jena GmbH, Jena 
Sterile bench (Euroflow class IIA) Clean Air Techniek bv, Woerden, 
Netherlands 
Thermocycler Eppendorf, Hamburg 
Thermoprinter (DPU-414) Eppendorf AG, Hamburg 
Trans-Blot SD semi-dry transfer cell Bio-Rad Laboratories GmbH, Munich 
UV transilluminator Intas Science Imaging Instruments GmbH, 
Göttingen 
Vacuum pump Schütt Labortechnik, Göttingen, Germany 
Vortexer-Genie 2 Scientific Industries, Inc., Woburn, USA 








Table 2: List of consumable materials 
Consumer good Supplier 
1.5 ml reaction tubes Ochs GmbH, Bovenden/Lenglern 
1.5 ml safeseal microtubes Sarstedt AG & Co., Nürnberg 
2.0 ml reaction tubes Sarstedt AG & Co., Nürnberg 
13 ml falcon tubes Sarstedt AG & Co., Nürnberg 
15 ml falcon tubes Greiner Bio-One GmbH, Frickenhausen 
50 ml falcon tubes Greiner Bio-One GmbH, Frickenhausen 
6-well tissue culture plate Sarstedt AG & Co., Nürnberg 
24-well tissue culture plate  Corning Inc., Corning, USA  
96-well assay plate (transparent) Costar, Corning Incorporated, Corning, 
USA 96-well assay plate (black) Life Technologies GmbH, Darmstadt 
384-well PCR plate (Framestar) 4titude Ltd., Berlin 
BD DiscarditTM II (2, 10, 20 ml) BD Biosciences GmbH, Heidelberg 
BD Microfine + Demi BD Biosciences GmbH, Heidelberg 
BD Plastipak BD Biosciences GmbH, Heidelberg 
BD Plastipak 1 ml Sub-Q BD Biosciences GmbH, Heidelberg 
Blotting paper (GB 33 B003) Heinemann Labortechnik GmbH, 
Duderstadt Cell culture dishes (100 mm) (Nuclon) 
Surface) 
N nc GmbH & Co.KG, Wiesbaden  
Cell culture inserts, 24 well, 0.4 μm  Corning Inc., Corning, USA  
Cell scraper  Sarstedt AG & Co., Nürnberg  
Cell strainers (70 μm)  BD Biosciences GmbH, Heidelberg  
Combitips (0.2, 0.5, 2.5, 5, 10, 25, 50 ml)  Eppendorf AG, Hamburg 
Coverslips  Menzel GmbH & Co.KG, Braunschweig  
CryoPure tubes  Sarstedt AG & Co., Nürnberg 
Cuvettes (UVette) Carl Roth GmbH & Co. KG, Karlsruhe 
Filter tips (10 μl) Sarstedt AG & Co., Nürnberg  




Flow cytometry tube  Sarstedt AG & Co., Nürnberg  
Fluted filters Sartorius AG, Göttingen  
Glassware  Schott AG, Mainz  
Hyperfilm ECL  Amersham Biosciences Europe GmbH, 
Freiburg  Microspin G-50 Columns GE Healthcare Europe GmbH, Freiburg 
Milliporefilter (Nuclepore Track-Etch) 
Membrane) 
Whatman GmbH, Dassel  
iscroscope slides (SuperFrost Plus) Menzel GmbH & Co.KG, Braunschweig  
Neubauer counting chamber  Brand GmbH & Co KG, Wertheim 
Nitrocellulose membrane (Hybond ECL) GE Healthcare Europe GmbH, Freiburg 
NuPAGE Novex 4 – 12% Bis-Tris Midi Gel Invitrogen GmbH, Karlsruhe  
NuPAGE Novex 3-8% Tris-Acetate Midi 
Gel 
Invitrogen GmbH, Karlsruhe  
Nylonmembran: Hybond-XL GE Healthcare Europe GmbH, Freiburg  
Pasteur pipettes Brand GmbH & Co.KG, Wertheim  
Petri dishes  Ochs GmbH, Bovenden/Lenglern  
Pipette tips (10 μl, 200 μl)  Ochs GmbH, Bovenden/Lenglern 
Pipette tips (20 μl, 1000 μl)  Sarstedt AG & Co., Nürnberg  
QPCR Adhesive Clear Seal 4titude Ltd., Berlin 
Scalpel blade #10, #24 Aesculap AG & Co.KG, Tuttlingen  
Serological pipettes (2 ml, 5 ml, 10 ml, 25 
ml, 50 ml)  
Sarstedt AG & Co., Nürnberg  
SOC Medium Invitrogen GmbH, Karlsruhe 
Sterile filter Omnilab-Krannich, Göttingen 
Syringe (30 ml, 50 ml) Terumo Medical Corp., Elkton, MD, USA 
4.3. Reagents and chemicals 
The chemicals or reagents that are not listed below were purchased from AppliChem GmbH, 






Table 3: List of chemicals and reagents 
Chemicals and reagents Supplier 
Acetic acid  Carl Roth GmbH & Co. KG, Karlsruhe  
Acetic acid anhydride Carl Roth GmbH & Co. KG, Karlsruhe  
Agarose Bio-Budget Technologies GmbH, Krefeld 
Ampuwa  Fresenius Kabi Deutschland GmbH, Bad 
Homburg 
AnnexinV-FITC  BD Biosciences GmbH, Heidelberg  
BM Purple substrate Roche Diagnostics GmbH, Mannheim  
Boric acid  MP Biomedicals LLC, Illkirch, France 
Bovine serum albumin (BSA)  Carl Roth GmbH & Co. KG, Karlsruhe  
Chloroform  Carl Roth GmbH & Co. KG, Karlsruhe  
Citric acid  Carl Roth GmbH & Co. KG, Karlsruhe  
DAPI mounting medium Vector Laboratories, Inc., Burlingame, 
CA, USA  
Denhardt’s solution, lyophilised powder (50x) Carl Roth GmbH & Co. KG, Karlsruhe  
Deoxyribonucleotide triphosphate (dNTP)  Roche Diagnostics GmbH, Mannheim  
Diethyl pyrocarbonate (DEPC) Carl Roth GmbH & Co. KG, Karlsruhe  
Dextransulphat Carl Roth GmbH & Co. KG, Karlsruhe  
Dithiothreitol, 100 mM (DTT)  Invitrogen GmbH, Karlsruhe  
DNA ladder (100 bp plus) Fermentas GmbH, St. Leon-Rot 
DNase/RNase-free water  GIBCO Invitrogen GmbH, Karlsruhe 
Eosin Y  Merck KGaA, Darmstadt  
Ethanol (EtOH) 99%  J.T. Baker B.V., Deventer, Netherlands  
Ethanol (EtOH) 99%  denatured CVH Chemie-Vertrieb GmbH & Co. 
Hannover KG, Hannover  
Ethidium bromide (0.07%)  inna-TRAIN-Diagnostics, Kronberg  
Ethylenediaminetetraacetic acid (EDTA) ICN Biochemicals Inc., Aurora, USA  




Formamide Carl Roth GmbH & Co. KG, Karlsruhe 
Glutaraldehyde solution  25% Merck KGaA, Darmstadt  
Glycergel mounting medium Dako GmbH, Hamburg 
Haematoxylin, Mayer’s  Medite GmbH, Burgdorf 
Hydrogen peroxide  Carl Roth GmbH & Co. KG, Karlsruhe  
I-Block  Tropix, Bedford, USA  
Levamisole Merck KGaA, Darmstadt  
Liquid Barrier Marker Carl Roth GmbH & Co. KG, Karlsruhe  
Methanol  Carl Roth GmbH & Co. KG, Karlsruhe  
Milk powder Carl Roth GmbH & Co. KG, Karlsruhe  
NuPAGE MES SDS Running Buffer, 20x  Invitrogen GmbH, Karlsruhe  
NuPAGE Tris-Acetate SDS Running Buffer, 
20x  
Invitrogen GmbH, Karlsruhe  
Orange G Carl Roth GmbH & Co. KG, Karlsruhe  
Paraformaldehyde  Carl Roth GmbH & Co. KG, Karlsruhe  
PBS-Tablets GIBCO Invitrogen GmbH, Karlsruhe 
Pertex mounting medium  Medite Medizintechnik GmbH, Burgdorf  
Phosphatase inhibitor cocktail tablets 
(PhosSTOP)  
Roche Diagnostics GmbH, Mannheim  
Propidium Iodide (PI)  Miltenyi Biotec, Bergisch Gladbach  
Protease inhibitor cocktail tablets (Complete, 
mini)  
Roche Diagnostics GmbH, Mannheim  
Random Hexamer-Oligonucleotides  Invitrogen GmbH, Karlsruhe  
SeeBlue® Plus2 Pre-Stained Standard  Invitrogen GmbH, Karlsruhe 
Triethanolamine Merck KGaA, Darmstadt  
Sodiumdodecylsulfate (SDS)  Carl Roth GmbH & Co. KG, Karlsruhe  
Triton-X100 Merck KGaA, Darmstadt  
TRIzol Reagent Invitrogen GmbH, Karlsruhe 
Tween-20 Scharlau Chemie S.A., Barcelona, Spain  





Xylene  J.T. Baker B.V., Deventer, Netherlands  
Yeast tRNA Merck KGaA, Darmstadt  
4.4. Enzymes 
Table 4: List of enzymes 
Enzyme Supplier 
Apa1 Invitrogen GmbH, Karlsruhe  
BamH1 Invitrogen GmbH, Karlsruhe  
Dispase Corning Inc., NY, USA  
EcoRI Invitrogen GmbH, Karlsruhe  
Hind III Invitrogen GmbH, Karlsruhe  
Kpn1 Invitrogen GmbH, Karlsruhe  
Not1 Invitrogen GmbH, Karlsruhe  
Proteinase K  Carl Roth GmbH & Co. KG, Karlsruhe  
RNase A  Carl Roth GmbH & Co. KG, Karlsruhe  
SuperScriptII Reverse Transcriptase  Invitrogen GmbH, Karlsruhe  
T3-RNA Polymerase Promega GmbH, Mannheim 
T7-RNA Polymerase Promega GmbH, Mannheim 
Thermolysin  Sigma-Aldrich Inc., St. Louis, MO, USA  
Xba1 Invitrogen GmbH, Karlsruhe  
4.5. Kits and Ready-to-use reaction Systems 
If not otherwise stated all kits and ready-to-use reaction systems were used according to the 
manufacturer’s instructions. 
Table 5: List of used kits and ready-to-use reaction systems 
Reaction system Supplier 
Amersham ECL Plus™ Western Blotting 
Detection Reagents 
GE Healthcare Europe GmbH, Freiburg 




BigDye Terminator v3.1 Cycle Sequencing kit Life Technologies GmbH, Darmstadt 
Cell Proliferation ELISA, BrdU 
(chemiluminscent) 
Roche Diagnostics GmbH, Mannheim 
Dako EnVisionTM detection System  Dako Denmark A/S, Glostrup, 
Denmark  
DIG RNA Labeling Mix Roche Diagnostics GmbH, Mannheim 
Dual-Luciferase® Reporter Assay System Promega GmbH, Mannheim 
HiPerFect transfection Reagent Qiagen GmbH, Hilden 
HiPure Plasmid DNA Purification Kit  Invitrogen GmbH, Karlsruhe  
Pierce BCA Protein Assay kit Fisher Scientific GmbH, Schwerte 
Pierce ECL western blot substrate  Fisher Scientific GmbH, Schwerte  
Platinum SYBR Green qPCR SuperMix  Invitrogen GmbH, Karlsruhe  
Platinum SYBR Green qPCR SuperMix-UDG 
with ROX 
Invitrogen GmbH, Karlsruhe, Germany 
PureLink®HiPure Plasmid Midiprep Invitrogen GmbH, Karlsruhe 
Roti-Fect transfection reagent  Carl Roth GmbH & Co. KG, Karlsruhe  
QuantiTect SYBR Green RT-PCR Qiagen GmbH, Hilden 
Taq-Polymerase (MolTaq)  Molzym GmbH & Co. KG, Bremen  
4.6. Buffers and solutions 
If not otherwise stated, all buffers and solutions were prepared using double distilled water 
(ddH2O). 
Table 6: List of buffers and solutions 
Buffer Composition 
AEC chromogen, pH 5.2  
 
70 mM Sodium acetate trihydrate  
30 mM Acetic acid  
16 mM 3-Amino-9 Ethylcarbazole  
in dimethylformamide 
 
Blotting buffer 20% (v/v) Methanol  
6% (w/v) Tris  




0,0375% (v/v) SDS  
 
Boric acid, pH 5.1 0.2 M Boric acid 
BSA/sodium azide solution 0.02% Sodium azide  
2% BSA  
in PBST  
 
Buffer 1 100 mM Tris/HCl pH 7.5 
150 mM NaCl 
Buffer 2 100 mM Tris/HCl pH 9.5 
100 mM NaCl 
50 mM MgCl2 
Buffer 3  10 mM Tris/HCl pH 8 
1 mM EDTA  
Casein (0.2%) 0.2% (w/v) I-Block 
0.1% (v/v) Tween 20 
in PBS 
Citric acid buffer, pH 3.0  10 mM Sodium Citrate  
Citric acid buffer, pH 6.0  10 mM Sodium Citrate  
Cresol 0.1% (w/v) Cresol  
in saturated sucrose-solution 
DEPC H2O 0.1% DEPC in ddH2O 
dNTP-Mix  
 
10 mM dATP  
10 mM dCTP  
10 mM dGTP  
10 mM dTTP  
 
EDTA, pH 8.0 0.5 M EDTA in DEPC-ddH2O 
Eosin solution  80% (v/v) EtOH  
1% (w/v) Eosin y (water soluble)  
 
Formamide/2x SSC 50% formamide, 2x SSC 
Haematoxylin solution, Mayer’s  
 
5% (w/v) Potassium aluminum sulfate  
5% (w/v) Trichloro acetaldehyde hydrate  
1% (w/v) Citric acid  




0.015% (w/v) Sodium iodate  
 
Hybridization Buffer with tRNA (Hyb M) 10% dextrane sulfate 
50% formamide 
0.3 M NaCl 
20 mM Tris/HCl pH 8,0 
5 mM EDTA 
10 mM „NaPO4“* 
1 x Denhardts solution 
0.5 mg/ml tRNA 
In RNase-free H2O 
Lysogeny broth medium (LB medium) 1% (w/v) bacto-tryptone 
0.5% (w/v) yeast extract 
1% (w/v) NaCl (pH7.0) 
Lysogeny broth medium (LB-agar) LB-medium 
1.5% (w/v) agar 
Magnesium chloride (MgCl2) - DEPC 1 M in DEPC-H2O 
MBSTL Buffer pH 7.5 100 mM maleic acid 
150 mM NaCl 
5.7 M NaOH 
0.1% Tween-20 
2 mM Levamisol 
Modified RIPA buffer 50 nM Tris/HCl pH 7.4  
1% NP-40 0.25% Na-Deoxycholat  
150 mM NaCl  
1 mM EDTA  
1 protease inhibitor cocktail tablet per 
10ml  
1 PhosSTOP tablet per 10ml 
NT Buffer 0.15 M NaCl 
0.1 M Tris pH 7.5 
NTMLT Buffer 100 mM NaCl 




50 mM MgCl2 
2 mM Levamisol 
0.1% Tween-20 
Paraformaldehyde 4% (w/v) paraformaldehyde 
In PBS 
PBS (cell culture) 1 PBS tablet in 500 ml ddH2O 
PBS-Tween 20 (PBST)  0.1% Tween-20 in PBS  
PFA/glutaraldehyde 0.2% glutaraldehyde in 4% PFA 
Phosphate buffered saline solution, 
10 x, pH 7,4 (PBS, stock solution) 
1.4 M NaCl 
27 mM KCl 
15 mM KH2PO4 
65 mM Na2HPO4 
Proteinase K, pH 8.0  
 
50 mM Tris/HCl  
5 mM EDTA  
10 mg/ml Proteinase K  
 
Saline, 20 x 2.85 M NaCl in DEPC-H2O 
SSC 20 x, pH 6.4 3 M NaCl, 0.3 M Trisodium Citrate 
Dihydrate in DEPC-H2O 
SDS loading buffer, 6 x 35% (v/v) Glycerol 
9% (w/v) SDS 
8.5% (w/v) DTT 
0.1% (w/v) Bromphenolblue 
in Upper gel buffer 
Sodium chloride (NaCl) - DEPC 5 M in DEPC-H2O 
STE Buffer 0.5 M NaCl 
10 mM Tris pH 8 
5 mM EDTA pH 8 
STOP Buffer 1% SDS  
0.1 M Tris pH 8 
10 mM EDTA pH 8 
0.5% Orange G 





100 mM ß-Mercaptoethanol 
Triethanolamin 0.8 M in ddH2O 
Tris pH 7.5; pH 8.0; pH 9.5 1 M Tris in DEPC H2O 
Tris-EDTA buffer pH 9.0; pH 8.0 (TE) 10 mM Tris  
1 mM EDTA 
Tris-boric acid-EDTA solution, 
10 x (TBE) 
890 mM tris/HCl pH 8.0 
730 mM boric acid 
12.5 mM EDTA 
Tris-buffered saline solution, 10 x 
(TBS) 
0.5 M tris/HCl pH 7.4 
1.5 M NaCl 
TBS-Triton X-100 0.1% Triton X-100 in TBS  
TBS-Tween 20  0.1% (v/v) Tween-20 in TBS 
*NaH2PO4 and Na2HPO4 were prepared at 0.5 M concentration, pH 8.0 and mixed as follows: 
6,7 ml NaH2PO4 + 93,3 ml Na2HPO4 to prepare 10 mM „NaPO4“ solution. 
4.7. Media 
4.7.1. Media for culture of prokaryotic cells. 
For cultivation of bacterial cells LB and LB-agar media were prepared as listed in Table 6. 
After autoclaving and cooling down, Ampicillin or Kanamycin were added at a concentration 
of 100 µg/ml or 50 µg/ml, respectively. Both, LB-agar plates and liquid LB medium were 
stored at 4°C. 
4.7.2. Media and reagents for culture of eukaryotic cell. 
Table 7: List of cell culture media and reagents 
Medium or reagent Supplier 
Accutase PAA Laboratories GmbH, Pasching 
Amphotericin B  Sigma-Aldrich Inc., St. Louis, MO, 
USA  
Dulbecco’s Modified Eagle Medium (DMEM) Gibco, Invitrogen GmbH, Karlsruhe 




Fetal calf serum (FCS) Gibco, Invitrogen GmbH, Karlsruhe 
G 418 disulfate salt solution (50 mg/ml) Sigma-Aldrich Chemistry GmbH, 
Steinheim 
Gelatin Sigma-Aldrich Chemistry GmbH, 
Steinheim 
Hank’s balanced salt solution (HBSS) without 
Ca2+ and Mg2+ 
Gibco, Invitrogen GmbH, Karlsruhe 
Human keratinocyte growth supplement 
(HKGS)  
Gibco, Invitrogen GmbH, Karlsruhe  
L-Glutamine PAN Biotech GmbH, Aidenbach 
Minimum essential medium, Non-essential 
Amino Acids (MEM NEAA) 
Gibco, Invitrogen GmbH, Karlsruhe 
Mitomycin C Sigma-Aldrich Chemistry GmbH, 
Steinheim 
Penicillin (10.000 U/ml)/Streptomycin (10 
mg/ml) (P/S) 
PAN Biotech GmbH, Aidenbach 
RPMI 1640 (RPMI) Gibco, Invitrogen GmbH, Karlsruhe 
TrypLE Express Gibco, Invitrogen GmbH, Karlsruhe 
Trypsin-EDTA (0.05%, 0.25%) Gibco, Invitrogen GmbH, Karlsruhe 
4.8. Biological material 
4.8.1. Bacterial strains 
For the transformation protocol, the competent Escherichia coli (E. coli) strain DH5α was 
used. 
4.8.2. Eukaryotic cell lines and primary cells 







Table 8: List of eukaryotic cells with corresponding media and supplements 
Cell line Description Medium Supplements Reference 
A-431 Epidermoid 
carcinoma cell line 




B9 Murine adult 
fibroblasts cell line 




HaCaT Human keratinocyte 
cell line 




HaCaT-ras II-4 HaCaT cells 








HEK293 Human embryonic 
kidney cell line 






HEK293-Shh HEK293 cells 
secreting Shh-N 
DMEM (+++) 10% FCS, 1% 
P/S 
(J. K. Chen 
et al., 
2002b) 
MCF-7 Breast cancer cell 
line 
DMEM (+++) 10% FCS, 1% 
P/S 
(Soule et al., 
1973) 
MET-1 Human cSCC cell 
line, primary tumor 
DMEM (+++) 10% FCS, 1% 
P/S 
(Popp et al., 
2000) 
MET-4 Human cSCC cell 
line, metastasis 
DMEM (+++) 10% FCS, 1% 
P/S 
(Popp et al., 
2000) 
MEFs Mouse embryonic 
fibroblasts (E12.5) 
DMEM (+++) 10% FCS, 1% 
P/S 
- 
NIH/3T3 Adult murine 
fibroblast cell line 


















- DMEM (+++) 
+ F-12 Nutrient 
Mix (3:1) 
10% FCS, 1% 
P/S, 1% 
Amphotericin 
B, 1% HKGS 
- 
SCC-12 Human cSCC cell 
line 





SCC-13 Human cSCC cell 
line 
RPMI 10% FCS, 1% 






SCL-I Human cSCC cell 
line 
RPMI 10% FCS, 1% 





SCL-II Human cSCC cell 
line 
RPMI 10% FCS, 1% 





4.8.3. Mouse lines 
C57BL/6N inbred mice were bred in house and used for MEFs isolation. All the experiments 
were done in compliance with ethical and legal regulations. 
4.8.4. Patient samples 
Patient skin samples were obtained from the breast reduction surgery performed in the 
Evangelical Hospital Goettingen-Weende in the Plastic, Aesthetic and Reconstructive Surgery 
Department. All experiments were done in compliance with ethical and legal regulations 




4.9. Synthetic oligonucleotides  
4.9.1. Synthetic DNA-oligonucleotides 
All synthetic DNA-oligonucleotides were purchased from Eurofins MWG Operon. 100 µM 
stock and 10 µM working solutions were prepared with ddH2O and stored for a long term at  
-80˚C or for a short term at -20 ˚C. 
Table 9: List of synthetic DNA-oligonucleotides used for qPCR 
Transcript Primer name Primer sequence (5’-3’) Control 
cDNA 




























hGLI1 hsaGLI1 tq F 
































































Table 10: List of synthetic DNA-oligonucleotides used for sequencing PCR 







4.9.2. Preparation of riboprobes 
Riboprobes were synthesized in RNase-free conditions. All probes were diluted in 50% 
formamide/RNase-free H2O, aliquoted and stored at -80˚C. 
For hGLI1 mRNA detection, 2 different riboprobes were designed, one recognizing 5’ end 
(hGLI1 5’) and the other one detecting 3´end (hGLI1 3’) of hGLI1 mRNA to increase the 
efficiency. Both probes were used in combination. 
Table 11: List of synthetic RNA-oligonucleotides (riboprobes) used for ISH 
Gene Plasmid template Probe orientation Polymerase Dilution 
hGLI1 5’ pBS-hGli1 5' (#26) Sense T7 1:500 
Anti-sense T3 1:500 
hGLI1 3’ pBS-hGli1 3' (#27) Sense T7 1:500 









siRNAs used in this study are listed in Table 12. 
Table 12: List of siRNA 













The plasmids listed below were used for the chemical transfection of eukaryotic cell lines. 
Table 13: Plasmids used for transfection of eukaryotic cells 
Plasmid name Application Reference or supplier 
9xGli BS Gli reporter assay (plasmid contains 
firefly luciferase under control of 
Gli1 responsive elements) 
(Beer et al., 2003) 
HA-Akt-DN (K179M) blocking the function of endogenous 
AKT 
(B. P. Zhou et al., 
2000a), Addgene 
(plasmid # 16243) 
myrAkt delta4-129 overexpression of AKT (Kohn et al., 1996; H. 
Zhou et al., 2000b), 
Addgene (plasmid # 
10841) 





overexpression of constitutively 
active mTOR 
(Sato et al., 2010), 








overexpression of rapamycin 
resistant mTOR 
(Vilella-Bach et al., 
1999), Addgene 
(plasmid # 26605) 
pcDNA3-Flag mTOR 
wt  
overexpression of WT mTOR (Vilella-Bach et al., 
1999), Addgene 
(plasmid # 26603) 
pcDNA4/TO control plasmid for GLI1 
overexpression 
Qiagen Inc., Valencia, 
CA, gift from Prof. Fritz 
Aberger 
pcDNA4NLSMT-Gli1 overexpression of human GLI1 gift from Prof. Fritz 
Aberger 




pCR 3.1-mGli1 positive control for Gli reporter 
assay 
(Fritsch, 2014) 
pEGFP-N1 transfection efficiency control BD Bioscience 
Clontech, 
Heidelberg  
pGL-TK Gli reporter assay, positive control 
(plasmid contains firefly luciferase 
under constitutively active promoter)  
Promega GmbH, 
Mannheim 
pRL-CMV Gli reporter assay, internal control 
(plasmid contains Renilla luciferase 
under constitutively active promoter) 
Promega GmbH, 
Mannheim 
pRK7-hSMO-WT overexpression of WT SMO Gift from Prof. Rune 
Toftgard 
pRK7-SMO-M2 overexpression of constitutively 
active SMO variant 







4.12. Synthetic inhibitors and agonists 
Table 14: List of inhibitors and agonists used in cell culture system 
Inhibitor Solvent Concentration Supplier 
Cyclopamine EtOH 1-10 µM Sigma-Aldrich, Steinheim 
EGF 0.1% BSA/10 mM 
acetic acid 
100 ng/ml R&D Systems, Inc., 
Minneapolis, MN, USA  
Everolimus EtOH 50 nM Sigma-Aldrich, Steinheim 











10 µM Genentech, San 





10-60 µM Genentech, San 
Francisco, USA  
MK-2206  DMSO  5 µM Selleckchem, Munich  
PI103  DMSO  3-6 µM Axxora Deutschland 
GmbH, Lörrach  
Rapamycin  
 
DMSO 100 nM Calbiochem, Merck 
KGaA, Darmstadt  
Recombinant 
human IGF protein 
PBS 50 ng/ml R&D Systems, Inc., 
Minneapolis, MN, USA  
SAG (SMO 
agonist)  
DMSO 10 nM – 1 µM Cayman chemicals, Ann 
Arbor USA  
UO126 DMSO 20 µM Cell signaling, Danvers, 
MA, USA 
4.13. Antibodies 
Table 15: List of neutralizing antibodies used in cell culture experiments 
Antibody Dilution Supplier 
Human EGFR, clone LA1 10 µg/ml Merck Millipore 




Table 16:  List of primary antibodies used for IHC 





Sheep 1:5000 - Roche 11 093 
274 910 
pAKT (Ser473)  Rabbit, 
monoclonal 
1:50 Citric acid, pH 
6.0 
Cell Signaling  
#4060 
p44/42 MAPK (Erk1/2) Rabbit, 
monoclonal 








1:200 Citric acid, pH 
6.0 
Cell Signaling  
 
GLI2  Rabbit, 
polyclonal 










Human EGF Mouse, 
monoclonal 
1:40 Boric acid R&D System 
*This Fab fragments from polyclonal anti-digoxigenin antibodies, conjugated to alkaline 
phosphatase, was used in ISH to detect digoxigenin-labelled RNA 
 
Table 17: List of primary antibodies used for Western Blot 
Target protein Host Dilution Supplier 
AKT Mouse, monoclonal 1:1000 BD Bioscience, 610861 
Flag M2 Mouse, monoclonal 1:1000 Sigma Aldrich Chemistry 
GmbH, Steinheim 
HA tag Rat, monoclonal 1:500 Sigma Aldrich Chemistry 
GmbH, Steinheim 
HSC70 Mouse, monoclonal 1:5000 Santa Cruz, sc-7298 
MAP Kinase (ERK1, 
ERK2) 
Rabbit, polyclonal 1:1000 Sigma Aldrich Chemistry 
GmbH, Steinheim 






Rabbit, polyclonal 1:1000 New England Biolabs 
GmbH, Frankfurt am 
Main 
pS6 (Ser240/244) Rabbit, polyclonal 1:1000 Cell Signaling 
S6  Mouse, monoclonal 1:1000 Cell Signaling, 54D2 
 
Table 18: List of secondary antibodies for IHC and Western Blot 
Antibody Host Dilution Supplier 
Anti-Mouse/HRP Sheep, polyclonal 1:5000 GE Healthcare, NA931 
Anti-Rabbit/HRP Goat, polyclonal 1:5000 Sigma-Aldrich, A0545 
Anti-Rat/HRP Goat, polyclonal 1:400 Dianova 
Dako Envision/HRP 
(anti-mouse/rabbit) 
- 1:1 in TBS Dako 
4.14. Software 
Table 19: Software used for data analysis 
Name Developer 
AlphaView Q SA 3.2.2 Cell Bioscience, California, USA 
CellSens Dimension Olympus GmbH, Hamburg 
Endnote X5 Thomson ISI ResearchSoft, California, USA 
FlowJo Tree Star Inc., Oregon, USA 
GraphPad Prism 6 GraphPad Software, Inc., La Jolla, CA, USA 
Gen5 1.11 BioTek Instruments, Inc., Bad Friedrichshall 
Microsoft Office Microsoft Co., Redmont, USA 









Table 20: Databases 
Database Webpage 





National Center for Biotechnology 
Information 
http://www.ncbi.nlm.nih.gov/ 
Reverse complement http://www.bioinformatics.org/sms/rev_comp.html 





5.1. Molecular biology methods 
5.1.1.  RNA isolation 
Total RNA was isolated from cultured eukaryotic cells using TRIzol reagent according to the 
manufacturer’s instructions. If not otherwise stated the entire procedure was performed on ice 
to maintain RNA integrity and avoid its degradation. Briefly, cells were washed once with 
PBS and 1 ml of TRIzol was added to the cells. Cell suspension was transferred to RNase-free 
2.0 ml reaction tubes and vortexed for 2 min at the highest speed. After 5 min of incubation at 
room temperature (RT) 200 µl of chloroform was added to each sample and vortexed for 15 
sec. To separate less dense aqueous phase containing RNA from heavier organic phase 
samples were incubated at RT for 3 min and then centrifuged for 10 min at 4°C with the speed 
of 13.000 rpm. Afterwards, the upper aqueous phase (~450-500 µl) was transferred into new 
RNase-free 1.5 ml reaction tube and gently mixed with equal amount of ice-cold 100% 
isopropanol by inverting. Remaining organic and protein phases were discarded. Precipitation 
of RNA was performed overnight (O/N) at -20°C and accomplished by centrifugation (10 
min, 13.000rpm, 4°C). Obtained RNA pellets were washed twice with 1 ml of ice-cold 70% 
ethanol (EtOH), each round followed by centrifugation (15 min, 13.000 rpm, 4°C). Finally, 
RNA was dried at 56°C for 2-5 min, resuspended in desired amount of DNase/RNase-free 
water (10-30 µl) and stored at -80°C. 
5.1.2. Photometric quantification of nucleic acids 
DNA and RNA concentration was assessed using spectrophotometer (NanoDrop 8000). 1 µl 
of undiluted sample was loaded into the instrument and optical density at 260 nm (OD260) and 
280 nm (OD280) was measured to determine nucleic acid concentration and sample purity, 
respectively. Since OD260 equal to 1.0 corresponds to 50 µg/ml of pure DNA and 40 µg/ml of 
RNA, the final concentration was calculated according to the formula below: 
 
Concentration (µg/ml) = OD260 x 50 (for DNA) or x 40 (for RNA). 
 
Additionally, OD280 was measured to determine protein content in the sample and the ratio 




nucleic acids. All samples with OD260/OD280 ~1.8 (for DNA) and ~2.0 (for RNA) were 
considered as pure. 
5.1.3. Reverse transcription (cDNA synthesis) 
cDNA was reverse-transcribed from 2 µg of RNA diluted with RNase/DNase-free water to 
the volume of 7 µl. Each RNA sample was incubated with 250 ng of random hexamers for 10 
min at 70°C to allow binding of complementary sequences. Subsequently, 0.5 mM 
deoxynucleotides (dNTPs) and 10 mM dithiothreitol (DTT) in 1st strand buffer were added to 
reaction tubes and incubated at RT for 10 min. Reverse transcription was performed using 
100U of SuperScript II reverse transcriptase for 1 h at 42°C in the final reaction volume of 20 
µl. Finally, the enzyme was inactivated by the incubation at 70°C for 10 min and obtained 
single stranded cDNA was stored at -20°C. Based on the common assumption that the 
reaction efficiency is ~50% the concentration of synthesized cDNA was ~50 ng/µl. 
5.1.4. Quantitative polymerase chain reaction (qPCR) 
Quantity of target gene expression was assessed using the fluorescently labeled, double-strand 
DNA intercalating dye SYBR Green. The reaction was performed in a volume of 10 µl using 
the components listed below: 
 
SYBR Green (Qiagen or Invitrogen)  4 µl 
Forward primer    0.4 µM (in 0.4 µl ddH2O) 
Reverse primer    0.4 µM (in 0.4 µl ddH2O) 
ddH2O      3.2 µl 
cDNA template    50 ng (0.35 pg for 18S) 
 
Each PCR reaction was performed in 40 cycles, each composed of 3 or 2 major steps 








Table 21: Thermal profile of qPCR reaction 
 SYBR Green (Qiagen) SYBR Green (Invitrogen) 
Denaturation 95°C; 15 sec 95°C; 15 sec 
Annealing of specific primers 60°C; 30 sec 
72°C; 1 min 
Elongation of the product 72°C; 30 sec 
 
The specific primers used to amplify target genes are listed in the Table 9. At the end of every 
reaction a melting curve was generated to assess the specificity of the product.  
 
Quantity of the gene expression was calculated using the standard curve method. Thus, cDNA 
from cell line or tissue known to express the gene of interest served to prepare serial 5-fold 
dilutions starting from a concentration of 10 ng/µl for all transcripts and also for the 
housekeeper HPRT. For the 18S housekeeping gene the first concentration equaled 35 pg/µl. 
Based on the logarithm of the cDNA amount plotted against the cycle threshold values for 
each dilution, a trendline with corresponding formula (y=mx+b) was established and served to 
interpolate the cDNA content in each sample. The final transcript expression was normalized 
to 18S and HPRT. All qPCR assays were performed in 3 biological replicates, each based on 3 
technical replicates. Obtained data were analyzed using SDS 2.2.1, Microsoft Excel 2010 and 
GraphPad Prism 6. 
5.1.5. Sequencing PCR 
DNA nucleotide sequence was determined by the Sanger sequencing method. The reaction 
was based on Big Dye 3.1 (BD) and the corresponding BigDye buffer. The primers used for 
sequencing PCR are listed in Table 10. 
The reaction reagents were as follow: 
 
BigDye 3.1  1 x 
BigDye Buffer 1 x 
Primer   100 pmol  
ddH2O   up to 10 µl 





The reaction was performed in 30 cycles in ABI3500XL sequencing device. The thermal 
profile for each reaction was as follows: 
 
95°C   1 min 
95°C  30 sec 
60°C   2.5 min 
60°C  5 min 
8°C  ∞ 
Obtained electropherograms and the nucleotide sequences were analyzed manually. 
5.1.6. E.coli transformation 
For transformation with plasmid DNA (pDNA), the competent DH5α E.coli that were stored 
in 50 µl aliquots at -80°C, were thawed on ice and gently mixed with 100 ng of pDNA. This 
mixture was incubated on ice for 20 min and subsequently subjected to a heat shock at 42°C 
for 45 sec. Afterwards bacteria were cooled down on ice for 2 min, mixed with 500 µl of 
super optimal broth with catabolite repression (S.O.C.) medium and incubated at 37°C for 1 h 
with 900 rpm shaking. In the end, 50 µl of the mixture containing transformed bacteria were 
plated on lysogeny broth (LB) agar plates containing the desired antibiotics (Ampicillin or 
Kanamycin) and incubated O/N upside down in a 37°C incubator. Single colonies were 
subsequently used for pDNA amplification and isolation. 
5.1.7. Plasmid DNA amplification, isolation and purification 
Single bacterial colonies transformed with desired plasmids were incubated O/N in 100 ml of 
LB medium with desired antibiotics in the concentration of 100 µg/ml or 50 µg/ml Ampicillin 
or Kanamycin. Plasmid purification (medium-scale) was performed using 
PureLink®HiPurePlasmid Midiprep according to the manufacturer’s instruction. Briefly, the 
O/N culture was transferred into 50 ml falcon tubes and centrifuged at 10,000 rpm, 4°C for 10 
min. The supernatant was discarded and the cell pellet was resuspended in 4 ml of ice cold 
Resuspension Buffer (R3) using a plastic transfer pipette. To lyse the cells, 4 ml of Lysis 
Buffer (L7) was added and mixed gently by inverting. Next, the suspension was again 
centrifuged with the same settings to discard cell debris. In the meantime, HiPure Midi 





of the columns to bind pDNA. Afterwards, the supernatant from the second centrifugation 
was applied to the equilibrated column and was drained by gravity flow. pDNA bound to the 
resin columns was then washed with 20 ml of Washing Buffer (W8) and finally eluted into 15 
ml falcon tubes with 5 ml of 37°C pre-warmed Elution Buffer (E4). Obtained pDNA solution 
was then mixed with 3.5 ml of ice cold 100% isopropanol by inverting and incubated O/N at -
20°C to allow precipitation. The next day, pDNA was pelleted by 30 min centrifugation at 
4°C, 13,000 rpm and subsequently washed twice with 70% ethanol followed by centrifugation 
under the same conditions. Finally, DNA pellets were dried at 56°C for 2-3 min, resuspended 
in 100 µl of RNase/DNase-free water at thermomixer for 10 min and stored at -20°C. 
5.1.8. Restriction enzyme hydrolysis 
Diagnostic restriction hydrolysis was performed to verify plasmid size and insert orientation. 
In all settings two restriction enzymes known to cut the plasmid backbone at two sites but not 
the insert were chosen. For each reaction, buffers with different salt concentration were used 
according to the manufacturer’s recommendation. The general reaction mixture was as 
follows: 
Buffer  1 x 
pDNA  0.5 µg 
enzyme 0.1 U 
ddH2O  up to 20 µl 
Hydrolysis was performed for 1 h at 37°C and afterwards the enzymes were heat-inactivated 
by incubation at 70°C for 10 min. Digested DNA fragments were separated and analyzed by 
agarose gel electrophoresis. All restriction enzymes (listed in Table 4) and corresponding 
buffers were purchased from Invitrogen or NEB. 
5.1.9. Gel electrophoresis 
DNA size was determined by separation in the agarose gels in a constant electric field of 
120V. Agarose concentration differed within the range of 0.5%-2% depending on the 
expected DNA size. All gels were prepared by boiling an appropriate amount of agarose 
diluted in 1 x TBE buffer in a microwave. 1-2 drops of 0.07% ethidium bromide were used as 




5.1.10. Generation of digoxigenin-labeled riboprobes 
5.1.10.1. Amplification and digoxigenin labelling of the RNA probes 
For the amplification of human riboprobes the plasmid containing the sequence of interest 
was linearized by restriction hydrolysis for 2 h at 37°C. The reaction components were as 
follows: 
Plasmid  10 µg 
Buffer (10 x)  1 x 
Enzyme  30-45 U 
RNase-free ddH2O up to 50 µl 
The linearized pDNA was precipitated with 300 µl of 100% EtOH at -20°C. The next day 
pDNA was pelleted by 30 min centrifugation at 13,000 rpm, 4°C and washed with 70% EtOH 
as described above (section 5.1.7.). The pellet was resuspended in 20 µl of RNase-free H2O. 1 
µl of undiluted linearized pDNA as well as 1 µl of a 1:5 dilution were loaded on the agarose 
gel and subjected to gel electrophoresis.  
The labelling and the amplification of the probes were performed using T7 or T3 polymerase 
for amplification of sense and antisense probe, respectively, in the presence of DIG RNA 
labelling mix containing DIG-11-UTP. The reaction mix was as follows: 
Linearized plasmid   1 µg 
DIG RNA labelling mix (10 x) 2 µl 
Transcription buffer (5 x)  4 µl 
DTT (100 mM)   2 µl 
RNA polymerase (T7/SP6) 20 U/µl 1 µl 
Rnase-free H2O   up to 20 µl 
The reaction was performed for 90 min at 30oC. Afterwards DNase was added to clear the 
product from DNA: 
DNase Buffer (10 x)  4 µl 
RQ1-DNase   2 µl (1U/1 µl) 




After 8 min of incubation at 37°C, the reaction was stopped with 10 µl of Stop-Buffer 
containing 0.5% Orange G. 
To further purify the product, the probes were loaded on Sephadex columns placed in 1.5 ml 
reaction tubes and centrifuged for 2 min at 3,000 rpm. This step was repeated until the eluate 
containing the RNA probes was colorless. 1 µl of undiluted probe was loaded on an agarose 
gel along with linearized plasmids and another 2 µl of undiluted probes were used for Dot-
Blot (see next section). Finally, stock solutions of the probes were prepared by diluting them 
in total volume of 200 µl RNase-free H2O/50% formamide then aliquoted and stored at -80°C. 
Working solutions were prepared always freshly and were assessed for each probe separately 
based on the Dot-Blot results (see the section below). 
5.1.10.2. Assessment of labeling efficiency – Dot-blot 
To assess the efficiency of digoxigenin labeling the serial dilutions of the probes (S1-S6) were 
prepared in 6x SSC and loaded on a Nylon Membrane. The RNA was fixed on the membrane 
by short exposure to UV light at 125 mJ. Next, the membrane was blocked with 4% 
BSA/Buffer 1 warmed up to 55°C (see Table 6) for 5 min on a shaker. Then it was shortly 
washed in Buffer 1. Anti-Digoxigenin AP-conjugated antibody was diluted 1:5000 in Buffer 1 
and applied to the membrane for 7 min. Unbound antibodies were washed away by incubation 
with Buffer 1, 3 times for 2 min and then for 3 min in Buffer 2. The colorimetric reaction was 
accomplished by adding BM Purple substrate. The reaction was stopped after 10-20 min by 
incubation in Buffer 3 and then in ddH2O. The intensity of the staining resembled the labeling 
efficiency for each probe. 
5.1.11. Protein isolation from cultured cells 
To isolate proteins from cultured cells, cells were scraped off from the culture plate using a 
disposable cell scraper. The plate was additionally washed with 2 ml of PBS and the cell 
suspension was transferred into 15 ml falcon tubes. Cells were then collected by 
centrifugation at 4°C, 2,000 rpm for 5 min and subsequently washed with 500 µl PBS 
followed by a second round of centrifugation under the same conditions. Subsequently, the 
supernatant was discarded while cell pellets were snap-frozen in liquid nitrogen. After 




the final step, lysed cells were centrifuged at 13,000 rpm, 4°C for 30 min and the supernatant 
containing soluble proteins was transferred into new reaction tube and stored at -80°C. 
5.1.12. Photometric quantification of proteins (BCA assay) 
Protein concentration was measured using Pierce BCA protein kit according to the 
manufacturer’s instruction. Briefly 1 µl of each protein sample was pipetted into a transparent 
96-well plate in triplicates. Serial dilutions of BSA at known concentration served to build a 
standard curve. 200 µl of substrate was added to each well and the plate was incubated for 30 
min at 37°C. Based on the absorbance at 540 nm measured with Synergy Mx Luminometer 
the final protein content was calculated using Microsoft Excel 2010.  
5.1.13. Western Blot 
Prior to Western Blot 30-60 µg of proteins were diluted in a final volume of 24 µl, mixed with 
SDS-containing loading buffer and denatured by incubation at 95°C for 5 min with shaking at 
the speed of 450 rpm. The denatured proteins and SeeBlue Plus2 Prestained Standard were 
loaded on Nu PAGE Novex 4-12% Bis-Tris Protein Gels or Tris-Acetate for separation of 
bigger proteins. The proteins were separated according to the size in 1 x NuPAGE MES SDS 
or Tris-Acetate SDS Running buffer in the electric field of 160 mA, 160 V, 100 W for 2 h. 
Afterwards, the proteins were transferred to a nitrocellulose membrane by semi-dry blotting at 
120 mA, 20 V, 100 W for 1 h 30 min in Blotting Buffer (Table 6). Bigger proteins separated 
in Tris-Acetate gel and corresponding buffer were subjected to a wet-blot. The blotting 
chamber was filled with Blotting Buffer and the proteins were transferred to a membrane in 
the electric field of 100 V, 500 mA, 100 W for 2 h 30 min in the cold room. The scheme of 
“Blotting Sandwich” is presented below: 
 
 
After all proteins were transferred to the membrane, the unspecific binding was blocked with 
5% milk in PBST for 1 h at RT. Afterwards the membrane was washed 3 x 10 min with PBST 
and incubated O/N with primary antibody (Table 17) diluted in BSA-azide/PBST solution at 
2x Whatman Paper 






4°C. The next day, the unbound antibodies were washed away by 3 x 10 min incubation in 
PBST on the shaker at RT and the HRP-conjugated secondary antibody (Table 18) diluted in 
5% milk in PBST was applied to the membrane for 1 h at RT. During the last 3 washing steps 
the signal detection substrate was prepared by mixing Substrate A with Substrate B from the 
ECL Detection Reagents System in a 1:1 ratio. After 3 min, the excess of the substrate was 
removed and the signal was detected with the Fluorchem Q Imaging System and analyzed 
with AlphaView Q SA 3.2.2. 
5.1.14. Membrane stripping 
To strip off bound proteins from the Nylon membrane used for Western Blotting, the 
membrane was incubated with Stripping Buffer (Table 6) for 30 min at 55°C. Afterwards the 
membrane was washed and blocked as described above and incubated with another primary 
antibody.  
5.2. Cell biology methods 
5.2.1. Culture of adherent cells 
All cell lines as well as primary cultured cells were maintained in the incubator with a stable 
temperature of 37°C, 5% CO2 and 95% humidity. Depending on the cell type different culture 
media were used as listed in Table 8. Cells were washed every second or third day with 1 x 
PBS under sterile conditions. 
5.2.2. Passaging of adherent eukaryotic cell lines  
Cells grown up to 80-90% confluency were washed with 1 x PBS and subsequently detached 
from the culture plate using 1-3 ml of TrypLe Express. After incubation for 2-10 min at 37°C, 
the enzymatic activity was stopped by adding an equal amount of serum-containing medium. 
Detached cells were collected in 15 ml or 50 ml falcon tubes and the culture plates were 
additionally washed with ~4 ml of 1 x PBS to remove all remaining cells. Cell suspension was 
then centrifuged at 300 xg, 4°C for 5 min and the pellets were resuspended in fresh culture 
medium. Finally, cells were counted in Neumeyer chamber and seeded in desired number and 





5.2.3. Cryopreservation of eukaryotic cells 
For cryopreservation, the cells were typically grown in 2-3 10 cm culture dishes until they 
reached ~90% confluency. Next, they were subjected to the same procedure as described 
above in the section ‘passaging of adherent eukaryotic cells’. In the final step cell pellets were 
resuspended in fresh culture medium containing 1% DMSO as cryoprotectant. 1 ml aliquots 
were gradually frozen by incubation at -20°C for 2 h, at -80°C O/N and were then transferred 
into liquid nitrogen for long term storage. 
To restore cells, they were thawed in a 37°C water bath and immediately transferred to a 15 
ml falcon containing 9 ml of culture medium. Afterwards cells were pelleted, resuspended in 
fresh culture medium and seeded in 10 cm culture plate. The next day cells were washed with 
1 x PBS to remove remaining DMSO and dead cells. 
5.2.4. Generation of Shh-N conditioned medium 
For a generation of Shh-N and respective control medium, stably transfected HEK293-Shh 
and non-transfected HEK293 cells were incubated in a serum-depleted medium (DMEM 
supplemented with 2% FCS and 1% P/S) to stimulate the release of soluble N-Shh to the 
medium. After 24 h the medium was collected and filtered through a 0.2 µm pore size 
disposable filters to remove any remaining cells. The medium could be stored at 4°C for up to 
4 months and was tested prior use on Shh-responsive B9 cells. 
5.2.5. Feeder layer preparation 
Feeder layer needed for cultivation of primary keratinocytes was prepared by isolation and 
inactivation of mouse embryonic fibroblasts (MEFs).  
5.2.5.1. Isolation and cultivation of mouse embryonic fibroblasts 
To obtain MEFs, 5 C57/B6 mice were superovulated with PMSG/hCG gonadotropins and 
mated. Obtained embryos were isolated from the uterus at the embryonic day E12.5. Single 
embryos were taken out of the yolk sack and placed in 37°C warm PBS in Petri dish. Using 
forceps, the head, limbs, tail and all the organs were removed under the binocular while the 
remaining embryo core was placed in a fresh Petri dish and cut into small pieces using scalpel 




in a flat-bottom flask containing sterile glass beads and magnetic stirrer. The suspension was 
then incubated at 37°C on a magnetic plate and stirred with a speed of ~300 rpm for exactly 5 
min. After this time, trypsin was neutralized with FBS-containing DMEM (2 ml DMEM/1 ml 
trypsin) and the cells were distributed into desired number of T75 flasks (8-10 ml of cell 
suspension per flask). After 3-4 h cells were thoroughly washed with PBS to remove trypsin 
and larger tissue pieces. Cells were expanded by passaging whenever they reached 80-90% 
confluency and either frozen (see above) or inactivated with Mitomycin C at the passage P4, 
the latest. 
5.2.5.2. Fibroblast inactivation with mitomycin C 
90-95% confluent cells were thoroughly washed with PBS and incubated with medium 
containing Mitomycin C at a concentration of 10 µg/ml. After 3 h, inactivating medium was 
removed, cells were washed with 1 x PBS, frozen and stored in liquid nitrogen or used for 
further experiments. 
5.2.6. Isolation and cultivation of primary keratinocytes from human skin 
The entire procedure of keratinocytes isolation was performed as described in Nature 
Protocols (Aasen and Izpisua Belmonte, 2010). 
Human skin was obtained from breast reduction surgery and cut into ~1.5 x 1.5 cm pieces 
using a sterile scalpel. Small pieces were then placed with the epidermal side up in a sterile 60 
mm Petri dish filled with 5-6 ml of HBSS supplemented with 1% P/S and dispase to digest 
the tissue. The enzymatic reaction was carried out O/N (12-16 h) at 4°C. The next day the thin 
epidermal layer was peeled off from the dermis using forceps and placed in a fresh 60 mm 
Petri dish containing HBSS with antibiotics. The dermal part was preserved in HBSS with 
antibiotics at 4°C for fibroblasts isolation (see below). The epidermis was then cut into 
smaller pieces using a disposable scalpel and transferred into a 50 ml Falcon tube containing 
20 ml of HBSS supplemented with 1% P/S and thermolysin. The suspension was incubated 
for 45 min at 37°C and mixed gently by shaking every 10 min. Subsequently, the thermolysin 
was inactivated with HBSS containing 10% FCS and 1% P/S and the solution was transferred 
into 2 plastic Petri dishes which were then stirred slowly (~100-150 rpm) on a magnetic stirrer 
at RT for 20 min. To discard undigested tissue the suspension was passed through a 70 µm 
filter and the flow-through was collected in a new 15 ml falcon tube. Afterwards cells were 




cells were resuspended in 5 ml RM+ medium. Finally, cells were counted and seeded on 0.1% 
gelatin-coated culture plate containing feeder layer. 
5.2.7. Isolation and cultivation of primary fibroblasts from human skin 
The entire procedure of fibroblasts isolation was performed as described in Nature Protocols 
(Aasen, T & Belmonte, 2010). 
To isolate fibroblasts, the preserved dermal part was cut into small pieces, which were then 
placed in a Petri dish (~10 pieces/plate) and covered with 1-2 drops of DMEM supplemented 
with 10% FCS and 1% P/S. The next day, when the pieces were firmly attached to the plate, 
8-10 ml of medium was added and the tissue was cultured for 5 days until the outgrowth of 
fibroblasts appeared and for another 7-10 days until plate was 70% confluent. The cells were 
washed every 3 days with PBS, passaged and expanded according to the procedure described 
above (section ‘Passaging of adherent eukaryotic cells’). 
5.2.8. Co-culture of eukaryotic cells 
In co-culture experimental system, the cSCC cell line was grown at the bottom of 24-well 
plate at the number of 4-6 x 103 cells/well in 500 µl culture medium. The nourishing 
fibroblasts were seeded in 200 µl culture medium in cell culture inserts with 0.4 µm pores in 
diameter, which do not allow for migration of the cells. The inserts were then placed in the 
24-well plate to allow exchange of secreted molecules. After the desired incubation time, 
inserts were discarded while the cells remaining in the plate were subjected to the desired 
assays.  
5.2.9. Immunocytochemistry 
Immunocytochemistry of cultured cells was performed on round cover slips placed at the 
bottom of 24-well plate. The number of seeded cells was 3 x 105 cells/well. First, cells were 
washed with PBS and fixed with 4% PFA in PBS at RT for 30-40 min followed by 10 min 
incubation in NH4Cl at 37°C. After two rounds of washing with PBS cell membranes were 
permeabilized with 0.2% Triton X-100 in PBS (3 x 4 min). The primary antibodies were 
diluted 1:100 in 0.2% Triton 100-X/PBS and applied to the wells for 1 h at RT. Afterwards, 
cells were washed 3 x 4 min with 0.2% Triton X-100 in PBS and the secondary antibody was 
added for 1 h at RT followed by another round of washing with 0.2% Triton X-100/PBS and 




DAPI mounting medium and placed on the slides. The staining was analyzed using Olympus 
BX 60 fluorescent microscope. 
5.2.10. Chemical transfection of eukaryotic cells 
5.2.10.1. pDNA transfection 
Chemical transfection of pDNA was performed using RotiFect® as transfection reagent 
according to the manufacturer’s instructions. Briefly, cells were seeded in a 6-well (or a 24-
well) plate at the number of 1.5 x 105 (3 x 104) cells/well. Number of seeded cells, ratio 
between nucleic acid and transfection reagent as well as transfection time were established for 
each cell line based on the efficiency of pEGFP transfection. To find the best transfection 
conditions we varied the amount of pDNA (2 and 4 µg), the ratio between transfected pDNA 
and Rotifect (1:2, 1:4, 1:5 and 1:6) as well as incubation time with transfection mixture (3, 6 
and 16 h). The best transfection conditions for each cell line are presented in Table 22. In 
some cell lines, all applied settings resulted in a great toxicity and thus, those cells were 
considered as not possible to transfect with this method. 
Table 22: Transfection conditions for cSCC cell lines 







SCL-I 1:2 4 8 16 h ~75% - 
SCL-II 1:6 4 24 3-6 h ~25% Toxic 
SCC-13 1:6 2 12 3-6 h ~40% Toxic 
MET-1 1:2 2 4 3-6 h ~5% Toxic 
MET-4 1:5 2 10 6 h ~70% - 
HaCaT-
ras II-4 
1:2 2 4 16 h ~75% - 
SCC-12 1:2 4 8 3-16 h ~15% - 
 
The appropriate amount of pDNA and RotiFect was diluted in separate reaction tubes in 200 
µl (or 30 µl for 24-well plate) of serum-free medium without antibiotics each. Afterwards, 
both components were mixed by pipetting and incubated at RT for 40 min to let the 




was replaced with 1.5 ml (250 µl) antibiotic-free medium supplemented with 10% FCS. 
Finally, the complexes were added dropwise to the cultured cells for desired time (6-18 h), 
after which the transfection medium was replaced with complete culture medium. 
5.2.10.2. siRNA transfection 
For the transfection of siRNA HiPerFect was used according to the supplier’s guidance. 
Briefly, 1.5 x 105 cells were seeded in each well of a 6-well plate (or 3 x 104 for a 96-well 
plate). 300 ng (or 25 ng) of the siRNA was mixed with 18 µl (1.5 µl) of HiPerFect in 400 µl 
(30 µl) of pure DMEM or RPMI in 1.5 ml reaction tubes. The mixture was incubated for 10 
min at RT to let the complexes form. In the meantime, cells were washed with PBS and the 
medium was replaced with 1.5 ml (70 µl) of fresh DMEM or RPMI supplemented with 10% 
FCS and 1% P/S. Afterwards, complexes were added dropwise to each well and cells were 
incubated for 24 h. After this time cells were either collected for RNA isolation or re-seeded 
in a 96-well plate for another 24 h in the presence of BrdU for proliferation assay. 
5.2.11. Dual-luciferase assay 
For the dual-luciferase assay cells were transiently transfected with experimentally regulated 
Firefly expression vector and constitutively active Renilla expression vector that served as an 
internal control. The assay was performed using the Dual-Luciferase® reporter assay system 
according to the supplier’s instructions. Shortly, 100 µl of passive lysis buffer (PLB) was 
added to each well of a 24-well plate and placed on the shaker at RT for 15 min at ~300 rpm 
to lyse cells. Afterwards the plate was frozen at -80°C for 30 min and after thawing, 20 µl of 
cell suspension was transferred per well of a black 96-well plate, in triplicates. 100 µl of LAR 
II and Stop&Glow substrates were pipetted sequentially into each well to induce the reaction 
conducted by Firefly and Renilla luciferases, respectively, and the luminescence was 
measured using a Synergy Mx luminometer at 550-570 nm and 480 nm, respectively. The 
data normalization and calculation were done in Microsoft Excel 2010. 
5.2.12. Proliferation assay (BrdU incorporation) 
The proliferation of the cells was measured based on 5-Bromo-2-Deoxyuridine (BrdU) 
incorporation in DNA during the S-phase. The assay was done at RT temperature using a 
BrdU cell proliferation kit in accordance with manufacturer’s instructions. In brief, cells were 




24 h. Afterwards the cells were fixed and DNA was denatured with 200 µl of Fix-Denat for 
30 min followed by incubation with peroxidase coupled anti-BrdU antibody diluted 1:100 in 
Antibody-dilution-solution for 1 h. Negative controls lacking either anti-BrdU antibody or 
BrdU itself were included in the assay. To remove unbound antibodies, cells were thoroughly 
washed 3 x 5 min with 200 µl of 1 x Washing Buffer. The enzymatic reaction was started by 
adding 100 µl of peroxidase substrate to each well and the emitted luminescence was 
measured in the Synergy Mx Luminometer. Each sample was measured in triplicates and the 
proliferation rate was calculated in Microsoft Excel 2010. 
5.2.13. Metabolic activity assay (WST-1)  
Metabolic activity assay was based on tetrazolium salt WST-1, which is cleaved to a soluble 
formazan dye only in the presence of NAD(P)H in living cells. Shortly, cells were seeded in a 
transparent 96-well plate (6 x 103 cells/well) and incubated at 37°C with WST-1 for the last 3 
h of culture time. Colorimetric reaction was then measured in a microplate reader at a 
wavelength of 450 nm. All samples were measured in triplicates and the data were analyzed 
using Microsoft Excel 2010.   
5.2.14. Annexin V/Propidium iodide (PI) staining (FACS analysis) 
To assess the number of early and late apoptotic as well as viable and necrotic cells, cells 
were seeded in a 6-well plate at a number of 1.5 x 105 and grown for 24 h. Afterwards, the 
cells were detached from the plate using 1 ml of accutase/well, collected in the 15 ml falcon 
tube, pelleted by centrifugation at 300 xg, 4°C for 5 min and washed once with 1 x PBS. After 
a second centrifugation step with the same settings, the supernatant was discarded and 2 µl 
Annexin V-FITC in 100 µl of Annexin V binding buffer was added to each tube. The mixture 
was shortly vortexed and incubated at RT for 10 min followed by 5 min incubation with PI. 
Prior to measurement, 300 µl of Annexin V binding buffer was added to each reaction tube. 
Finally, cells were sorted by flow cytometry in a FACS Calibur machine using the channel 
FL-1 and FL-3 for Annexin V FITC and PI, respectively, giving rise to 4 populations with the 
corresponding phenotype: 
1. Annexin V negative and PI negative – viable cells 
2. Annexin V positive, PI negative – early apoptotic cells 
3. Annexin V positive, PI positive – late apoptotic cells 




All samples were measured in triplicates and the data were analyzed using the FlowJo 
software, Microsoft Excel 2010 and GraphPad Prism 6. 
5.3. Histological methods 
5.3.1. Immunohistochemistry 
For immunohistochemistry, 5 µm paraffin tissue sections were prepared on a microtome and 
mounted on Superfrost slides. If not otherwise stated, the entire procedure was performed at 
RT. Sections were first deparaffinized 2 x 10 min in Xylene and then rehydrated in serial 
ethanol dilutions 100%, 95%, 80%, 70%, 50%, 30% and ddH2O. Depending on the antibody, 
different pretreatments for antigen retrieval were applied: 
1. Citric acid pH 6.0 – samples were boiled in buffer in a microwave 1 x 4 min and 4 x 3 
min at 600W 
2. Tris/EDTA (TE) buffer pH 9.0 – the same procedure as above 
3. Citric acid pH 3.0 – samples were incubated at 37°C for 30 min 
4. Boric acid pH 5.1 – samples were incubated at 55°C for 30 min 
Irrespective of the pretreatment, sections were cooled down and washed in TBS/0.1% Triton. 
To block endogenous peroxidase activity, slides were incubated with 3% H2O2 for 20 min. 
Afterwards they were washed with ddH2O for 5 min and briefly rinsed in TBS/0.1% Triton.  
To block unspecific antibody binding, the slides were incubated with either 0.02% Casein or 
5% FCS/10% BSA in 1 x PBS in a moist chamber. After 20 min, the blocking solution was 
discarded and the primary antibody diluted in 1 x TBS/0.1% Triton was applied onto the 
sections at required concentration. Incubation was carried O/N at 4°C in a moist chamber. The 
next day, the slides were washed 3 x with TBS/0.1% Triton to remove unbound primary 
antibodies. Then the secondary HRP-conjugated antibody was applied. After 30 min of 
incubation in a moist chamber at RT slides were washed again and the staining solution, 
either DAB chromogen or AEC was added. Intensity and specificity of the staining were 
monitored under the microscope and finally the reaction was stopped after 5-30 min with 
ddH2O. Subsequently, counterstaining of nuclei was performed by incubation with hemalum 
solution for 20 sec. The excess of staining solution was removed with ddH2O followed by 





5.3.2. Hematoxylin & eosin (HE) staining 
To visualize morphology of the tissue, paraffin sections were prepared on a microtome and 
fixed on SuperFrost slides. First, tissue sections were deparaffinized by incubation in Xylene 
(2 x 10 min) and hydrated in descending ethanol series: 100%, 96%, 70%. After washing with 
ddH2O slides were incubated with a hemalum solution for 20 min and washed again under 
running warm tap water. Then the slides were transferred to a cuvette containing 1% eosin 
staining solution for no more than 20 sec. After a washing step with ddH2O, tissues were 
dehydrated in a series of ascending ethanol solutions: 70%, 96%, 100% and placed in Xylene 
before mounting them with Pertex. In the final step, slides were dried at 55°C for 30 min. 
5.3.3. In situ hybridization (ISH) of paraffin embedded tissue sections 
ISH was performed on paraffin tissue sections using digoxigenin-labeled ribo-probes. To 
eliminate RNases from the working environment, all the solutions (except for TEA) were 
DEPC-treated and autoclaved along with all equipment. To detect mRNA within tissue 
samples, the 5 µm paraffin sections were prepared. Prior to ISH the sections were incubated at 
65°C for 30 min. Deparaffinization with Xylene and hydration of the tissues in serial ethanol 
dilutions were done as described in IHC section. After incubation in 30% ethanol, the slides 
were washed in 1 x Saline and 1 x PBS, 5 min each and fixed in 4% PFA in PBS for 20 min. 
After 2 rounds of washing with 1 x PBS (5 min each) tissues were subjected to proteinase K 
treatment for 7.5 min on ice to digest proteins that may obstruct target mRNA. Subsequently 
slides were washed with 1 x PBS and re-fixed with 4% PFA in PBS for 5 min on ice to 
maintain tissue integrity. To reduce non-specific binding of the probes and thus background 
signals, the tissues were treated with acetic anhydride diluted in 0.1M triethanolamine (TEA). 
After 2 washing steps with 1 x PBS and 1 x Saline the slides were dehydrated with ascending 
ethanol dilutions (30%-100%) with prolonged incubation (5-10 min) in 70% EtOH to avoid 
salt deposition on dehydrated slides and air-dried. Then a liquid barrier marker from Carl 
Roth GmbH & Co. KG, Karlsruhe was used to separate sections placed on the same slide for 
application of sense (negative control) and anti-sense probes. hGLI1 riboprobes were diluted 
1:1000 in HybM hybridization buffer, 65 µl were pipetted on sections and the slides were 
covered with coverslips. Hybridization was performed in a moist chamber soaked with 50% 




a 56°C incubator. The next day, samples were subjected to high-stringency washing steps 
involving: 
1. 20 min at 63°C in 50% formamide/2xSSC 
2. 10 min at RT in STE buffer 
3. 3 x 10 min at 37°C in STE buffer 
To digest all unbound single-stranded riboprobes, sections were exposed to RNase A 
treatment for 30 min in STE buffer followed by further washing steps: 
4. 15 min at 37°C in STE buffer  
5. 20 min at 63°C in 50% formamide/2xSSC 
6. 15 min at RT in 2 x SSC 
Afterwards the slides were incubated in NT buffer for 10 min at RT and then 3 x 5min in 
MBSTL buffer. 0.02% Casein solution was placed on sections for 1 h at RT to block 
unspecific binding of the secondary antibody. AP-conjugated anti-digoxigenin antibody that 
was diluted 1:1000 in 0.02% Casein/MBSTL and placed on sections for O/N at 4°C in a moist 
chamber. On the third day, the slides were thoroughly washed 6 x 15 min in MBSTL on the 
orbital shaker at RT to block endogenous AP activity. Subsequently, they were placed 
horizontally in a moist chamber and incubated with NTMLT buffer 3 x 5 min at RT. For the 
final colorimetric reaction, BM-purple substrate was placed on the sections for at least 24 h. 
When the staining signal was strong enough, the enzymatic reaction was stopped with 10 mM 
Tris pH 8/1 mM EDTA solution and the tissues were fixed with 4% PFA/0.2% glutaraldehyde 
for 1-2 h at RT with shaking. After washing in PBS slides were mounted with Glycer-gel 









6.1. Expression of GLI1, SHH, pS6, pAKT, pERK and EGF in human cSCC samples 
PTCH mutations have been identified in 15% of cSCC cases (Ping et al., 2001). In addition, 
besides HH and PTCH1, cSCC were reported to express GLI1, the major target of active HH 
signaling (Celebi et al., 2016). Our lab also has tested the antibodies described by Celebi and 
colleagues. However, in our hands the respective antibodies gave very unspecific signals. We 
here have used an antibody against SHH from abcam that detects the N-terminal end of SHH 
and stained 10 human cSCC specimens. Due to the lack of an adequate GLI1 antibody the 
staining for GLI1 was done by GLI1 ISH. Using adjacent slides, the tumors were also stained 
with antibodies against pERK (readout for MEK/ERK pathway activation), pAKT (readout 
for PI3K/AKT activity), pS6 (hallmark of active mTOR signaling) and EGF. 
As shown in Fig. 5 A the anti-SHH antibody showed positive staining in ductal epithelium of 
pancreatic adenocarcinoma that was used as a positive control (Fig. 5 A). Similar expression 
pattern of SHH in pancreatic cancer has been described in the literature (Thayer et al., 2003). 
However, the antibody stained neither cSCC tumor cells nor cSCC stroma (Fig. 5 A). This 
shows that SHH is not expressed by cSCC. In contrast, when we measured HH signaling 
activity by performing a GLI1 specific ISH on adjacent slides, we found that GLI1 expression 
was high in the tumor center whereas tumor cells invading the dermis were not or only 
moderately positive for GLI1 (Fig. 5 A, B). Most interestingly, this staining pattern was 
inverse to that using an antibody that specifically detects phosphorylation at S240/244 sites of 
the mTORC1/S6K-downstream target S6 (Fig. 5 B; please note that in the following the term 
mTORC1 will be substituted by mTOR). Thus, positivity for pS6 was frequently revealed in 
invading tumor cells, whereas it was low in the tumor center (Fig. 5 B, E). In contrast, the 
anti-pAKT antibody recognizing pSER473 of AKT did not show any positive staining in 
tumor cells (Fig. 5 B) and unfortunately positive control tissue (glioblastoma) raised too much 
background staining (picture not shown). These data question the reliability of this anti-pAKT 
antibody although Barrette et al. has reported a positive staining of invasive cSCC tissue 
samples when using it. On the other hand, pERK was mostly expressed in stromal cells 
surrounding neoplastic tissue with only rare and weak signals detected in single tumor cells 




negative (Fig. 5 D). EGF was expressed all over the tumor with sometimes stronger 































Figure 5: Immunohistochemical analysis of SHH, pS6, pERK, pAKT and EGF as well as in situ 
hybridization of GLI1 of human cSCC biopsies. A. Representative pictures of adjacent sections from human 
cSCC (n=10) showing strong GLI1 expression within the tumor mass (as measured by ISH) and no SHH signals 
(as measured by antibody staining/IHC) throughout the whole tissue. Pancreatic adenocarcinoma served as a 
positive control for SHH staining. The pictures are presented at 10 x magnification. B. GLI1 ISH and IHC for 
pS6 and pAKT on adjacent cSCC sections. Inverse pattern of GLI1 mRNA expression and pS6 protein is shown. 
No specific signal for pAKT was detected. Pictures are shown at 10 x magnification. Black asterisks indicate the 
areas strongly positive for pS6 but negative for GLI1. White asterisks show the regions weakly positive for pS6 
but strongly expressing GLI1. C. Representative pictures showing pERK positive stromal (left) and tumor (right) 
cells. Upper panel 10 x and lower panel 20 x magnification. Arrows point to pERK positive cells. D. 
Representative pictures showing GLI1 positive tumors surrounded by pERK positive stromal cells, 10 x 
magnification. E. Representative pictures of adjacent cSCC sections showing overlapping or inverse staining for 
GLI1, EGF and pS6. White asterisks indicate areas positive for GLI1, EGF and pS6, black asterisks indicate the 
regions that are EGF positive but GLI1 and pS6 negative. Invasion front of the tumor, which is positive for EGF 
and pS6 but negative for GLI1, is indicated with an arrow. The pictures are shown at 10 x magnification. All 
staining reactions were performed using either AEC (red) or DAB (brown) in case of IHC and using BM-purple 
(blue) in case of ISH. The expression pattern and staining intensity were assessed by a pathologist. 
Due to the lack of SHH staining in tumor tissue but GLI1 positivity in the tumor center (Fig. 5 
A), we hypothesized that HH/GLI signaling in cSCC might be activated in a noncanonical 
way. The opposing expression pattern of GLI1 and pS6 (Fig. 5 B) also may indicate that 
HH/GLI and mTOR pathways may regulate each other in a negative manner. Moreover, both 
HH/GLI and mTOR activation may be driven by EGF signaling as EGF staining sometimes 
overlapped both the GLI1 and pS6 positive areas (Fig. 5 E). On the other hand, EGF positivity 
overlapped GLI1 negative areas (black asterisks and black arrows in Fig. 5 E), which may 
indicate a negative regulation of GLI1 by EGF. In addition, there might also be a negative 
interaction between GLI1 expressing tumor cells and pERK positive stromal cells. Thus, as 
shown very impressively in Fig. 5 D, pERK positive stromal cells surround the tumor areas, 
which are GLI1 negative (Fig. 5 D). As already stated we were not sure about the reliability of 














6.2. Basal expression of components of the HH/GLI, PI3K/AKT/mTOR and 
MEK/ERK pathways in cSCC cell lines 
To investigate the role of HH/GLI, PI3K/AKT/mTOR (please note, mTOR is frequently 
activated by AKT and in the following will be sometimes combined with PI3K/AKT 
signaling) and MEK/ERK signaling and a putative interaction between them in cSCC, we 
performed in vitro experiments involving initially 6 different cSCC cell lines, namely, SCL-I, 
SCL-II, SCC-13, SCC-12, MET-1 and MET-4 as well as HaCaT ras II-4 transformed cells 
also resembling the cSCC phenotype (Boukamp et al., 1990). 
6.2.1. Expression of canonical HH/GLI pathway components on mRNA level 
We first checked to what extent the used cell lines express the major HH/GLI pathway 
components GLI1, GLI2, GLI3, SMO, PTCH and SHH. For this purpose, we performed 
qPCR. As shown in Fig. 6 almost all pathway components were expressed at a variable level 
in all 7 cell lines. The exception was SHH, which was markedly expressed only by MET-1 
and MET-4 cells. In addition, GLI3 was not expressed in SCC-13 that also expressed SMO at 
extremely low levels. SMO was also not expressed in SCL-II cells. We also compared the 
expression levels of cSCC cell lines to primary keratinocytes as well as immortalized HaCaT 
cells commonly used in studies on human keratinocytes, to see whether the HH/GLI pathway 
is upregulated in cSCC. The data show that primary keratinocytes expressed low levels of 
GLI1 and GLI2 but none of the other pathway components, whereas HaCaT cells expressed 
GLI1, low levels of GLI2, PTCH and SMO. These data indicate that both primary 
keratinocytes and immortalized keratinocyte cell line express only moderate amounts of GLI2 
and completely lack GLI3, which are important factors for activation of both noncanonical 
and canonical HH signaling. Out of all cell lines, MET-1 and MET-4 expressed the highest 
levels of GLI2, GLI3, SMO and SHH. Moreover, we also noted relatively high level of GLI1 
expression in these two cell lines (Fig. 6). Therefore, we chose them as representative cell 
lines for further analysis. Furthermore, we chose the cell line SCL-I that – as the human tumor 
samples – does not express SHH, but otherwise all components necessary for stimulation of 





Figure 6: Basal expression of canonical HH/GLI pathway components in cSCC/cSCC-like cell lines and 
keratinocytes. qPCR showing relative expression levels of GLI1, GLI2, GLI3, PTCH, SMO and SHH in the 
cSCC cells lines SCL-I, MET-1, MET-4, SCL-II, SCC-13, SCC-12, in the cSCC-like cell line HaCaT ras II-4 
cell (black bars), as well as in the keratinocyte cell line HaCaT and primary human keratinocytes (keratinocytes) 
(grey bars). The target gene expression was normalized to the 18S rRNA housekeeping gene. The data are 
presented as mean +/- SEM of one experiment measured in triplicates. 
6.2.2. Expression of pERK, pAKT and pS6 on protein level 
We next checked the basal levels of pAKT, pERK and pS6 as readouts for active PI3K/AKT, 
MEK/ERK and mTOR signaling pathways, respectively. All examined cell lines showed high 





























































































































































































































































































































































loading control. Also, all cell lines expressed pAKT and pERK, however to a variable extent. 
In detail, SCL-I cells highly expressed pAKT and pERK, SCL-II cells showed strong 
expression of only pERK while HaCaT ras II-4 and MET-1 cells displayed a moderate 
expression of pAKT and quite low pERK levels. In the remaining cell lines pERK and pAKT 
levels were rather low (Fig. 7). Interestingly, in the cell lines showing the highest level of 
pERK i.e. SCL-I and SCL-II (Fig. 7) we had measured the lowest level of GLI1 by qPCR (see 
Fig. 6). Taken together, all cSCC cell lines seem to differ between each other, but most of 
them express all major components of the HH pathway and show activation of 
PI3K/AKT/mTOR and MEK/ERK signaling pathways, which are downstream effector 
pathways of RTKs. 
 
Figure 7: Basal activity of PI3K/AKT, MEK/ERK and mTOR signaling pathways in cSCC/cSCC-like cell 
lines. Representative Western Blot showing activity of AKT/pAKT, ERK/pERK and S6/pS6 in the cSCC-like 
HaCaT ras II-4 cell line and in the cSCC cell lines SCC-12, MET-1, MET-4, SCL-I, SCL-II and SCC-13. 
HSC70 served as a loading control. The size of the proteins (in kDa) is indicated on the left side of the blot.  
6.3. Modulation of canonical HH signaling activity in cSCC cell lines 
In order to investigate whether it is possible to activate HH signaling in cSCC via the 
canonical PTCH/SMO/GLI axis we incubated the cells with different molecules modulating 
PTCH or SMO activity and measured its influence on GLI1 expression level. For this 
purpose, we used SCL-I, MET-1 and MET-4 cells. As already said, these cell lines all express 



















































SHH. Whereas MET-1 and MET-4 also express SHH, SCL-I, similar to cSCC tumor samples, 
does not (see Fig. 5 A and Fig. 6). In addition, SCL-I and MET-4 cells were easy to transfect 
(see Table 22 in the Material and Methods section). 
6.3.1. Activation with SHH conditioned medium or SAG 
To see whether GLI1 expression level raises upon activation of canonical HH/GLI signaling 
we incubated the cells with either SHH conditioned medium (SHH-CM) or Smoothened 
agonist (SAG; at concentrations ranging from 10 nM – 1 µM) for 24 h. Control- and SHH–
CM were prepared as described in the Materials and Methods (section 5.2.4). Prior to the 
experiment, the functionality of freshly prepared SHH-CM was always tested on the SHH-
responsive murine cell line B9 (Table 8, Materials section). As shown in Fig. 8 A, SHH-CM 
induced at least 100-fold increase in Gli1 expression in B9 cells, when compared to cells 
treated with control-CM. This was observed in all experiments. A representative graph shows 
a 400-fold induction in Gli1 expression upon incubation with SHH-CM (Fig. 8 A). However, 
none of the three cSCC cell lines responded to SHH-CM as indicated by the lack of increased 
GLI1 transcription (Fig. 8 A). When the cells were treated with SAG, GLI1 expression was 
slightly increased in all three cell lines especially after incubation with 100 nM, however 
these changes were statistically not significant (Fig. 8 B). To further verify these data, we also 
performed a Dual-Luciferase GLI reporter assay in SCL-I cells due to their best transfection 
efficiency (Table 22, Methods section). For this purpose, the cells were transfected with a 
plasmid encoding firefly luciferase under the herpes simplex virus thymidine kinase (HSV 
TK) promoter containing 9xGli-BS and a plasmid encoding renilla firefly luciferase for 
normalization. The cells were then incubated with either control-CM or SHH-CM. 
Transfection along with a plasmid encoding Gli1 was used as a positive control. As expected, 
the control transfection resulted in a 3-fold increase in luciferase activity (Fig. 8 C). However, 
in line with the GLI1 qPCR data, incubation with SHH–CM did not change GLI-driven 
luciferase activity in comparison to cells incubated with control-CM (Fig. 8 C). Therefore, we 






Figure 8: Impact of SHH ligand or SAG on GLI1 expression in cSCC cell lines. A. qPCR showing relative 
expression of GLI1/18S in SCL-I, MET-1 and MET-4 cells incubated with control- or SHH- CM for 24 h. The 
data represent a summary of three independent experiments, each performed in triplicates. B. qPCR showing 






































































































































































































































SAG. The data represent the summary of three independent experiments, each performed in triplicates. C. 
Changes in relative luciferase activity upon transfection of SCL-I cells with a plasmid encoding firefly luciferase 
under the HSV TK promoter containing 9xGli-BS and incubation with either control-CM or SHH-CM. Co-
transfection of plasmids encoding Gli1 served as a positive control (Gli1). The graph represents one experiment 
performed in three technical replicates. All data are shown as mean values +/- SEM; ctrl-CM, control medium; 
SHH-CM, SHH conditioned medium. 
6.3.2. Overexpression of SMO 
In a final experimental setting, we directly overexpressed a constitutively active variant of 
SMO, namely SMO-M2, or wild type SMO (SMO-WT) in SCL-I cells according to the 
established conditions described in Table 22 in the Methods section. After 24 h the cells were 
collected for RNA isolation and subjected to GLI1 expression analysis. Additionally, we 
transfected the cells with the SMO-M2 plasmid along with the plasmid encoding firefly 
luciferase under the control of HSV TK promoter containing 9xGli binding sites as well as the 
plasmid encoding constitutively active renilla firefly (as described in 5.2.11. in Methods 
section) and performed Dual-Luciferase GLI reporter assay. Also in this experiment co-
transfection of Gli1 and luciferase served as a positive control and resulted in more than 8-
fold increase in luciferase activity (Fig. 9 B). In accordance with the data obtained with SHH 
or SAG, overexpression of SMO neither altered GLI1 expression nor GLI activity (Fig. 9).  
 
Figure 9: Effects of active SMO on GLI1 expression and GLI activity in cSCC cell lines. A. Relative GLI1 
expression level in SCL-I cells transfected with SMO-WT or SMO-M2 (active SMO variant) plasmids 
normalized to the 18S rRNA housekeeping gene. The data show a summary of four independent experiments, 
performed in triplicates. The GLI1 expression in mock transfected cells was set to 1. B. Relative GLI-driven 
luciferase activity in SCL-I cells after transfection with SMO-WT and SMO-M2 compared to that in mock 








































































encoding Gli1 served as a positive control (Gli1). The graph represents a summary of two independent 
experiments. All data are shown as mean +/- SEM. 
6.3.3. Incubation with SMO inhibitors 
In a next approach, we tried to inhibit the canonical HH/GLI axis and thus GLI1 expression 
via application of three different small-molecule SMO antagonists, which were cyclopamine 
(CP), vismodegib and HH Antag (HhA). Although SCL-I cells do not express the ligand SHH 
(see Fig. 6) we incubated this cell line together with MET-1 and MET-4 cells (that express 
high levels of the HH ligand) for 24 h with different concentrations of the inhibitors i.e. 1 - 10 
µM CP and 10 - 60 µM vismodegib or HhA. Our data show that CP did not alter GLI1 
expression in any of the cell lines at any applied concentration (Fig. 10 A). Similarly, 
incubation with 10 µM and 30 µM vismodegib did not affect GLI1 expression and 
paradoxically resulted in a significant upregulation of GLI1 in SCL-I and MET-4 cells at a 
concentration of 60 µM (Fig. 10 B). A paradox increase in GLI1 expression was also seen in 
SCL-I cells that had been incubated with HhA (Fig. 10 C). However, treatment with HhA led 


































































































Figure 10: Impact of SMO inhibitors on GLI1 expression in cSCC cell lines. qPCR showing relative 
expression of GLI1/18S rRNA in cells incubated with A. cylopamine (CP), B. HhA or C. vismodegib at the 
indicated concentrations for 24 h. Each graph represents a summary of two independent experiments analyzed in 
triplicates, with the solvent control set to 1. All data are presented as mean +/- SEM; *, p<0.05; **, p<0.01. 
Statistical comparisons were done with Mann-Whitney test. 
Based on the lack of activation of the pathway upon stimulation with either SHH or SAG, we 
assume that canonical HH signaling cannot be activated in cSCC cell lines. Nevertheless, the 
fact that GLI1 as a main target of canonical HH/GLI signaling pathway can in principle be up- 
or downregulated indicates that GLI1 is not silenced in any of the used cell lines. 
The paradoxical upregulation of GLI1 in SCL-I cells after treatment with HhA may also 
indicate that this drug might regulate other signaling pathways in SCL-I cells that are not 
regulated in MET-1 or MET-4 cells. 
Because the results from the patient samples indicated a negative crosstalk between HH/GLI1 
and mTOR or HH/GLI1 and ERK signaling (see section 6.1., Fig. 5 B and D), we checked 
whether the induction of GLI1 expression observed in SCL-I cells after treatment with HhA 
































































































































































































performed Western Blot analyses. Indeed, we noted a decrease in phosphorylation of ERK 
and a decrease in AKT/pAKT in SCL-I cells (Fig. 11). However, in contrast to our hypothesis 
of a negative regulation between GLI1 and mTOR pathway, we observed that GLI1 induction 
was accompanied by an increase in S6 phosphorylation in SCL-I cells (Fig. 11). Interestingly, 
in MET-1 cells, in which HhA has downregulated GLI1 (see Fig. 10 C), we noticed an 
increase in pERK, whereas again the AKT/pAKT was decreased (Fig. 11). Due to these data 
and although no changes in the respective molecules were observed in MET-4 cells, we 
hypothesized that it might be the MEK/ERK axis that can negatively regulate GLI1 
expression and thus the HH/GLI axis. 
 
Figure 11: Influence of HhA treatment on PI3K/AKT/mTOR and MEK/ERK pathway activity in cSCC 
cell lines. Western Blot showing changes in phosphorylation level of AKT, ERK and S6 in cSCC cell lines after 
treatment with 10 µM and 30 µM of HhA. HSC70 served as a loading control. Size of the proteins (in kDa) is 
indicated on the left side of the blot.  
6.4. Modulation of noncanonical HH signaling activity in cSCC cell lines 
In the following, we focused on the interaction between HH/GLI and PI3K/AKT/mTOR and 
MEK/ERK signaling pathways that are known to be able to influence the activity of GLI 
proteins family (Eberl et al., 2012; Stecca et al., 2007; Y. Wang et al., 2012). We furthermore 
put into focus potential ligands that activate the respective pathways. These were EGF that we 
detected in the IHC analysis of cSCC samples (see Fig. 5 E) and IGF1 that besides EGF is an 
important factor in cSCC pathogenesis (Oh et al., 2014). 
SCL-I MET-1 MET-4 
 
 










































































6.4.1. Impact of PI3K/AKT, mTOR and MEK/ERK signaling on GLI1 expression level 
To figure out whether PI3K/AKT, MEK/ERK or mTOR may regulate GLI1 mRNA levels we 
treated the cells with specific inhibitors of the aforementioned pathways i.e. GDC-0941 
(specific PI3K inhibitor), PI103 (dual PI3K and mTOR inhibitor), MK-2206 (specific AKT 
inhibitor), UO126 (MEK1/2 inhibitor) as well as everolimus and rapamycin (mTOR 
inhibitors). Prior to GLI1 expression analysis we assessed efficiency and specificity of the 
inhibitors at given concentrations (Table 14, Materials section). The obtained results after 48 
h of incubation were consistent for all 3 cell lines. Thus, everolimus and rapamycin inhibited 
mTOR and therefore S6K, which cannot further phosphorylate the ribosomal protein S6. 
GDC-0941 and MK-2206 blocked PI3K and AKT activity, respectively, which was indicated 
by reduction in AKT phosphorylation level. PI103 as a dual inhibitor of PI3K and mTOR 
decreased the level of pAKT and pS6 and UO126 as a MEK1/2 inhibitor reduced the level of 
pERK. One exception was MET-1 cell line, in which PI103 inhibitor did not exert expected 
results (Fig. 12). 
Additionally, we noted that GDC-0941 and MK-2206 inhibitors also decreased the level of 
pS6 in SCL-I and MET-1 cells, whereas in MET-4 cells this effect was only observed after 
treatment with MK-2206. Furthermore, in SCL-I and MET-4 cells, the treatment with UO126 
resulted not only in a decreased signal for pERK but also for pS6 (Fig. 12). This is in line with 
the fact that mTOR activity can be regulated by both PI3K/AKT and MEK/ERK signaling 
(Mendoza et al., 2011). We also observed an interaction between PI3K, AKT and mTOR 
signaling with MEK/ERK. Thus, treatment with GDC-0941 resulted in decreased pERK level 
in SCL-I and MET-1 cells. A similar effect was observed in SCL-I and MET-4 cells upon 
incubation with PI103 and in MET-1 and MET-4 cells after treatment with MK-2206 (Fig. 
12). On the other hand, we noted an increased level of pAKT after treatment with UO126 
suggesting the existence of a negative feedback loop between pERK and pAKT in MET-4 
cells. Such a feedback has been described by two groups who showed that MEK1/2 inhibition 
leads to the activation of the PI3K/AKT pathway (Yu et al., 2002; Lehr et al., 2004). 
Moreover, specific inhibition of mTOR signaling with everolimus or rapamycin resulted in 





























































































































Figure 12: Effects of PI3K, AKT, mTOR and MEK1/2 inhibition on cSCC cell lines. Representative blots 
showing changes in pAKT, pERK and pS6 levels upon treatment of SCL-I, MET-1 and MET-4 cells with 50 nM 
everolimus, 100 nM rapamycin, 5 µM MK-2206, 3 µM PI103, 10 µM GDC-0941 and 20µM UO126. HSC70 
expression served as a loading control. The size (in kDa) of the analyzed proteins is indicated on the left side of 
the blots.  
To further see whether these changes affect the GLI1 expression level, we incubated the cells 
with the same set of inhibitors for 24 h and performed GLI1-specific qPCR analysis. 
Treatment with PI3K/AKT and/or mTOR inhibitors consistently inhibited GLI1 expression. 
The inhibition was significant in all cell lines with the exception of MET-1 cells after 
treatment with rapamycin or PI103 (Fig. 13). Interestingly, GLI1 was significantly 
upregulated in SCL-I cells upon treatment with UO126, whereas in MET-1 and MET-4 cells 
this drug did not influence GLI1 expression level (Fig. 13). This indicates that in general 
inhibition of PI3K/AKT/mTOR signaling decreases GLI1 transcription, whereas inhibition of 
MEK1/2 (and concomitant decrease in ERK phosphorylation) results either in activation of 
GLI1 transcription (i.e. in SCL-I cells) or does not impact on GLI1 expression (i.e. in MET-1 
and MET-4 cells). In other words, whereas PI3K/AKT/mTOR signaling may in general 




























































Figure 13: Impact of PI3K, AKT, mTOR and MEK1/2 inhibition on GLI1 expression level in cSCC cell 
lines. Relative GLI1/18S expression upon 24 h treatment of SCL-I, MET-1 and MET-4 cells with 50 nM 
everolimus, 100 nM rapamycin, 5 µM MK-2206, 3 µM PI103, 10 µM GDC-0941, 20µM UO126 and solvent 
control that was set to 1. Each graph summarizes data from 3 independent experiments performed in triplicates. 
Data are presented as mean +/- SEM; *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. Statistical 
comparisons were done with Mann-Whitney test. 
To further analyze the potential role of mTOR or PI3K/AKT pathway in activation of GLI1 
expression and/or its relevance for pathogenesis of cSCC we first transfected SCL-I cells with 
one of three mTOR plasmids expressing wild type mTOR (pcDNA3-Flag mTOR wt), a 
constitutively active (pcDNA3-AU1-mTOR-S2215Y) or a rapamycin-resistant (pcDNA3-
Flag mTOR S2035T) variant as well as a corresponding empty vector (pcDNA3). Prior to the 
expression analysis we confirmed the specificity of the plasmids by sequencing the part of 
insert bearing the indicated mutation (data not shown). If mTOR indeed should positively 
regulate GLI1, then all three mTOR variants should increase GLI1 expression level under full-
serum conditions. Moreover, in case of wild type and constitutively active variants, GLI1 





























































































































































active mTOR variant bearing S2215Y point mutation is still sensitive to rapamycin treatment 
(Sato et al., 2010). However, it should not decrease in cells transfected with the rapamycin-
resistant mTOR variant. Unfortunately, we were not able to detect any overexpression of 
mTOR, neither with anti-AU1 nor with anti-flag tag antibody (data not shown). We also 
checked the level of pS6 as readout for mTOR pathway activity but we did not observe any 
differences when compared to the empty vector control (data not shown). Therefore, we did 
not put more effort in this experiment.  
In order to investigate the potential role of PI3K/AKT in GLI1 activation, the cells were 
transfected with either a constitutively active variant of AKT1 (Akt1-CA) or its dominant 
negative form (Akt1-DN). If AKT indeed should positively regulate GLI1 expression, then 
the transfection with constitutively active variant should result in increase, whereas the 
dominant negative variant should decrease the GLI1 expression level. The constitutive 
activation of Akt1-CA variant is achieved by fusing src myristoylation signal (myr) to N-
terminal end of Akt1 sequence. Myristoylation signal targets Akt1 to the cell membrane and 
results in its constitutive activation. Furthermore, Akt1-CA has a depleted PH domain and 
thus the protein size is smaller (~52 kDa) than the full length Akt1-DN (~60 kDa) and both 
plasmids contain an HA-tag (Fig. 14 A). To first assess the efficiency of the transfection and 
the functionality of the plasmids we performed Western Blot with an anti-HA tag antibody as 
well as anti-AKT/pAKT antibodies. In addition, we used HEK293 cells as a positive control 
due to their great transfection efficiency. The results show that the HA-tagged forms of AKT1 
are expressed in HEK293 cells at the expected sizes (Fig. 14 B). As expected, the Akt-CA 
variant was highly phosphorylated, whereas phosphorylation of endogenous AKT did not 
change in HEK293 cells. Also, Akt1-DN was highly expressed as indicated by the detection 
of HA tag. As expected the expression of Akt1-DN was accompanied by a decrease in 
endogenous AKT phosphorylation confirming thereby functionality of the plasmid (Fig. 14 
B). When the plasmids were expressed in the experimental SCL-I cell line we detected a band 
corresponding to the Akt1-CA variant with the anti-HA tag antibody, which was accompanied 
by a slight increase in phosphorylation of endogenous AKT detected with anti-pAKT 
antibody. On the other hand, only a very faint band was detected for the Akt1-DN variant 
with the anti-HA tag antibody. Overall, either the transfection efficiency or the expression of 
the plasmids in SCL-I cells was lower than in HEK293 cells. (Fig. 14 B). When GLI1 




either 18S rRNA or HPRT expression, no significant changes in GLI1 expression were 
detected when compared to untransfected cells or to cells that have been transfected with a 
plasmid that expresses EGFP (Fig. 14 C). Together these data suggest that i) GLI1 expression 
is not regulated by AKT and ii) that the downregulation of GLI1 upon incubation of the cells 
with MK-2206 and PI103 (and also with GDC-0449; see Fig. 13) must be due to other 


















































































Figure 14: Expression of a constitutively active and dominant-negative form of AKT and impact on GLI1 
expression level in cSCC cells lines. A. A scheme depicting specific mutations and modifications of the 
constitutively active (CA) and dominant negative (DN) form of AKT within the plasmid used for transfection; 
myr, N-terminal myristoylation signal in the Akt1-CA plasmid; K179M, dominant negative point mutation in 
Akt1-DN plasmid; the HA tag is located at the C- or N- terminus of Akt1-CA and Akt1-DN plasmids, 
respectively. B. Western Blot analysis for the detection of the HA tag and total AKT/pAKT showing the 
efficiency of transfection and functionality of the plasmids in HEK293 control cell line and SCL-I cells at 
indicated time points. HSC70 served as a loading control. Protein sizes (kDa) are indicated on the left side of the 
blot. The 60 kDa size corresponds to the full-length Akt1-DN variant as well as endogenous AKT. 52 kDa size 
corresponds to the Akt1-CA variant, which has a depleted PH domain. C. qPCR analysis of GLI1 in SCL-I and 
MET-4 cells 24 h after transfection with the AKT plasmids or EGFP control plasmid. GLI1 expression was 
normalized to the expression of either 18S rRNA or HPRT and compared to values of untransfected and EGFP 
transfected cells. The expression in untransfected cells was set to 1. Each graph summarizes three technical 
replicates of one experiment. The data are presented as the mean +/- SEM; untr, untransfected. Statistical 

























































































































To investigate the impact of MEK/ERK on GLI1 expression we have pursued a different 
approach. As described in section 6.1. we observed pERK expression in stromal cells 
surrounding the cSCC cells that were negative for GLI1 (see Fig. 5 D). We also described that 
cells located in outer parts of the tumor are strongly pS6 positive (see section 6.1, Fig. 5 B and 
E) and might therefore play a role in integration of the signals derived from stroma. Due to 
the experiments indicating that the MEK/ERK axis may indeed negatively impact on GLI1 
expression (see section 6.3.3. and 6.4.1.), we decided to check whether fibroblasts that 
express pERK (Wayne et al., 2006) and are a common type of stromal cells may influence 
GLI1 expression. For this purpose, we co-cultured SCL-I, MET-1 and MET-4 cells with the 
human fibroblast cell line BJ. Our co-culture system allows for clear distinction between 
different cell types as “feeder cells” are cultured in inserts with pore size that enables 
exchange of nutrients but not cell migration. We observed that co-culture of SCL-I cells with 
BJ cells significantly inhibited GLI1 expression. A similar tendency was also observed in co-
cultured MET-1 cells when compared to the MET-1 monoculture system, whereas in MET-4 
cells this effect was not visible (Fig. 15 A). This shows that fibroblasts that express pERK can 
inhibit GLI1 expression in a paracrine manner. To exclude effects of the factors included in 
the serum, we also performed the same experiment under serum depletion conditions (0.5% 
FCS). Under starved conditions we also noted the decrease in GLI1 expression in all 3 cell 
lines, which however did not reach significance (Fig. 15 A). Unfortunately, we so far have not 
checked for pERK expression in BJ ourselves, which will be done in the future.   
Based on the opposing staining pattern between pS6 and GLI1 in human cSCC tissue sections 
(see Fig. 5 B), we also wanted to know whether the decrease in GLI1 expression level was 
accompanied by changes in S6 phosphorylation. For this purpose, we co-cultured fibroblasts 
with SCL-I cells in 10% FCS-containing medium and stained the SCL-I cells via 
immunofluorescence with a Cy3 anti-pS6 antibody. However, we did not observe any 
changes in the number of pS6 positive cells between mono- and co-culture (Figure 15 B, C). 
Nevertheless, it remains to be said that the basal expression level of pS6 in monocultured 
control cells is high and reaches nearly 100%. Thus, an increase in pS6 positive cells or an 
upregulation of pS6 protein expression would have been hard to detect. Together, although we 
could neither confirm nor exclude a negative regulation between GLI1 and pS6, the results 
indicate that the tumor microenvironment may play a role in GLI1 downregulation within the 
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Figure 15: Impact of co-cultured human fibroblasts on GLI1 and pS6 expression in cSCC cell lines. 
Analysis of the cSCC cell lines SCL-I, MET-1 and MET-4 that were co-cultured with the human fibroblast cell 
line BJ (co-cultured) in comparison to monocultured cells (ctrl). A. Comparison of GLI1 expression levels under 
full-serum and serum-depleted conditions. All data are presented as the mean value +/- SEM of three 
independent experiments; **, p<0.01. Statistical analysis was performed using Mann-Whitney test; ctrl, control. 
B. Expression analysis of pS6 by immunofluorescence. Representative pictures show pS6-Cy3 expression in red 
and DAPI-stained nuclei in blue at a 20 x magnification. C. pS6-Cy3 positive cells (red) shown as the percentage 
of all cells visualized by DAPI staining (blue). 
6.4.2. Impact of EGF/EGFR and IGF1/IGF1R on GLI1 expression level 
The RTKs EGFR and IGF1R are known to be highly expressed in a high percentage of cSCC 
in patients (Oh et al., 2014; Shimizu et al., 2001) and are also expressed in MET-1 and MET-
4 cells (Clayburgh et al., 2013). 
Because RAS/MEK/ERK and PI3K/AKT/mTOR signaling are downstream of RTKs and 
because cSCC express high levels of at least the EGF ligand (see Fig. 5 E), we next wanted to 
know whether EGF or related RTK ligands are involved in the modulation of noncanonical 
HH/GLI signaling. Hence the cell lines were stimulated with commercially available EGF and 
IGF1. To exclude effects of growth factors included in the serum of the cell culture medium, 
all the experiments with EGF or IGF1 were done under serum depletion conditions (0.5 % 
FCS containing medium). To first establish the most efficient conditions for stimulation of the 
pathways, cells were incubated with different concentrations of the ligands and for different 
time durations. As revealed by Western Blot, incubation with 100 ng/µl EGF as short as for 5 
min was sufficient to trigger phosphorylation of ERK1/2, the downstream target of MEK, 
while phosphorylation of AKT appeared after 30 min of stimulation (Fig. 16 A). These 
























































































thus activation of mTOR signaling. This activation was sustained throughout the experiment 
(Fig. 16 A). However, ERK and AKT phosphorylation was only a temporary effect as the 
phosphorylation of pAKT and pERK decreased after 6 h of incubation in all three cell lines 
and after 3 h in SCL-I and MET-4 cells, respectively (Fig. 16 A). The decrease in pS6/S6 
levels after 5 min of treatment in MET-4 cells is a matter of protein loading (see fainter 
HSC70 signals in Fig. 16 A), and was not seen in the other 2 blots that have been done. 
We next examined the changes in GLI1 transcription. Indeed, as shown in Fig. 16 B, EGF 
significantly decreased the expression of this HH signaling marker in all 3 cell lines after 3 h 
of incubation (Fig. 16 B). This is in line with the opposing staining pattern observed for EGF 
and GLI1 in some human tissue samples in invading parts of the tumors (see Fig. 5 E). 
 
 


























































































































































Figure 16: Effects of EGF on PI3K/AKT, MEK/ERK and mTOR downstream signaling pathways on 
GLI1 expression level in cSCC cell lines. A. Representative Western Blot showing activation of PI3K/AKT, 
MEK/ERK and mTOR signaling pathways upon treatment with 100 ng/µl EGF in a time-dependent manner. Red 
frames highlight the strongest induction of phosphorylation of AKT, ERK and S6 in each cell line. HSC70 
served as a loading control. Protein size in kDA is indicated on the left side of the blot. B. Changes in GLI1/18S 
rRNA expression level upon 3 h stimulation with EGF in SCL-I, MET-1 and MET-4 cells. Each graph represents 
a summary of three independent experiments measured in triplicates with solvent control set to 1. All data are 
displayed as a mean +/- SEM; **, p<0.01; ***, p<0.001. Statistical comparisons were done by Mann-Whitney 
testing. 
On the other hand, 50 ng/µl IGF1 activated the downstream signaling pathways after 3-6 h 
with phosphorylation of AKT appearing already after 3 h of incubation in all three cell lines 
and less prominent phosphorylation of ERK after 6 h of incubation in SCL-I and MET-1 cells. 
No changes in pERK were observed in MET-4 cells (Fig. 17 A). As observed upon EGF 
stimulation, IGF1-mediated increase in pAKT and pERK was accompanied by increased pS6 
levels occurring already after 3 h of incubation and indicating activation of mTOR signaling. 
Moreover, increase in pS6 expression clearly overlapped with induction of AKT 
phosphorylation. These data might indicate that IGF1 mainly stimulates AKT phosphorylation 
that further activates mTOR. Similar effects have been described in the literature, suggesting 
that IGF1 strongly induces PI3K/mTOR but only weakly activates RAS/ERK activity 
(Mendoza et al., 2011). Importantly, and as seen with EGF, the incubation with IGF1 also 
decreased GLI1 transcription after 6 h, which was significant for SCL-I and MET-4 cells (Fig. 
17 B).  
Together these data suggest a negative regulation of GLI1 expression by EGF and IGF1 






Figure 17: Effects of IGF1 on PI3K/AKT, MEK/ERK and mTOR downstream signaling pathways and on 
GLI1 expression level in cSCC cell lines. A. Representative Western Blot showing phosphorylation of AKT, 
ERK and S6 in MET-1, MET-4 and SCL-I cells upon incubation with 50 ng/µl IGF1 for the indicated time 
points. Red frames highlight the strongest induction of pAKT, pERK and pS6 in each cell line. HSC70 served as 
reference controls. Protein size is indicated on the left side of the blot. B. qPCR showing changes in GLI1 
expression upon incubation with 50 ng/µl of IGF1 for 6 h in SCL-I, MET-1 and MET-4 cells. The GLI1 data 
were normalized to the expression of the 18S rRNA housekeeping gene and the relative expression of control 
cells was set to 1. Each graph represents a summary of two independent experiments performed in 3 technical 
replicates. The data are shown as a mean +/- SEM; *, p<0.05; **, p<0.01. Statistical comparisons were done 
with Mann-Whitney test. 
 






























































































































































6.4.3. Impact of EGF plus MEK, PI3K, AKT and/or mTOR inhibitors on GLI1 
expression level 
We next wanted to see, whether the EGF-induced significant GLI1 inhibition was also 
mediated by the MEK axis. For this purpose, we combined EGF with UO126, but also with 
the inhibitors of the PI3K/AKT or mTOR pathway. As already described in the section 
before, a 3 h incubation with EGF resulted in a decrease in GLI1 transcription. However, the 
inhibitors have been used for 24 h (see section 6.4.1.). Therefore, in this experimental design, 
we preincubated the cells for 21 h and added EGF to the cells for the last 3 h of incubation. 
Afterwards, the cells were collected for RNA isolation and subjected to gene expression 
analysis. Indeed, the qPCR data suggest that GLI1 inhibition is mediated by MEK/ERK rather 
than by mTOR or PI3K/AKT signaling. This is due to the fact that the combined treatment of 
EGF plus UO126 (MEK1/2 inhibitor) led to an upregulation of GLI1 in comparison to EGF 
treatment alone. This upregulation was observed in all 3 cell lines and resulted in GLI1 
expression that was not significantly modulated with respect to either the solvent- or EGF-
mediated values. In MET-1 cells, UO126 even significantly upregulated EGF-mediated GLI1 
expression, when compared to EGF-treatment alone (Fig. 18). On the contrary, treatment with 
PI3K, AKT or mTOR inhibitors, either alone or in combination with EGF, strengthened the 
downregulation of GLI1 expression level, which points to a positive regulatory mechanism 
between these pathways and HH/GLI signaling (Fig. 18).  
In summary, these data foster the assumption that EGF-mediated GLI1 downregulation is 





Figure 18: Effects of EGF plus PI3K, AKT, mTOR or MEK1/2 inhibition on GLI1 expression level in 
cSCC cell lines. qPCR representing GLI1 expression upon treatment with EGF or EGF combined with 50 nM 
everolimus, 100 nM rapamycin, 5 µM MK-2206, 3 µM PI103, 10 µM GDC-0941 or 20µM UO126 in SCL-I, 
MET-1 and MET-4 cells. The expression level was normalized to 18S rRNA gene expression and solvent treated 
controls were set to 1. Data are presented as mean values of three independent experiments measured in 
triplicates +/- SEM; *, p<0.05; **, p<0.01. Statistical comparisons were done with Mann-Whitney test. 
Besides investigation of the impact of the ligands EGF and IGF1 on GLI1 expression level we 
also started to use EGFR and IGF1R blocking antibodies (EGFR ab and IGFR ab, 
respectively) in order to block the respective receptors. So far, we have used only one 
condition for EGFR ab (10 ng/µl for 24 h) and have varied the concentration (0.5-10 ng/µl) 
and the incubation time (1-24 h) for the IGF1R ab.  Since the experiments have been done 

















































































































































































In the preliminary setting for EGFR ab treatment, the cells were incubated with 10 ng/µl of 
EGFR ab for 24 h. This incubation time was chosen because it has been shown that 24 h of 
treatment with anti-EGFR monoclonal antibodies efficiently decreases levels of pEGFR, 
pAKT and pERK levels in HNSCC cell lines (Zhang et al., 2008). We noted a strong decrease 
in pAKT level when compared to the solvent treated control, but we did not detect any 
obvious changes in phosphorylation of ERK or S6 proteins (Fig. 19). Since the latter effect 
however is expected, EGFR ab will be used in future experiments at higher or lower 
concentrations and for shorter or longer incubation times. 
 
Figure 19: Impact of EGFR neutralizing antibody on PI3K/AKT, MEK/ERK and mTOR signaling in 
SCC cells. Western Blot showing AKT/pAKT, ERK/pERK and S6/pS6 levels in SCL-I cells that have been 
treated for 24 h with either 100 ng/µl EGF, 10 ng/µl of the EGFR blocking antibody (EGFR ab) or combination 
of both (EGF + EGFR ab), HSC70 served as a loading control. Protein sizes in kDA are indicated on the left side 
of the blot; untr, untreated. 
The experiments using the IGF1R ab were first done in MCF-7 control cells, in which 11 
ng/µl of the antibody neutralizes IGF1-stimulated proliferation by 50-75% (as specified by 
R&D Systems, Inc). Moreover, the incubation for 24 h with 11 ng/µl IGF1R ab apparently 
effectively decreases pAKT level in human astrocytes (Garwood et al., 2015). In our setting, 
we incubated MCF-7 cells with 0.5-2 ng/µl IGF1R ab for 24 h. Figure 20 A shows that the 
concentration as low as 0.5 ng/µl of IGF1R ab is sufficient to reduce AKT phosphorylation in 
MCF-7 cells. This effect is even stronger with increasing concentrations of the antibody. 











































by unchanged pERK and pS6 level (Fig. 20 A). In parallel, we tried to establish optimal 
conditions in MET-1, MET-4 and SCL-I cSCC cell lines. For this purpose, we applied the 
antibody within the same concentration range but unfortunately, we did not observe any effect 
on AKT, ERK or S6 phosphorylation (data not shown). Thus, in the next step we increased 
the concentration of the antibody to 10 ng/µl (Fig. 20 B). As shown in Figure 20 B, incubation 
with IGF1R ab may result in a moderate decrease in pAKT level in MET-4 cells, however, as 
seen on the same blot, the detection of HSC70 was inadequate (Fig. 20 B). Otherwise we did 
not observe any changes. Since EGF/IGF1 stimulation showed that phosphorylation of AKT, 
ERK and S6 in cSCC cell lines is a rapid process (see section 6.4.3., Fig. 16 A and 17 A), we 
also decreased the incubation time of IGF1R ab and examined AKT/pAKT, ERK/pERK and 
S6/pS6 upon incubation with 5 ng/µl or 10 ng/µl within the time course ranging from 1 - 6 h 
in SCL-I cells (Fig. 20 C). The data show a slight decrease in pAKT level after 3 h of 
incubation with either 5 ng/µl or 10 ng/µl. Furthermore, a decrease in pERK was observed 
after 1 h and 3 h of incubation with the antibody, whereas pS6 remained unchanged (Fig. 20 
C).  
Taken together, we showed that IGF1R and EGFR inhibition with blocking antibodies still 













































Figure 20: Impact of IGF1R neutralizing antibody on PI3K/AKT, MEK/ERK and mTOR signaling in 
MCF-7 and cSCC cells. A. Representative Western Blot showing the effects of 24 h incubation with IGF1R 
neutralizing antibody (IGF1R ab) at the concentration of 0.5, 1, and 2 ng/µl in MCF-7 control cells on the level 
of AKT/pAKT, ERK/pERK and S6/pS6. B. Representative Western Blot showing changes in AKT/pAKT, 
ERK/pERK and S6/pS6 levels upon treatment with 1, 5 or 10 ng/µl IGF1R ab for 24 h in MET-1, SCL-I and 
MET-4 cells. C. Western Blot showing AKT/pAKT, ERK/pERK and S6/pS6 levels in SCL-I cells that have 
been treated for 1, 3 or 6 h with either 5 or 10 ng/µl of the IGF1R ab or with the solvent for 3 h. HSC70 served 
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6.5. Impact of canonical and noncanonical HH signaling on metabolic activity, 
proliferation and apoptosis of cSCC cell lines 
6.5.1. Impact of MEK, PI3K/AKT, mTOR and SMO inhibitors 
As described in sections, 6.4.1. and 6.4.3. (see Fig. 13 and 18), the incubation of cSCC cells 
with the mTOR antagonists everolimus or rapamycin and the PI3K and/or AKT inhibitors 
GDC-0941, PI103 and MK-2206 resulted in a decrease in GLI1 expression and thus of HH 
signaling activity. In contrast, the MEK inhibitor UO126 did not change or even increased 
GLI1 levels. The SMO inhibitor HhA decreased (in MET-1 and MET-4) or increased (in 
SCL-I) GLI1 expression level, whereas vismodegib increased it at the high dose of 60 µM. 
(see Fig. 10). In order to get an impression if the level of HH signaling activity and EGF-
associated decrease in GLI1 expression alters metabolic activity, proliferation and apoptosis 
of cSCC cells, we performed WST-1 assay, BrdU incorporation assay and Annexin V/PI 
staining, respectively, as described in 5.2.13., 5.2.12. and 5.2.14. in the Methods section. To 
roughly assess the time that cells need to double the population and incorporate BrdU, we 
counted the cells at the time of seeding and after 24 h of culture. Based on just these two 
values, the accurate doubling time could not be calculated. However, as shown in Fig. 21, 24 
h is more than enough for SCL-I and MET-4 cells lines to double the population (Fig. 21).  

























Figure 21: Growth curves showing proliferation of SCL-I and MET-4 cells. The graph shows the absolute 
number of untreated SCL-I and MET-4 cells at the time of seeding (0 h = 1.5 x 105 cells) and after 24 hours of 
culture (24 h). Dead cells were stained with trypan blue and the living cells were counted using Neubauer 
counting chamber. The graph represents one exemplary experiment. 
Therefore, the inhibitor treatments as well as BrdU labeling were done for 24 h. The same 




determined. As shown in Fig. 22, everolimus, rapamycin and vismodegib were well-tolerated 
by all three cSCC cell lines because metabolic activity as shown by WST-1 assay was not 
severely affected (Fig. 22). Additionally, they did not strongly affect proliferation rate of 
cSCC tumor cells as indicated by the percentage of BrdU positive cells (Fig. 23). MK-2206 
was also well-tolerated by SCL-I cells and did not influence the proliferation rate of this cell 
lines. However, this drug displayed a moderate toxicity on MET-1 and MET-4 cells, which 
was accompanied by a decrease in BrdU incorporation. GDC-0941 and PI103 strongly 
reduced both metabolic activity and proliferation rate showing their cytotoxic effects in all 
three cell lines. In contrast, the MEK1/2 inhibitor UO126 exerted only minor effect on 
metabolic activity of MET-1 cells and slightly decreased the proliferation of all three cell 
lines. HhA showed moderate toxicity but at the same time reduced the proliferation rate. The 
reduction was around 50 – 60% for all cells at a concentration of 30 µM (Fig. 22 and 23). 
Concerning Annexin V staining, the results show that UO126 increased the number of early 
apoptotic SCL-I cells (Fig. 24). This stays in contrast to the observation that UO126 only 
slightly decreased the proliferation of SCL-I cells. However, we did not observe an increase 
in late apoptotic cells which might indicate that after 24 h of the treatment the cells only start 
undergoing apoptosis and that this time is too short to observe changes in proliferation. 
Otherwise, none of the inhibitors induced apoptosis in any of the cell lines examined. Having 
in mind that UO126 treatment of SCL-I cells resulted in inhibition of MEK1/2 and ERK and 
concomitantly upregulated GLI1 expression (see Fig. 12, 13) the data might indicate that 
GLI1 in this cell line may promote apoptosis. Finally, the moderate inhibition of proliferation 
of all UO126-treated cell lines together with GLI1 upregulation or lack of GLI1 modulation 





Figure 22: Influence of PI3K/AKT, MEK/ERK, mTOR and HH/GLI inhibitors on metabolic activity of 
cSCC cells. WST-1 metabolic activity assay showing the influence of 50 nM everolimus, 100 nM rapamycin, 5 
µM MK-2206, 3 µM PI103, 10 µM GDC-094, 20µM UO126 as well as HhA and vismodegib at the 
concentration of 10 µM and 30 µM on the viability of SCL-I, MET-1 and MET-4 cells 24 h after incubation. The 
number of viable cells from the solvent treated group was set to 100 %. Each graph represents the mean value +/- 































































































































































































































































Figure 23: Influence of PI3K/AKT, MEK/ERK, mTOR and HH/GLI pathways inhibitors on proliferation 
of cSCC cells. BrdU incorporation assay showing the influence of 50 nM everolimus, 100 nM rapamycin, 5 µM 
MK-2206, 3 µM PI103, 10 µM GDC-094, 20µM UO126 as well as HhA and vismodegib at the concentration of 
10 µM and 30 µM on proliferation of SCL-I, MET-1 and MET-4 cells 24 h after incubation. The data are 
presented as the percentage of BrdU positive with the value of solvent treated cells set to 100 %. Each graph 
represents the mean value +/- SEM of three independent experiment; *, p<0.05; **, p<0.01; ***, p<0.001; ****, 








































































































































































































































































Figure 24: Influence of PI3K/AKT, MEK/ERK, mTOR and HH/GLI pathways inhibitors on apoptosis of 
cSCC cells. FACS analysis of Annexin V/PI positive cells showing the influence of 50 nM everolimus, 100 nM 
rapamycin, 5 µM MK-2206, 3 µM PI103, 10 µM GDC-094, 20µM UO126 as well as HhA and vismodegib at 
the concentration of 10 µM and 30 µM on apoptosis of SCL-I, MET-1 and MET-4 cells. The data show the 
percentage of viable cells, early- and late- apoptotic as well as necrotic cells in each sample. 5 µM staurosporin 
(SS) was used as a positive control. Representative graphs from one out of three experiments are shown. 
6.5.2. Impact of EGF and IGF1 
Since also EGF and IGF1 led to a significant downregulation of GLI1 mRNA (see Fig. 16 B 
and 17 B), we also incubated the cells with either EGF or corresponding solvent control along 
with BrdU for 24 h. 
We first incubated MCF-7 cells with EGF, which are known to express EGFR (Comsa et al., 
2015) and measured BrdU incorporation after 24 h. Piling up the results from three 
independent experiments measured in triplicates, MCF-7 cells showed a significant and 30% 

























































































































































































































































































However, when cSCC cell lines were incubated with EGF, we did not observe any changes in 
BrdU incorporation in MET-1 and MET-4 cells when compared to the solvent control. This 
suggested that EGF has no impact on proliferation of these cSCC cell lines. Paradoxical, for 
SCL-I cells, we even noted a statistically significant decrease in proliferation upon incubation 
with EGF (Fig. 25). Together, because EGF strongly inhibits GLI1 expression and thus HH 
signaling in cSCC, these data once again suggest that HH/GLI1 signaling activity is unrelated 
to cellular proliferation of cSCC cells. It is rather unlikely that the concentration of EGF was 
too low or that incubation time was too short because in one experimental setting we doubled 
the EGF concentration (200 ng/µl) and incubation time (48 h) and we did not observe any 
increase in proliferation (data not shown). However, since this assay was performed under 
serum starvation conditions (0.5 % FCS), it is possible that cSCC cells in addition to EGF 
require other factors that are normally included in the serum to boost proliferation. Thus, it 
would be worth to perform this assay also under full-serum conditions in the future.  
 
Figure 25: Influence of EGF on proliferation of MCF-7 and cSCC cell lines. BrdU incorporation in solvent 
treated (set to 100 %) and EGF stimulated MCF-7, SCL-I, MET-1 and MET-4 cells. The cells were 
incubated with EGF or the solvent along with BrdU for 24 h in the medium containing 0.5 % FCS. Each graph 
summarizes three independent experiments performed in triplicates. **, p<0.01. Statistical analysis was 
performed using Mann-Whitney test. 
6.5.3. Impact of GLI1 knockdown or GLI1 overexpression  
Finally, in order to prove that GLI1 is not involved in proliferation of cSCC cells a GLI1 
specific siRNA was transfected into SCL-I and MET-4 cells. In a control experiment and to 
check for transfection efficiency, MAPK1 was first knocked down using a siRNA from the 
Qiagen kit. Indeed, MAPK1 transcription level was remarkably downregulated in both SCL-I 
and MET-4 cells (Fig. 26 A, SCL-I data not shown). When MET-4 cells were transfected with 


















































































































GLI1 specific siRNA, GLI1 transcripts were significantly downregulated 24 h after 
transfection in comparison to the scrambled siRNA control (Fig. 26 A) and the effect was 
sustained at least for 48 h (data not shown). Unfortunately, the transfection and GLI1 
downregulation did not work well in SCL-I cells, which were thus excluded from the analysis.  
We next assessed BrdU incorporation in MET-4 cells upon GLI1 knockdown. BrdU was 
added to the cells 24 h after transfection for another 24 h. As shown in Figure 26 B, the 
proliferation rate of the cells was not affected (Fig. 26 B).  
 
Figure 26: Influence of GLI1 levels on proliferation of MET-4 cells. A. qPCR of MAPK1 and GLI1 
expression level upon MAPK1 (used as a positive control) and GLI1 specific knockdown in MET-4 cells. B. 
Influence of siRNA mediated GLI1 knockdown on proliferation shown by BrdU incorporation assay. Each graph 
summarizes three independent experiments. ****, p<0.0001. Statistical analysis was performed using Mann-
Whitney test; untr, untransfected; scram, scrambled. 
On the other way around, we overexpressed GLI1 in SCL-I and MET-4 cells by transfection 
with plasmids encoding murine Gli1 or human GLI1. To first verify the efficiency of 
overexpression, we analyzed the GLI1 as well as GLI2 mRNA levels 24 h after transfection. 
Since the GLI1 specific primers detect both endogenous and exogenous GLI1 we used GLI2 
expression as readout for GLI1 overexpression. Thus, it is known that GLI2 expression can be 
regulated via GLI1 (Regl et al., 2002). qPCR showed that overexpression of either Gli1 (data 
not shown) or GLI1 led to the increase in GLI1 and GLI2 transcription level (Fig. 27 A), that 
however was not significant because the experiment so far has been done only once in 
triplicates. The data were normalized to the two housekeeping genes 18S rRNA (Fig. 27 A) 












































































































To investigate the role of Gli1 or GLI1 on proliferation of cSCC cells Gli1 or GLI1 were 
overexpressed for 48 h in SCL-I and MET-4 cells. BrdU was added to the cells after 24 h and 
its incorporation was measured after 24 h. The data show that there was no significant change 
in the cellular proliferation rate after Gli1 (data not shown) or GLI1 overexpression when 
compared to the empty vector control in either of cell lines (Fig. 27 B). Taken together, these 
data suggest that GLI1 is dispensable for proliferation of cSCC cell lines as neither GLI1 
knockdown nor Gli1/GLI1 overexpression influenced the cellular proliferation of cSCC cells. 
Nevertheless, these data are only preliminary because they summarize only one single 


















































































































































Figure 27: Influence of GLI1 overexpression on proliferation of SCL-I and MET-4 cells. A. qPCR showing 
changes in GLI1 and GLI2 expression level after transfection with a plasmid expressing human GLI1 or 
pcDNA4 empty vector in comparison to mock transfected cells. The data show relative expression levels 
normalized to 18S rRNA housekeeping gene with the value of mock-transfected cells set to 1. Each graph 
represents a summary of three independent experiments displayed as mean +/- SEM. B. BrdU incorporation 
assay showing changes in proliferation of SCL-I and MET-4 cells upon overexpression of GLI1 in comparison to 
mock-transfected and the empty vector controls. The proliferation of mock-transfected cells was set to 100 %. 
Each graph represents a summary of three independent experiments displayed as mean +/- SEM. Statistical 














































































7. Discussion   
HH signaling pathway plays an important role in embryonic development and is deregulated 
in many various cancer entities including non-melanoma skin cancer. The link between 
canonical HH signaling and cancer formation has been well established in BCC and the 
majority of BCCs are driven by inactivating mutations in PTCH (reviewed in (Epstein, 
2008)).  
PTCH mutations were also described in a minority of cSCCs (Ping et al., 2001), however 
there are not many studies showing relevance of canonical HH signaling pathway as a driving 
force of this tumor. For example, one study claims that canonical HH/GLI signaling plays an 
important role in proliferation, migration and invasiveness of cSCC. This was due to the fact 
that the A431 cSCC cell line apparently highly expresses Gli1, which seems to be important 
for tumor biology since cyclopamine treatment resulted in inhibition of proliferation, 
migration and invasiveness of this cell line. In addition, the authors showed that GLI1 and 
SHH are correlated with poor overall survival of cSCC patients. Furthermore, the authors 
claim that the mice treated with cyclopamine or those with a Gli1 knockdown show a lower 
cSCC incidence in a DMBA/TPA induced model (Sun et al., 2016). However, there are many 
inconsistencies in this paper so that the data is hard to believe. One example is the animal 
experiment: Although the authors show data from mice, the animals are described as rats in 
the material and methods section. Furthermore, the mice are not specified and only described 
as Gli1- or Gli1+. In addition, the authors talk about “Tumor xenografts in nude mice” when 
describing the DMBA/TPA treatment of the animals. In contrast to this report, numerous 
clinical data show that treatment of BCC with vismodegib and thus inhibition of HH signaling 
and concomitant downregulation of GLI1 results in development of cSCC. Nevertheless, the 
mechanism behind it is not yet known and might be quite complex (Aasi et al., 2013; 
Iarrobino et al., 2013; Orouji et al., 2014) (G. A. Zhu et al., 2014).  
Whereas data about the role of HH signaling in cSCC is still conflicting, several other 
signaling pathways are better described in cSCC. Clinical data show that EGFR receptors are 
frequently overexpressed in patients suffering from cSCC and thus are a main target for the 
therapy with however no approved drugs so far (G. B. Fogarty et al., 2007a). Additionally, the 
fact that OTRs receiving Sirolimus, an immunosuppressive medication that blocks mTOR, 




in cSCC pathogenesis (Leblanc et al., 2011; Salgo et al., 2010; Tessmer et al., 2006). 
Moreover, clinical examination revealed that mutations in p53 carrying hallmarks of UV-
induced mutagenesis are detectable in a majority of patients (Brash et al., 1991). Wnt/ß-
catenin-, calcium- and integrin- signaling were also shown to be upregulated in cSCC when 
compared to the normal skin (Ra et al., 2011) (see 2.1. in Introduction section). Also RAS and 
AKT are frequently activated in cSCC (Barrette et al., 2014; Uribe and Gonzalez, 2011) and 
thus might be involved in cSCC pathogenesis (for detailed description see 2.1. and 2.3.4. in 
Introduction section). 
However, experimental data unraveling putative crosstalks between different pathways and 
their influence on expression of genes involved in crucial processes i.e. proliferation in cSCC 
are scarce. 
Here, we investigated the role of canonical and potential noncanonical HH signaling in human 
tissue samples as well as human cSCC cancer cell lines. Our data reveal that the major 
downstream target of HH signaling GLI1 is highly expressed in the tumor center of cSCC, but 
not in cSCC cells invading the dermis. Furthermore, we suggest that its expression is not 
regulated via the canonical SHH/PTCH/SMO axis but it is rather suppressed via 
EGF/MEK/ERK signaling. Moreover, our preliminary data show that GLI1, although highly 
expressed in cSCC, is dispensable for proliferation of cSCC.  
7.1. Canonical HH signaling in cSCC 
7.1.1. GLI1 is highly expressed and SHH is not detectable in human cSCC tissue 
samples 
In the first part of this study we examined the expression of important components of 
canonical HH signaling pathway i.e. GLI1 and SHH in human cSCC samples. The data show 
that GLI1 is highly expressed in the tumor center but not in cSCC cells invading the dermis. 
This suggests that GLI1 might play a role in cSCC tumorigenesis but its downregulation is 
required for tumor progression. Indeed, clinical data show that treatment of BCC with 
vismodegib which inhibits GLI1 expression results in the development of cSCC (Orouji, 
Goerdt, Utikal, & Leverkus, 2014; Poulalhon, Dalle, Balme, & Thomas, 2015; Saintes et al., 
2015). In addition, there was no positive staining for SHH throughout the tumor tissue (Fig. 5 




thereby possibility of paracrine signaling. This suggests that GLI1 is an important factor in 
cSCC pathogenesis, which however, unlike in BCC, seems to be regulated via mechanism 
independently of the canonical HH/PTCH/SMO axis. This is in contrast to the study showing 
expression of GLI1, GLI2, GLI3, PTCH, SMO, SHH and IHH via IHC in cSCC. Thus, the 
tissue microarray data presented by Schneider and colleagues suggest that canonical 
HH/PTCH/SMO/GLI pathway is important in cSCC pathology. However, all examined 
proteins display mostly only weak positive signal or no signal at all. Moreover, great majority 
(85%) of the analyzed tumors were completely negative for GLI2, which is important 
activator of the HH pathway. In contrast to our data, the authors show that SHH is weakly and 
moderately expressed in 58% and 9% of analyzed tumors, respectively. However, it is neither 
indicated on pictures nor stated in the description, which antibody staining is presented on 
which picture and therefore cannot be reassessed. In addition, they showed that GLI1 is only 
weakly or moderately expressed in 37% or 5% of analyzed tumors, respectively, while the 
majority of samples (58%) are negative. This again is in contradiction to our study, in which 
we presented strong GLI1 expression in all analyzed tumor samples. However, here we 
examined mRNA GLI1 expression but not protein level and thus these data cannot be directly 
compared. Furthermore, the authors claim that all analyzed HH pathway components were 
expressed in the cytoplasm of cSCC, however the staining pattern can be hardly assessed 
based on provided pictures. Nevertheless, cytoplasmic localization of GLIs would indicate 
that they are sequestered in the cytoplasm and thus not active as transcription factors. 
Altogether, this data are contradictory and do not provide a reliable proof for canonical HH 
pathway activity in cSCC (Schneider et al., 2011). In addition, another study showed GLI1 
expression in 60% of analyzed cSCC cases, however again the subcellular localization 
revealed cytoplasmic positivity (Bakry et al., 2015). Nevertheless, we cannot exclude the 
possibility that in our model, PTCH/SMO activity in cSCC samples might be also regulated 
via IHH or DHH. Indeed, IHH has been shown to be expressed in 11% of human cSCC cases 
(Schneider et al., 2011). Although our cell culture experiments rather argue against an 
involvement of HH ligands in the regulation of GLI1 expression in cSCC (see GLI1 
expression analysis and GLI reporter assay upon stimulation with SHH-CM in Fig. 8 shown 





7.1.2. No impact of HH/SMO pathway activators and diverse effects of SMO inhibitors 
on GLI1 expression level in cSCC cell lines 
As already mentioned, the relevance of canonical HH/GLI signaling pathway in cSCC is still 
poorly understood. In this study, we investigated the expression of HH pathway components 
in 6 different cSCC cell lines and HaCaT ras II-4 cells that shows a cSCC phenotype. Via 
qPCR we could show that most, but not all cSCC cell lines expressed the main pathway 
components i.e. GLI1, GLI2, GLI3, SMO and PTCH while SHH was expressed only by MET-
1 and MET-4 cells (Fig. 6). The latter two cell lines and the cell line SCL-I that except SHH 
does express all other components, were chosen for further analysis. When we tried to 
regulate the activity of canonical HH/GLI signaling via application of SHH-CM or the SMO 
agonist SAG or direct overexpression of SMO, we were not able to activate the pathway. On 
the other hand, treatment of the cells with SMO inhibitors revealed that GLI1 can be regulated 
in cSCC cell lines, however the effects were cell type-, concentration- and inhibitor- 
dependent. Whereas none of the cell lines showed a response towards cyclopamine and lower 
doses of vismodegib, HhA significantly decreased GLI1 expression level in MET-1 and MET-
4 cells and unexpectedly increased it in SCL-I cells. Similar paradox effect was observed 
when SCL-I and MET-4 cells were treated with high doses of vismodegib. The lack of 
response towards cyclopamine and vismodegib could be due to specific SMO mutations that 
are located in binding pockets that are specific for cyclopamine and vismodegib but not for 
HhA  (Atwood et al., 2015; Sharpe et al., 2015). However, no SMO mutations have been 
described in cSCC so far (Ransohoff et al., 2015) and detailed genomic analyses of available 
cSCC cell lines have not been performed. Thus, although it is unlikely that the resistance to 
cyclopamine and vismodegib in cSCC cell lines is due to SMO mutations, we cannot 
completely exclude it.  
The different effects exerted by the inhibitors on cSCC cell lines can also be explained by 
different modes of action. Thus, the inhibitors bind different domains of SMO receptor. 
Cyclopamine, the first discovered SMO inhibitor, apparently blocks the receptor’s activity via 
binding to its 7-transmembrane domain (7TM). This mechanism of action was proposed also 
for vismodegib. Interestingly, the SMO agonist and activator SAG activates SMO by binding 
to the same pocket as cyclopamine and vismodegib, suggesting that modulation of SMO 
activity is a much more complex process (J. K. Chen et al., 2002a; J. K. Chen et al., 2002b; C. 




conformation or promote a specific subcellular localization. While cyclopamine stabilizes 
SMO at its inactive state within the cilium, vismodegib or HhA sequester SMO in the 
cytoplasm and thus prevent its trafficking into the primary cilium, the process required for full 
activation (Dijkgraaf et al., 2011; Wilson et al., 2009; V. M. Wu et al., 2012). The 
concentration-dependent paradoxical effects of HhA and vismodegib could be due to 
overdosing. Such a scenario has been described for the SMO agonist SAG (J. K. Chen et al., 
2002b). Chen and colleagues presented that a concentration of SAG, which is higher than 1 
µM results in paradoxical pathway inhibition. In addition, they show that SMO inhibitors 
block the HH pathway activation mediated by low SAG concentrations, but they do not affect 
the inhibitory effects observed after high doses of SAG. Based on these data the authors 
suggest that SAG binds not only to SMO but also to other yet unknown factors, which 
cooperate with SMO in the regulation of the pathway’s activity. Thus, an excess of SAG 
would associate with both, SMO and its putative effectors thereby interfering with their 
interaction and leading to the pathway inhibition. Therefore, an optimal concentration of SAG 
is needed to effectively activate SMO function in association with its putative cellular 
effectors (J. K. Chen et al., 2002b). On the other way around it is possible that this could also 
be a mechanism resulting in paradoxical activation of the HH pathway when using SMO 
inhibitors. However, in our setting the increase in GLI1 expression upon treatment with HhA 
in SCL-I cells was not dose-dependent and occurred both with low and high doses of the 
inhibitor (Fig. 10 C). 
7.1.3. HhA-mediated changes in GLI1 expression negatively correlate with pERK levels 
Finally, the paradoxical increase in GLI1 expression in SCL-I cells upon HhA treatment could 
also be due to modulation of other signaling pathways. Indeed, our data show that an 
incubation of SCL-I cells with 10 and 30 µM HhA led to a decrease in the level of 
phosphorylated AKT and ERK proteins and an increase of pS6 (Fig. 11). In contrast, HhA 
inhibited GLI1 expression in MET-1 cells, which was also associated with a decrease in 
pAKT, but an increase of pERK. This suggests that HhA may influence not only SMO 
activity but also other effector pathways in dependency of the cellular context. Indeed, in 
RMS cell lines, HhA can decrease pAKT levels additionally to GLI1. However, in RMS it is 
not known whether changes in pAKT level were dependent or independent of SMO 




7.1.4. Weak and moderate decrease in cellular viability and proliferation upon 
treatment with vismodegib and HhA  
We also investigated the role of vismodegib and HhA in cellular viability, proliferation and 
apoptosis. In general, vismodegib did not or only moderately affect viability, proliferation or 
apoptosis of cSCC cells (Fig. 22, 23, 24). It is worth noticing that the same concentrations of 
the drug did not alter GLI1 expression level. In contrast, HhA, which decreased GLI1 
expression level in MET-1 and MET-4 cells showed low to moderate toxicity, which was 
accompanied by inhibition of proliferation by 50-60% and no changes in apoptosis. This is in 
line with well-known role of the canonical HH signaling in promoting proliferation. 
Interestingly, in SCL-I cells HhA exerted the same effects on viability, proliferation and 
apoptosis as in MET-1 and MET-4 cells, which however were accompanied by increase in 
GLI1 expression level. The fact that different levels of GLI1 caused the same effects on 
cellular biology suggests that growth inhibition of cSCC cells upon treatment with HhA might 
not be mediated via inhibition of the SMO/GLI axis. Indeed, the lack of correlation between 
HH pathway induced GLI1 expression and proliferation or apoptosis has been described in 
many different cancer cell types (Yauch et al., 2008). 
7.2. Noncanonical HH signaling in cSCC 
As already mentioned in section 2.2.4., noncanonical HH signaling have been described in 
various cancers. The pathways shown to be involved in GLI regulation in a SMO independent 
manner involve i.a. EGF/EGFR and its downstream effector pathways RAS/RAF/MEK/ERK, 
PI3K/AKT, and mTOR.  
Most of the data so far show a positive activation of GLI factors by the latter pathways. Thus, 
RAS/RAF/MEK/ERK signaling has been shown to regulate GLI transcriptional activity in 
pancreatic cancer (Eberl et al., 2012; Ji et al., 2007). Moreover, EGFR mediated MEK/ERK 
activation plays a role in malignant transformation of keratinocytes (Kasper et al., 2006a; 
Schnidar et al., 2009). PI3K/AKT has been shown to promote nuclear localization and thus 
activation of GLI transcription factors (Stecca et al., 2007) while mTOR signaling has been 
proved to phosphorylate and thus activate GLI1 via S6K1 effector kinase in esophageal 
cancer (Y. Wang et al., 2012). Nevertheless, it is likely that these pathways also can inhibit 




activation inhibits HH pathway target genes expression including GLI1 (M. P. Fogarty et al., 
2007b).   
The role of non-canonical HH signaling in the regulation of GLI transcription factors in cSCC 
is not known. However, due to i) the lack of SHH expression in human cSCC samples, ii) the 
inability of SHH or SAG to induce GLI1 in cSCC cell lines, iii) the inverse staining pattern of 
human cSCC samples using a GLI1 riboprobe and pS6 and pERK antibodies, iv) the 
sometimes inverse staining pattern between GLI1 and EGF in human cSCC samples, v) the 
fact that HhA upregulated GLI1 in SCL-I cells, which went along with a decrease in 
phosphorylation of ERK and vi) vice versa HhA downregulated GLI1 in MET-1 cells, which 
went along with an increase in phosphorylation of ERK, we hypothesized that GLI1 
expression and thus potentially the activity of GLI2 or GLI3 could be negatively regulated by 
EGF, RAS/RAF/MEK/ERK or mTOR signaling.  
7.2.1. Inhibition of GLI1 expression and decreased proliferation of cSCC cells upon 
inhibition of PI3K/AKT signaling 
As already mentioned in section 6.1., we were not able to detect signals in cSCC samples 
when using an antibody recognizing pSER473 of AKT (Fig. 5 B). However, the antibody also 
did not stain glioblastoma tissue which is usually used as a positive control (not shown). 
Therefore, we cannot exclude that lack of pAKT expression in cSCC is a false negative result. 
Moreover, there are studies showing that cSCC tumors are strongly positive for cytoplasmic 
and nuclear pAKT while normal skin stains negative (S. J. Chen et al., 2009). It has also been 
suggested that higher pAKT expression is related to the invasion capability of cSCC (Barrette 
et al., 2014). Therefore, and despite the lack of pAKT signals in the IHC analysis, we further 
assessed the role of PI3K/AKT signaling in cSCC cell lines.  
We showed that pharmacological inhibition of PI3K/AKT signaling at the level of PI3K or 
AKT indeed decreased levels of pAKT when using the pure AKT inhibitor MK-2206, the 
pure PI3K inhibitor GDC-0941 or the dual PI3K/mTOR inhibitor PI103 (Fig. 12). As already 
mentioned in section 2.3.2., mTORC1 is a downstream target of PI3K/AKT pathway and 
inhibition of PI3K/AKT pathway often results in concomitant inhibition of mTOR and thus 
S6 protein phosphorylation (Laplante and Sabatini, 2012). This was observed for MK-2206 in 
SCL-I, MET-1 and MET-4 cells and for GDC-0941 in the SCL-I and MET-1 cell lines. We 




MET-1 and MET-4 cells upon treatment with MK-2206 and in MET-1 cells upon treatment 
with GDC-0941. Why the drugs regulated pS6 and/or pERK levels in such a diverse manner 
is unclear. However, this suggests a crosstalk between PI3K/AKT, the mTOR and MEK/ERK 
pathways in cSCC. Similar effects of PI3K inhibitors have been described in breast cancer 
and may rely on PIP3-mediated activation of Raf/MEK/ERK cascade that is independent of 
RAS (Ebi et al., 2013). 
Nevertheless, the GLI1 expression level was significantly downregulated in all 3 investigated 
cSCC cell lines upon treatment with PI103, MK-2206 and GDC-0941 (Fig. 13). This suggests 
that PI3K/AKT signaling positively regulates GLI1 expression in cSCC. Indeed, a positive 
regulation of GLI1 expression by PI3K/AKT signaling has been shown in melanoma cells, 
where this pathway promotes GLI1 nuclear localization and thus its transcriptional activity 
(Stecca et al., 2007).  
However, no GLI1 regulation was observed upon transfection of SCL-I cells with a 
constitutively active or dominant negative variant of AKT (Fig. 14 C). This is surprising since 
the AKT isoforms, at least the constitutively active form, were expressed by the cells. One 
possibility is that the proteins expressed from the vectors have lost their function. Another 
possibility is that the decrease in GLI1 expression upon inhibitor treatment in an off-target 
effect. However, this scenario is rather unlikely because in this occasion all 3 inhibitors 
should have the same off-targets. Finally, it is possible that AKT is not involved in GLI1 
expression. Thus, PI103 and GDC-0941 were toxic to the cells and therefore could simply 
have abrogated the expression of GLI1 due to toxicity. However, toxicity was not observed 
when using MK-2206 that likewise suppressed GLI1 expression. Nevertheless, the possibility 
that AKT is indeed not involved in GLI1 transcription is fostered by the observation that AKT 
dephosphorylation by HhA was accompanied by an increase in GLI1 expression in SCL-I 
cells, but by a decrease in GLI1 expression in MET-1 cells.   
As already mentioned the application of GDC-0941 or PI103, which inhibit PI3K or 
PI3K/mTOR, respectively, showed high toxicity and thus also markedly decreased BrdU 
incorporation (Fig. 22, 23). So, it is hard to judge, whether inhibition of proliferation is not 
just a toxic effect. Indeed, when the cells’ morphology was assessed using the microscope, we 
observed many dead cells upon treatment with those inhibitors. However, it stays in contrast 




The treatment with the pure AKT inhibitor MK-2206 was not toxic for SCL-I cells and 
moderately toxic for MET-1 or MET-4 cells and toxicity correlated perfectly with BrdU 
incorporation, whereas again the cells showed no signs of apoptosis (Fig. 22, 23, 24). 
Together with the observation that the cells treated with MK-2206 neither changed their 
morphology nor died due to the treatment, these data argue against just toxic effects of this 
AKT inhibitor. Nevertheless, in the future experiments, lower concentration of PI3K and 
AKT inhibitors should be applied to verify their role in the downregulation of GLI1 
expression as well as in the regulation of metabolic activity, proliferation and apoptosis in 
cSCC cells. 
7.2.2. Inhibition of GLI1 expression and decreased proliferation of cSCC cells upon 
inhibition of mTOR signaling  
As already mentioned mTOR signaling pathway is a main downstream effector pathway of 
PI3K/AKT signaling. It regulates protein synthesis and thus plays a role in important cellular 
processes i.e. cell growth, proliferation and survival. Its activity can be modulated by many 
different factors such like growth factors, nutrients, cellular stress and importantly by both 
PI3K/AKT and MEK/ERK signaling pathways (reviewed in (Populo et al., 2012)). When the 
activity of the mTOR signaling pathway was investigated in cSCC human tissue samples, a 
strong expression of pS6 and thus mTOR activity was observed in all analyzed cSCCs. 
Interestingly, the staining was stronger in outer parts of the tumor and cells invading the 
dermis, which is opposed to the staining pattern of GLI1 (Fig. 5 B, E). This suggests that 
mTOR activity might be related to the aggressiveness of cSCC. Indeed, there is a study 
showing that increased pS6 expression is correlated with the tumor progression and thus may 
serve as a predictive biomarker for the tumor’s aggressiveness (Khandelwal et al., 2016). In 
the light of this data our analysis now supports a model, in which the cSCC cells invading are 
pS6 positive, but GLI1 negative. In other words, whereas mTOR signaling is associated with 
cSCC aggressiveness, HH/GLI signaling apparently is not. In addition, the opposing activity 
in cSCC samples also suggested that both signaling pathways may regulate each other in an 
inverse manner. However, this hypothesis was not supported by the in vitro data presented 
here. Thus, mTOR inhibition with either rapamycin or everolimus resulted in a significant 
decrease in GLI1 expression level in almost all settings with the exception of rapamycin-
treated MET-1 cells (Fig. 13). These effects were similar to that observed upon PI3K/AKT 




model. Indeed a positive crosstalk between HH and mTOR signaling has also been 
demonstrated e.g. for RMS (Kaylani et al., 2013), and esophageal adenocarcinoma (Y. Wang 
et al., 2012). We also observed that mTOR inhibition with either everolimus or rapamycin 
resulted not only in inhibition of pS6, but slightly decreased the phosphorylation of ERK in 
MET-1 cells. The decrease in ERK phosphorylation in the rapamycin treated MET-1 cells did 
not result in significant suppression of GLI1 transcription, which fosters our hypothesis that 
pERK and GLI1 transcription are negatively correlated.  
In contrast, mTOR inhibition in MET-4 cells increased ERK phosphorylation together with 
that of AKT. Whereas the role of mTORC1 in negative regulation of AKT and ERK is well 
established (reviewed in (Manning, 2004)) a positive regulation of ERK phosphorylation is 
not. 
We also showed that in most of the cases, mTOR pathway inhibition reduced both viability 
and proliferation of cSCC cells in all settings. Although in our cell culture experiments these 
just-mentioned antitumoral effects were moderate, they are in line with clinical data showing 
that sirolimus (rapamycin) used as an immunosuppressant in OTRs reduces the risk of 
development of cSCC. As already mentioned in section 2.1., OTRs are at increased risk for 
nonmelanoma skin cancer development (reviewed in (Leblanc et al., 2011)) and develop 
cSCC at 65-250 higher incidence when compared to general population (Euvrard et al., 2003). 
It has been shown that administration of mTOR inhibitors, when used as immunosuppressive 
drugs, reduce the number of de novo developing cSCC, decelerate development of already 
existing malignancies and can even induce regression of the tumors (Salgo et al., 2010).  
7.2.3. Activation of GLI1 expression and concomitant decreased proliferation of SCL-I 
cells upon inhibition of MEK/ERK signaling 
In human tissue specimens pERK is only expressed in single tumor cells in the tumor mass. 
However, its expression is strongly elevated in stromal cells surrounding the tumor tissue 
(Fig. 5 D, E). This suggests a role of tumor microenvironment in cSCC pathology (see also 
section 7.12.).  
The existing immunohistochemical data from other groups are different from ours and are 
also inconsistent in comparison to each other. Thus, three independent studies showed strong 




al., 2012; Zhang et al., 2007). However, while Khandelwal and colleagues showed no 
differences in pERK intensity between normal skin and local or metastatic cSCC, Zhang and 
his group noted an increase in pERK positive tumor cells in poorly differentiated cSCC in 
comparison to well-differentiated counterparts and no positive staining in normal skin (Zhang 
et al., 2007). However, none of these studies mentioned pERK positive stromal cells. It is 
hard to explain the differences between our results and the results obtained by other groups. It 
is unlikely that it is due to the antibody since Sonavane and colleagues used the same 
antibody as we did (namely the p44/42 MAPK (ERK 1/2) rabbit monoclonal antibody 
(Thr202/Tyr204) from Cell Signaling) (Sonavane et al., 2012). One of the reasons could be 
the staining procedure since different permeabilization and blocking conditions may markedly 
affect antibody binding. Unfortunately, the protocol for IHC is not clearly described by 
Sonavane and colleagues. However, in contrast to the tissue specimens, our in vitro analysis 
revealed that cSCC cell lines express pERK, although to a variable extent (Fig. 7). This 
difference between the tissue specimens and cell lines is hard to explain. However, the high 
pERK levels in the cultured cells might be due to some specific factors in the culture serum.  
Our data now show that cSCC cells with low pERK express high GLI1 and vice versa those 
with high pERK levels express low levels of GLI1 i.e. SCL-I and SCL-II (Fig. 6, 7). This 
suggested a negative regulation between MEK/ERK and GLI1. Indeed, when the cells were 
incubated with the specific MEK1/2 inhibitor UO126, GLI1 levels were significantly 
upregulated in SCL-I cells or did not change in the other cell lines, while pERK levels were 
downregulated. To our knowledge, this is the second report, in which GLI1 expression and 
thus probably HH signaling can be negatively regulated by the MEK/ERK axis. Thus, a 
negative regulation of HH/GLI1 by the FGF/ERK axis has been shown in MB (M. P. Fogarty 
et al., 2007b). However, up to date all other literature data rather show a positive crosstalk 
between RAS/MEK/ERK and GLI transcription factors (i.e.(Eberl et al., 2012; Seto et al., 
2009)).  
In addition, we assessed changes in viability, proliferation and apoptosis upon treatment with 
UO126. WST-1 assay shows that the drug is in general well-tolerated by the cells (Fig. 22). 
However, despite unchanged or even upregulated GLI1 levels, this drug was able to 
moderately but significantly reduce proliferation of the cells (Fig. 23). Paradoxically, in SCL-
I cells we measured increased number of early apoptotic cells in 3 independent experiments 




inconclusive. Nevertheless, the significant increase in GLI1 expression level upon UO126 
treatment (Fig. 13) suggests that GLI1 may induce apoptosis in this cell line. An experiment 
with a longer exposure to UO126 will help to verify these data. Together, these data suggest 
that active MEK/ERK signaling in cSCC counteracts GLI1 expression, but is necessary for 
proliferation of the cells. Of whether this inhibitory effect on GLI1 expression is downstream 
of MEK at the pERK level, remains to be established in the future using an ERK inhibitor 
such as SCH772984. 
Besides, the data show that there might be a positive crosstalk between MEK/ERK and 
mTOR and a negative crosstalk between MEK/ERK and pAKT signaling (Fig. 12). Thus, we 
noted that MEK1/2 inhibition can reduce phosphorylation level of S6 suggesting a positive 
crosstalk between MEK/ERK and mTOR. Similar effects have been already shown by other 
researchers who described that activated ERK can also phosphorylate and thus inhibit 
function of tuberous sclerosis complex 2 (TSC2), which is a negative regulator of mTOR 
signaling. The TSC complex is also negatively regulated by AKT-mediated phosphorylation 
but phosphorylation sites for ERK and AKT are different. Thus, pERK can activate mTOR 
via PI3K/AKT-independent inactivation of TSC complex (Roux et al., 2004). Furthermore, a 
negative crosstalk between MEK/ERK and PI3K/AKT has been documented in the literature. 
For example, one group proposed a mechanism in which ERK phosphorylates 4 amino 
residues on GAB1 and thus abrogates recruitment of PI3K to the EGFR leading to a decrease 
in AKT phosphorylation (Lehr et al., 2004). This mechanism could be also true for cSCC cell 
lines used in this study. If so, this also would foster our hypothesis that AKT is barely 
involved in regulation of GLI1 expression. 
7.2.4. MEK/ERK-mediated inhibition of GLI1 expression in cSCC cells upon EGF 
treatment  
As already mentioned, EGFR signaling is deregulated in many different cancer entities 
including cSCC (G. B. Fogarty et al., 2007a; Shimizu et al., 2001; Toll et al., 2010). Indeed, 
Toll and colleagues showed that 20% of analyzed cSCCs display amplification of EGFR, 
which positively correlates with EGFR overexpression, as shown by fluorescent ISH (FISH) 
and IHC, respectively. (Toll et al., 2010). Up to date many monoclonal antibodies targeting 
and blocking EGFR as well as TKI have been developed and are either being tested in clinical 




Cetuximab is a prior-ranking drug used in the anti-EGFR therapy and shows advantageous 
anti-cancer effects in colorectal, non-small cell lung and head and neck cancer and is currently 
being tested in phase 2 in clinical trials for treatment of cSCC (Maubec et al., 2011). In 
addition, activating mutations in TK or deletions in extracellular domain of EGFR that are 
related to anti-EGFR therapy resistance are quite rare in cSCC (Dziunycz et al., 2013; Ridd 
and Bastian, 2010). Altogether, given the high expression of EGFR and low mutation rate, 
these data suggest that EGFR is a promising target for cSCC therapy (Mauerer et al., 2011).  
Nevertheless, besides immunohistochemical and genomic analysis, there are not much data 
available that provide an insight into molecular mechanisms of EGF/EGFR signaling in 
cSCC. In this thesis, we focused on EGF stimulated EGFR signaling, its potential crosstalk 
with GLI1 and its impact on cell viability and proliferation. Our data revealed that the EGF 
ligand is strongly expressed throughout the tumor tissue of cSCC patients and that its 
expression pattern overlaps with that of pS6 and GLI1. However, sometimes the tumors had 
GLI1 negative areas in the invasion front that were positive for EGF, suggesting a negative 
regulation of GLI1 by EGF (see Fig. 5 E). We further investigated the role of EGF in GLI1 
regulation in our cell lines. The MET-1 and MET-4 cells express EGFR as demonstrated by 
Clayburgh and colleagues (Clayburgh et al., 2013). Western Blot analysis showed that EGF 
indeed stimulates its downstream signaling pathways i.e. PI3K/AKT, MEK/ERK and mTOR 
not only in MET-1 and MET-4 cells, but also in SCL-I cells. This was indicated by increased 
levels of pAKT, pERK and pS6, respectively (see Fig. 16 A). We also showed that the 
phosphorylation is a rapid process since elevated levels of pAKT, pERK and pS6 were 
already seen after 30 min of EGF incubation. Interestingly, when we measured the GLI1 
expression level upon EGF stimulation, we noted a significant decrease in GLI1 transcription 
after 3 h of incubation with the ligand (Fig. 16 B). To further unravel the mechanism by 
which EGF blocks GLI1 expression we combined EGF stimulation with inhibition of 
MEK/ERK, PI3K/AKT and/or mTOR signaling. All PI3K/AKT and/or mTOR inhibitors in 
combination with EGF significantly reduced the level of GLI1 (Fig. 18). This indicated that 
EGF-mediated GLI1 downregulation is not due to activation of PI3K/AKT since blockage of 
this pathway did not restore basal GLI1 expression level. These data again suggest that 
PI3K/AKT and mTOR pathways positively can regulate GLI1 expression in cSCC cells. 
On the contrary, combined treatment of EGF and the MEK1/2 inhibitor showed a tendency to 




significant in MET-1 cells (see Fig. 18). This is another indication that MEK/ERK signaling 
may negatively regulate GLI1 in human cSCC. However, in general GLI1 expression level 
was lower in EGF-UO126 combined treatment than in UO126 treatment alone when 
compared to the respective solvent controls (Fig. 13 and 18). This indicates that additional 
pathways stimulated by EGF probably inhibit GLI1 expression. In conclusion, we suggest 
here a mechanism, in which EGF-induced EGFR signaling stimulates MEK/ERK pathway 
that inhibits GLI1 expression in cSCC in vitro in specific settings.  
When the effect of EGF and the concomitant GLI1 downregulation on proliferation were 
analyzed, no changes in BrdU incorporation in MET-1 and MET-4 cells were detected upon 
treatment with EGF. In SCL-I cells we even noted a slight but significant decrease in the 
proliferation rate (Fig. 25). Together these data suggest a minor role of EGF in cellular 
proliferation of cSCC cells. This in contrast to breast cancer cells that show an increase in 
proliferation of about 25% (see Fig. 25).  
To our knowledge there are no studies showing similar experiments and we are not aware of 
studies that investigated the impact of EGF on GLI1 expression in cSCC cells. In contrast, 
several studies analyzed the impact of EGFR on cSCC cells. Thus, in one report, a MTT assay 
was used to study the effects of Cetuximab on cell survival. The authors showed that EGFR 
inhibition results in decreased metabolic activity of cSCC cells, including MET-1 and MET-4 
cell lines (Clayburgh et al., 2013). Another group presented similar results showing a 
reduction in metabolic activity upon treatment with Cetuximab in different cSCC cell line 
(Colo16) (Galer et al., 2011). However, since the MTT assay mirrors cellular viability and not 
the proliferation rate, Cetuximab may be only toxic to the cells. Moreover, Galer and 
colleagues also suggested that combined treatment with Cetuximab and the A12 monoclonal 
antibody that inhibits IGF1R signaling, increases apoptosis in cSCC cells but the data for 
Cetuximab treatment alone were not investigated. Nevertheless, the authors used propidium 
iodide (PI) staining to assess apoptosis. PI is known to enter the cells with disrupted cell 
membrane integrity and thus does not allow for the distinction between late apoptotic and 
necrotic cells. This again suggests that Cetuximab might be just toxic to the cells.  
7.3. GLI1 is dispensable for proliferation of cSCC cells 
All the so far performed experiments implicated that the expression of the HH downstream 




proliferation (H. Zhu and Lo, 2010), apparently is dispensable for proliferation of cultured 
cSCC cells. Indeed, a GLI1 knockdown did not influence proliferation of the MET-4 cell line 
(Fig. 26), thus again suggesting that GLI1 is dispensable for cSCC proliferation. This is also 
fostered by overexpression of GLI1 that did not influence percentage of proliferating MET-4 
and SCL-I cells when compared to the controls (Fig. 27 B). However, the overexpression data 
are only preliminary and require further validation. Nevertheless, these data indicate that 
GLI1 inhibition seems to be irrelevant for cSCC proliferation. One possible reason could be 
that the transfected GLI1 DNA is not translated into protein. Another scenario could be that 
GLI1 proteins derived from the plasmid lose their function or are even degraded within the 
cells. However, both of these explanations seem to be unlikely since in our model, GLI1 
transfection resulted not only in elevated GLI1 but also GLI2 expression. Indeed, regulation of 
GLI2 by GLI1 transcription factors has been described in the literature (Regl et al., 2002). 
7.4. Model of the crosstalk between EGF and HH signaling and/or GLI1 expression in 
cSCC 
Whereas data indicating a crosstalk between EGF and HH signaling is sparse in tumors, it has 
been extensively studied in neuronal development. The integration of EGF and HH signaling 
has been shown to be crucial for proliferation of neocortical cells with stem cell properties 
(Palma and Ruiz i Altaba, 2004). Thus, it has been shown that optimal concentrations of EGF 
and SHH synergize to induce cellular proliferation of neurosphere-forming stem cells as 
shown via BrdU incorporation assay. Furthermore, the authors showed that cyclopamine 
treatment inhibits not only Gli1 but also Egrf transcription in mice (Palma and Ruiz i Altaba, 
2004). This is in contrast to our study, where we showed that EGF strongly inhibited GLI1 
expression level suggesting rather a negative crosstalk. Palma and Ruiz I Altaba also 
discussed that both SHH/GLI and EGF/ERK signaling integrate at the level of SMAD 
proteins leading to their inactivation in the neocortex of mice (Palma and Ruiz i Altaba, 
2004). On the other hand, GLI1 has been shown to form complexes with SMAD4 to induce 
transcription of TGFβ target genes in various cancer cell lines (Nye et al., 2014). Moreover, 
bone morphogenetic protein (BMP)/SMAD signaling activity is cancer type-specific. Thus, it 
has been described that in a majority of sporadic colorectal cancers, BMP signaling is 
inactivated (Kodach et al., 2008), whereas BMP overexpression has been linked to the 
metaplastic transformation of esophageal squamous cells (Milano et al., 2007). Thus, it is 




which can no longer create complexes with GLI1 leading to changes in gene expression. 
Indeed, there are studies showing that inactivation of TGFß receptor/SMAD signaling 
promotes development of cSCC (Cammareri et al., 2016). It is also known that GLI1 
promoter contains GLI binding sites meaning that GLI1 can regulate its own expression 
(Winklmayr et al., 2010). However, whether in our model GLI1 transcription is regulated via 
GLI1/SMAD complexes remains to be investigated in the future. 
It also has been reported that in keratinocytes EGF and HH synergize at the promoter level to 
induce the transcription of the selected subset of GLI target genes (Kasper et al., 2006b). 
Additionally, Schnidar and colleagues provided evidence that HH/GLI and EGFR signaling 
pathways synergistically induce malignant transformation of keratinocytes and that dual 
inhibition of both pathways with Gefitinib and GLI inhibitor GANT61 is beneficial to inhibit 
growth of BCC in mice (Schnidar et al., 2009). Importantly both studies (Kasper et al., 2006b; 
Schnidar et al., 2009) suggest that EGFR signals via the MEK/ERK pathway to synergize 
with the activator form GLI1 and GLI2. In contrast, in vitro studies in medulloblastoma Daoy 
cells showed that simultaneous activation of EGFR and HH signaling with EGF and HH 
ligand, respectively, resulted in inhibition of expression of typical HH target genes i.e. GLI1, 
PTCH and HHIP, but in a stabilization of GLI proteins. The mechanism behind still requires 
clarification (Gotschel et al., 2013). However, Gotschel and colleagues also showed that 
single treatment with EGF did not inhibit GLI1 expression when compared to the control. 
This is in contrast to the results presented here. This discrepancy might be due to the 
differences in incubation time. Whereas we analyzed GLI1 expression levels after 3 h 
incubation with EGF, Gotschel and colleagues stimulated the cells for 24 h. Thus, GLI1 
downregulation might not be a stable effect and could have been overlooked by the other 
group. This might be due to activation of a feedback loop, in which EGF-mediated lower 
GLI1 levels may signal back to enhance activation of GLI transcription factors and thus of 
GLI1 expression, possibly via other signaling pathway. Another explanation could be 
instability and degradation of EGF after 24 h. Finally, EGF effects might be highly cell-type 
specific resulting in a decrease of GLI1 in cSCC cells, but not in other tumor cell lines such as 
the medulloblastoma cell line Daoy.  
To summarize our data, we here propose a model for cSCC, in which EGF via activation of its 
receptor activates EGFR signaling. This results in inhibition of GLI1 expression via the 




HNSCC is an epithelial tumor of the squamous epithelium of the mucosa of the head and neck 
(Keysar et al., 2013). As in our setting, cell culture experiments showed that EGF treatment 
led to a significant inhibition of GLI1 expression and decrease in GLI1 protein level. On the 
other way around, the EGFR inhibitor erlotinib treatment showed exactly opposite effects. 
Thus, erlotinib induced GLI1 expression and increased GLI1 protein levels. Most 
interestingly, EGF treatment of the cells induced an EMT-like phenotype. That means it 
induced epithelial-mesenchymal transition with upregulation of ZEB1 and VIM. This was 
associated with increased motility of the cells (Keysar et al., 2013). Thus, a similar 
mechanism could be proposed for cSCC and it would be highly interesting to investigate 
whether EGF treatment of the cells and concomitant GLI1 downregulation results in 
upregulation of the EMT markers ZEB1 and VIM and increased motility of cSCC cells. We 
also observed GLI1 downregulation upon incubation of cSCC cells with IGF1. Since IGF1R 
and EGFR signaling can induce the same downstream signaling pathways including 
MEK/ERK, IGF1-mediated GLI1 regulation probably follows the same mechanism. Indeed, 
simultaneous administration of cetuximab and A12, which is an IGF1R blocking antibody, 
results in inhibition of proliferation, tumor growth and angiogenesis as well as increased 
apoptosis, both in cSCC cell lines and tumor xenografts (Galer et al., 2011). Of whether this 
also involves upregulation of GLI1 is presently unknown. 
Together, these data suggest that both EGF/EGFR and IGF1/IGF1R are active in cSCC. 
Besides activating the PI3K/AKT/mTOR axis, the receptors also activate MEK/ERK 
signaling. Activation of MEK/ERK then leads to downregulation of GLI1. Of whether the 
inhibitory effect is mediated by MEK or by ERK remains to be established in the future. What 
is more important is the possibility that downregulation of GLI1 may contribute to cSCC 
pathogenesis. Thus, GLI1-downregulation may be associated with increased EMT and 
migratory and invasive capacity of cSCC cells (see above). It, however, does not influence the 


















Figure 28: Model of EGF/EGFR and probably also IGF1/IGF1R signaling and associated inhibition of 
GLI1 in cSCC. The model also includes the potential function of GLI1 suppression in cSCC. EGF-mediated 
activation of EGFR initiates both the PI3K/AKT/mTOR and MEK/ERK cascade. Although the exact role of 
PI3K/AKT and mTOR signaling in regulation of GLI1 expression is still obscure, it might have a positive effect 
on GLI1 expression. In contrast, the MEK/ERK axis rather inhibits GLI1. Since MEK/ERK signaling can also 
stimulate the mTOR and the PI3K/AKT pathway, GLI1 expression by MEK/ERK is not completely abrogated in 
cSCC. Moreover, GLI1 expression level has no influence on cSCC proliferation. However, it is likely that its 
downregulation is an important step in EMT and in cellular migration and invasion of cSCC cells. Black arrows 
indicate the most important processes in cSCC, whereas grey arrows apply to the auxiliary mechanisms. 
Of whether the MEK/ERK-mediated suppression of GLI1 expression involves GLI2 or GLI3, 
which are upstream of GLI1, is currently unknown. If so, we would expect that EGF treatment 
results in i) stabilization of the respective GLI repressor forms, ii) inactivation of the 
respective GLI activator forms, iii) lack of translocation of the respective GLI activator forms 
into the nucleus and/or in iv) degradation of GLI protein or mRNA.  
However, it is also possible that MEK/ERK signaling inhibits GLI1 expression without the 
involvement of the transcription factors GLI2 and GLI3. Thus, ERK also stimulates or 
activates a plethora of other factors including those that can inhibit gene expression (reviewed 
in (Whitmarsh, 2007)). One of these factors might be the myc-associated zinc finger protein 




consensus sequence for this transcription factor exists (data not shown). MAZ can both induce 
transcriptional activation and termination (Bossone et al., 1992) and is more and more 
becoming important as a transcriptional suppressor of several genes including human 
teleomerase (Su et al., 2007). In addition, MAZ induces EMT by upregulation of ZEB1 (Luo 
et al., 2016), which we also consider to occur in cSCC cells, in which GLI1 is downregulated 
(see above). However, we did not find any information of whether MAZ itself is regulated by 
MEK/ERK signaling. Nevertheless, it is possible that MEK/ERK inhibits GLI1 expression via 
a mechanism that does not involve the other GLI transcription factors. 
7.5. Translation of the cSCC cell culture data into the patient’s situation 
There are some difficulties, when trying to translate the cell culture data into the patient’s 
situation. We have immunohistochemical data for GLI1, pERK, pS6 and EGF. The IHC data 
shows that pERK is almost exclusively expressed in stromal cells resembling fibroblast. As 
described in the literature, these are also cells that express EGF (Wayne et al., 2006). The 
expression of EGF in fibroblast thus could explain the high levels of pERK in the fibroblasts 
due to an autocrine signaling. Since GLI1 is negatively regulated by EGF/MEK/pERK, GLI1 
is not expressed in the fibroblasts.  
Our data also shows that EGF is expressed by the cSCC tumor cells. Sometimes it overlaps 
with GLI1 positive areas and sometimes it overlaps with GLI1 low/negative areas. Whereas 
the latter setting fits to our cell culture data, the concomitant EGF staining with GLI1 positive 
areas does not. However, due to the more complex setting in the in vivo situation, it is 
possible that there are other more dominant factors than EGF that might positively regulate 
GLI1 expression in the tumor cells.  
A more important question is however, why GLI1 is not expressed in tumor cells that are 
invading the stromal environment. In compliance with the cell culture data one would expect 
that the invading cells that are GLI1 low also would express pERK. However, this is not the 
case. Nevertheless, one possible explanation is again the more complex setting in the in vivo 
situation, in which pERK in stromal cells may regulate the expression of other soluble factors 
that then signal back to the invasion front of the tumors and block GLI1 expression. This 
setting may also explain the fact that the GLI1 low/neg invading cells highly express pS6. 
High expression of pS6 is indicative for activation of mTOR signaling and mTOR signaling is 




important role in cSCC invasiveness. With respect to lack of GLI1 expression in the invading 
cells (and as already mentioned in section 7.1.) it would thus be highly interesting to analyze 
whether lack of GLI1 and concomitant activation of mTOR is necessary for cSCC invasivity 
and migration. Furthermore, in the style of HNSCC (Keysar et al., 2013), it also would be 
highly interesting to analyze, whether downregulation of GLI1 in the invasion front correlates 
with EMT and upregulation of VIM or ZEB1. 
The fact that the tumor center expresses GLI1 is also difficult to explain. Apparently, and 
according to our cell culture data, GLI1 is not necessary for cSCC proliferation. One 
possibility is that GLI1 overexpression in the tumor center is just a bystander effect and has 
nothing to do with the tumor’s biology. However, the fact that cSCC can develop from BCC 
after treatment with vismodegib strongly argues against such a scenario. BCC is a tumor that 
shows very high GLI1 expression throughout the whole tumor mass due to PTCH mutations. 
With respect to vismodegib treatment of advanced stages of BCC, it has been reported that 
cSCC can either develop in the regions distant from the primary BCC (Aasi et al., 2013; 
Iarrobino et al., 2013; Orouji et al., 2014), or within the bed of BCC (G. A. Zhu et al., 2014). 
In the light of these data it is highly interesting that both cSCC and BCC may develop from 
epidermal stem cells including those within the bulge region of hair follicles or from the 
interfollicular epidermis (reviewed in (Thieu et al., 2013)). With respect to GLI1 expression 
by both tumor entities with cSCC expressing GLI1 in the tumor center and BCC expressing it 
all over the tumor, it is possible that the tumors share similar molecular features at very early 
stages and eventually also the same precursor cell. However, when the tumors further 
develop, specific molecular changes may specify the fate of the cells, giving rise to either a 
cSCC or a BCC. Thus, it would be highly interesting to investigate whether the GLI1 positive 
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